

### University studies

**1992:** Admission to the Medical School of the Alma Mater Studiorum University of Bologna (Italy).

**1993-1994:** Probationer in the Neurophysiology Laboratory by the Human physiology institute of the Alma Mater Studiorum University of Bologna (Responsibles: Prof. Pierluigi Parmeggiani, Prof. Emanuele Perez): in this context he observed the planning and execution of basic researches on neurotransmitter modulation of REM sleep in murin models, actively participating to some phases of the tests.

**1995-1996:** Probationer by the Neurology Clinic of the Alma Mater Studiorum University of Bologna (Responsibles: Prof. Elio Lugaresi, Prof. Pasquale Montagna): in this context he could observe and cooperate to the clinical activity of the recovery dept., with particular attention to patients affected by chronic neurological disease, especially affected by motor coordination and sleep disorders.

**1997:** Probationer by the Autopsy room by the Pathological Anatomy institute of the Alma Mater Studiorum University of Bologna (Responsibles: Prof. Antonio M. Mancini, Prof. Paolo Scarani): in this context he assisted to post-mortem examinations and microscopic evaluation of bioptic sections.

**1998:** Atherosclerosis and Metabolic disease Research Unit by the Clinical medicine and applied biotechnology Dept. of the Alma Mater Studiorum University of Bologna (Responsibles: Prof. Ettore Ambrosioni, Prof. Antonio V. Gaddi): in this context he assisted to the ambulatory management of patients at high risk of cardiovascular disease, with particular attention to those affected by genetic diseases of the lipid metabolism, contributing to the enrolment and management of patients in the setting of the "Familial Combined Hyperlipoproteinemia - Wide Genoma" Telethon project.

**December 22th, 1998:** Medical Degree obtained at the age of 24 by the Alma Mater Studiorum University of Bologna (Italy) with a dissertation on "Variability of the lipid phenotype and diagnosis of Familial Combined Hyperlipidaemia in an adult and elderly population sample" (Mentor: Prof. Antonio V. Gaddi). The dissertation received the maximal note (110/110) and honours of the faculty (*cum laude*), and the main results were then reported in a full paper (*Vasc Dis Prev* 2007;4(3):185-189).

### **Post-graduated studies**

**1998:** Admission to the Post-Graduation School in Clinical Pharmacology by the University of Modena and Reggio nell'Emilia (Italy). Director: Prof. Emilio Sternieri.

During the Post-graduated school in Clinical Pharmacology he mainly attended two structures:

- Research Unit of Neuropsychopharmacology by the Biomedical science Dept. (Responsibles: Prof. Rossana Arletti/Prof. Maurizio Sandrini): In this context he actively participated to and planned studies on behavioural pharmacology, receptorial binding, pharmacognosy and pharmacoepidemiology
- Toxicology and Clinical pharmacology Research Unit by the Internal medicine Dept. (Responsibles: Prof. Alfio Bertolini/Prof. Emilio Sternieri): In this context he was actively involved in pharmacokinetic and pharmacovigilance studies, and he was co-ideator and responsible for data analysis of the Headache Treatment Safety Study (HTSS) -

pharmacoepidemiology and pharmacovigilance study on use and safety of drugs commonly used by headache patients -, and he co-worked to an EU project against doping.

**1999:** Post-graduate in “Statistical methodologies” by the “Louis Pasteur” University of Strasburg (France).

**2000:** Postgraduate in “Chronobiology” by the “Pitié-Salpêtrière” Medical Faculty, “Pierre et Marie Curie” University of Paris (France).

**2001:** Postgraduate in “Nutrition, Therapy and Aging” by the Medical faculty of the Paris XII University of Creteil (France).

**October 28th, 2002:** Board graduation in Clinical Pharmacology obtained at the age of 28 by the University of Modena and Reggio nell'Emilia (Italy) with a dissertation on “Prevalence of adverse events related to drugs used in the acute and chronic management of headache: results of a pharmacovigilance study involving 1232 patients visited by the Headache Research Unit of the Modena and Reggio nell'Emilia University” (Mentor: Prof. Emilio Sternieri). The dissertation received the maximal note (110/110) and honours of the faculty (*cum laude*), and the main results were then reported in two full papers (*Cephalalgia* 2004; 24(5): 356-362 and *European Journal of Clinical Pharmacology* 2005; 60:893-900).

**2002:** Admission to the PhD course on Experimental Medicine Atherosclerosis by the Medical School of the University of Siena (Italy). Director: Prof. Alberto Auteri.

**February the 16th, 2007:** PhD dissertation on “Epidemiological, clinical and laboratory determinants of Familial Combined Hyperlipoproteinemia, Metabolic syndrome and Type 2 diabetes in general population and selected ambulatory patients”. Mentor: Prof. Antonio V. Gaddi. Parts of the dissertation are currently published on numerous international journals.

#### ***Other intensive and/or professionalising courses***

**September 25-27, 2000.** Intensive course of “Methodology of systematic reviews” organized by the Italian Cochrane Network (Modena, Italy).

**November 02, 2000.** Course on Micromedex - database use (Modena, Italy).

**March 8, 2001.** Training on Basic Life Support (BLS) (Modena, Italy).

**July 02-04, 2001.** Good Clinical Practices (GCP) Training for Clinical Investigators organized from the Association of Clinical Research Professionals (ACRP) (Edinburgh, United Kingdom).

**October 26, 2001.** Course on “History of GCP globalization and description of ICH guidelines” (Chia Laguna, Italy).

**June 06, 2002.** ACRP Workshop on “SOPs for Investigator Sites” (Amsterdam, Holland).

**June 24, 2004.** Intensive course on “Heart and vessels in arterial hypertension: from physiopathology to treatment” organized by the Italian Society of Cardiology (Rome, Italy).

**June 30, 2004.** Updating seminar on “Project for clinical management and research in gerontology”. (Bologna, Italy).

**September 23, 2004.** Intensive course on “Clinical research: methodological, legal and statistic aspects”. (Bologna, Italy).

**April 25-29, 2005.** Selection for the EASD Robert Turner Clinical Research Course (Oxford, United Kingdom).

**Novembre 21-23, 2005.** Intensive course on “Antibiotic chemotherapy and discussion on pharmacological properties of azalides” (Rome, Italy).

**January 12, 2005.** Intensive course on scientific communication about antibiotic therapy in pediatric - organized by the SDA-Bocconi University (Milan, Italy).

**January 13, 2005.** Forum on “Clinical antibiotic therapy: Update on antibiotics in pediatric age” (Milan, Italy).

**June 13, 2006.** Intensive theoretical and practical course on “Brain and coronary disease in hypertensive emergency” (Advanced Life Support) (Madrid, Spain).

**October 19-20, 2006.** Master Course on “Ischemic Heart Disease” (Copenhagen, Danmark).

**December 14, 2006.** Intensive course on “Scientific communication on antibiotic therapy in pediatric” organized by the SDA-Bocconi University (Milan, Italy).

**December 15, 2006.** Intensive course on “Pharmacokinetics and pharmacodynamics for an optimal management of the antibiotic therapy” (Milan, Italy).

**Mai-June, 2007.** American Heart Association e-learning course on “Dyslipidemia: Assessment and Management”.

**September 13-14, 2007.** Intensive course on “Compliance Project. Cardiovascular disease risk reduction: appropriate prescription and therapeutic education” (Rome, Italy).

**June 23-26, 2009.** Course on “Intermediate Statistics using SPSS” (Imperial College of Science, Technology & Medicine, London, UK).

### ***Academic and scientific activities***

#### ***Previous research contracts***

**2007-2011:** Research contract with the Internal medicine, Aging and Kidney disease Dept. of the University of Bologna, Italy.

**2005-2006:** Research fellow for the National Institute of Cardiovascular Research (INRC)

**2002-2004:** Research contract with the Clinical medicine and Applied biotechnology Dept. of the University of Bologna, Italy.

**2012-2019:** Clinical researcher of Internal medicine and Aging (ex- Geriatrics and Gerontology) by the Medical School of the University of Bologna, Italy.

### ***Current professional position***

**2019:** Associate professore of Applied Dietary Sciences by the Medical School of the University of Bologna, Italy.

### ***Clinical experiences***

**1998-2002:** Certified clinical training as foreseen by the post-graduated school in clinical pharmacology by the University of Modena and Reggio nell'Emilia (Italy), including periods in Internal medicine dept, Emergency medicine, Headache Care Unit

**2001-2002:** Clinical activity by the ambulatory service of the Atherosclerosis and Metabolic disease research Unit of the University of Bologna, under the supervision of Prof. Antonio V. Gaddi

**2003-till now:** Clinical activity by the ambulatory service of the Atherosclerosis and Metabolic disease research Unit of the University of Bologna, consisting in diagnosis and management of genetic and secondary dyslipidemias, and more in general of patients at high cardiovascular disease risk. Clinical activity by the Internal Medicine Inpatient dept, bu the IRCCS S. Orsola-Malpighi University Hospital.

### ***Innovative research fields***

- ***Clinical pharmacology and therapeutics:*** Numerous clinical trials (mainly phase III and IV) aiming at testing new drug indication or properties, and new drug association efficacy and tolerability, in different fields including lipidology, diabetology, cardiology, neurology, nephrology, urology. Role covered: Planning, clinical research, data analysis, result divulgation. The most part of the results of this studies are published on peer-reviewed international journals with IF.
- ***Human nutrition and dietary supplementation:*** Preclinical and clinical trials aimed at identifying nutrients or plant derived drugs (also under the form of nutraceuticals and functional foods) able to modulate cardiovascular risk factors levels or other pathological condition such as nephrolithiasis, erectile dysfunction and others, to contribute at creating an - evidence based - background where previously unavailable. Planning, clinical research, data analysis, result divulgation. The most part of the results of this studies are published on peer-reviewed international journals with IF.
- ***Cardiovascular disease prevention:*** Main field of research, where the most part of effort in conducting epidemiological and clinical studies has been concentrated. Beyond the above cited clinical trials on drugs and nutrients, different studies have been carried out to identify new clinical and laboratory determinants of cardiovascular disease risk both in general and selected population, and new clinical and laboratory markers of lipid metabolism genetic disease

significantly increasing the cardiovascular disease risk. Planning, clinical research, data analysis, result divulgation. The most part of the results of this studies are published on peer-reviewed international journals with IF.

- *Clinical epidemiology*: Numerous transversal and longitudinal epidemiological studies carried out on general population and ambulatory setting (see list below). The main field of research has been the epidemiology of nutritional habit, conventional and non conventional cardiovascular disease risk factors, metabolic syndrome, genetic diseases of lipid metabolism, type 2 diabetes, and drug utilization. The most part of the results of this studies are published on peer-reviewed international journals with IF.
- *Internal medicine and geriatrics*: The most part of the above cited studies has been carried out on adult and elderly patients affected by diseases of interntistic interest, such as hypertension, obesity, diabetes, lipid metabolism diseases, headache, nephrolythiasis, chronic kidney failure, erectile dysfunction and others. Planning, clinical research, data analysis, result divulgation. The most part of the results of this studies are published on peer-reviewed international journals with IF.

### ***Scientific prizes***

- Poster Award at the 6th Congress of the European Headache Federation. Istambul, Turkey, June 30th, 2002.
- Winner of financial support in the context of the 4th EU Marco Polo program for the international mobility of young researchers. Academic year 2002-2003.
- Scholarship for participation and data presentation to the 9th Meeting of the International Diabetes Epidemiology Group/38th annual meeting of the European Diabetes Epidemiology Group. Tours, France, August 20th-23th, 2003.
- Prize for “The best scientific work” presentet at the 3rd Virtual Congress of Cardiology of the Argentine Cardiology Federation, Decembre 4th, 2003.
- Astra Zeneca prize fot the best poster presented at the 18th National Congres of the Italian Atherosclerosis Society (SISA). Palermo, Italy, November 26th -29th, 2004.
- Poster Award at the 21th National Congres of the Italian Atherosclerosis Society (SISA). Perugia, Italy, November 21th -24th, 2007.
- “Bracci” prize for the best scientific paper published on international press in 2007, assigned during the 100° National Congress of the Italian Urological Society (SIU). Rome, Italy, September 22th-28th, 2008.
- Accomodation Grant at the 19thEuropean Hypertension Congress. Milan, Italy, June 12-16, 2009.
- Scholarship for attending at the ESH Summer School. Smolenice Castle, SK, September 19-25, 2009.

### ***Active membership of scientific societies***

- *International Atherosclerosis Society (IAS)* (President: Prof. Peter Libby)
- *Italian Society for the Atherosclerosis Study (SISA)* (President: Prof. Marcello Arca)
- *Italian association of cardiologist and allied ambulatori specialists (ACSA)*: (President: Dr. Pietro Lentini)
- *Italian Society for the Cardiovascular disease Prevention (SIPREC)* (President: Prof. Massimo Volpe)
- *Italian Association of Phytotherapy and Phytoarmacology (AIFF)* (President: Prof. Ottavio Iommelli)
- *Italian Society for the Medical Pedagogy (SIPEM)* (President: Prof. Giuseppe Parisi)
- *Italian Society of Nutraceuticals (SINUT)* (President: Prof. Arrigo F.G. Cicero)

**Member of the reviewer board of the following international biomedical journals:**

- British Medical Journal
- The Lancet
- Medicine
- Quarterly Medical Journal
- Journal of General Internal Medicine
- Annals of Medicine
- Archives of Medical Science
- European Journal of Clinical Investigation
- Core Evidence
- PLOS One
- Hospital Practice
- Medical Science Monitor
- Canadian Medical Association Journal
- Int Research Journal of Medicine and Medical Sciences
- International Journal of General Medicine
- Journal of Symptoms and Signs
- Journal of Rheumatology
- Experimental Gerontology
- Aging Clinical and Experimental Research
- Circulation
- Hypertension
- Heart and Vessels
- Vascular Health and Risk Management
- Expert Opinion in Cardiovascular Medicine
- Expert Review of Cardiovascular Therapy
- The Open Cardiovascular Medicine Journal
- Cardiovascular Diabetology
- Cardiovascular Endocrinology
- American Journal of Cardiology
- Journal of Cardiovascular Medicine
- Clinical Cardiology
- Research Reports in Clinical Cardiology
- American Journal of Hypertension

- Clinical and Experimental Hypertension
- International Journal of Hypertension
- Atherosclerosis
- Lipids in Health and Disease
- Nutrients
- Nutrition Research
- Journal of Nutrition
- Clinical Nutrition
- British Journal of Nutrition
- European Journal of Clinical Nutrition
- Journal of the American College of Nutrition
- Journal of Human Nutrition and Dietetics
- Molecular Nutrition and Food Research
- Food and Function
- Journal of Nutrition Education and Behavior
- Nutrafoods
- Plant Foods for Human Nutrition
- International Journal for Vitamin and Nutrition Research
- Mediterranean Journal of Nutrition and Metabolism
- The Open Bioactive Compounds Journal
- Diabetes, Obesity & Metabolism
- Diabetic Medicine
- Diabetes Technology and Therapeutics
- Diabetes Therapy
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Metabolism, Clinical and Experimental
- Expert Review of Endocrinology and Metabolism
- Experimental and Clinical Endocrinology & Diabetes
- European Journal of Endocrinology
- Endocrinology Practice
- Endocrine
- Hormone and Metabolic Research
- The Open Obesity Journal
- European Journal of Gastroenterology and Hepatology
- Kidney International
- Urology
- International Urology and Nephrology
- Gynecological Endocrinology
- Journal of Sexual Medicine
- BMC Clinical Pathology
- Biomarkers in Medicine
- Clinical Biochemistry
- Clinical Drug Investigation
- Clinical Medicine: Therapeutics
- Clinical Pharmacology: Advances and Applications
- Journal of Pharmacy & Pharmacology
- Journal of Pharmacy and Pharmacology Research
- Pharmaceutical Biology
- Journal of Cardiovascular Pharmacology
- Reviews on Recent Clinical Trials
- Combination Products in Therapy

- Food and Chemical Toxicology
- Cell Biology and Toxicology
- Review for the Biochemistry and Cell Biology
- Fundamental and Clinical Pharmacology
- Expert Opinion in Pharmacotherapy
- Expert Opinion On Drug Metabolism and Toxicology
- Expert Opinion On Drug Safety
- Expert Opinion on Biological Therapies
- Molecules
- Biomedicine
- Diseases
- Open access Journal of Clinical Trials
- Therapeutics and Clinical Risk Management
- Trials
- Life Sciences
- International Journal of Molecular Sciences
- Evidence Based Complementary & Alternative Medicine
- BMC Complementary and Alternative Medicine
- International Journal of Public Health
- BMC Public Health
- Journal of Epidemiology and Community Health
- Clinical Epidemiology
- Journal of Public Health
- Journal of Clinical Rheumatology
- World Journal of Meta-analysis

He is also Member of the Editorial Board of “Clinical Lipidology” and “Current Topics in Nutraceutical Research”.

#### **Technical skills:**

- *Language spoken:* Italian (mother-language), French, English, German (Basic)
- *Software used:* All common softwares associated to Microsoft Office, Statistical Software for Social Science (SPSS), some pharmacokinetic softwares

**GCP :** He has been trained to the GCP at national and international level (see list of GCP courses he attended) and participated in a large number of RCTs carried out in the context of GCP.

#### ***List of publications***

**Papers published on international scientific journals** [N. 427, Total 2020 IF>2200, Scholar h-index= 70, Scopus h-index = 55, WOS h-index= 51 (update 12/2021)]

#### **2000-2002**



1. **Cicero AF**, Bandieri E, Arletti R. Orally administered *Panax notoginseng* influences rat spontaneous behaviour. *Journal of Ethnopharmacology* (J Ethnopharmacol.) 2000; **73(3)**: 387-391.
2. **Cicero AF**, Braiato A, D'Addato S, Sangiorgi Z, Gaddi A. A suggestion for Familial Hypercholesterolemia (FH) heterozygosity clinical diagnosis based on an epidemiological observation in a large Italian population. *International Journal of Cardiology* (Int J Cardiol.) 2000; **74(1)**: 5-11.
3. Gaddi A, Berto P, Mussoni C, **Cicero AF**, D'Addato S, Cantagalli F. Antihyperlipidaemic drugs: the results of a Drug Utilisation Review (DUR) research in the Bologna area. *Clinical Drug Investigation* (Clin Drug Invest.) 2000; **19(6)**: 457-464.
4. **Cicero AF**, Bandieri E, Arletti R. *Lepidium meyenii* Walp. improves sexual behaviour in male rats independently from its action on spontaneous locomotor activity. *Journal of Ethnopharmacology* (J Ethnopharmacol.) 2001; **75(2-3)**: 225-229.
5. **Cicero AF**, Gaddi A. Rice Bran oil and  $\beta$ -oryzanol in the treatment of hyperlipoproteinemias and other conditions. *Phytotherapy Research* (Phytother Res.) 2001; **15(4)**: 277-289.
6. **Cicero AF**, Martini C, Fiorito A, Gaddi A. Case Problem: Dietary treatment for children with hyperlipidemia. *Journal of the American Dietetic Association* (J Am Diet Ass.) [currently Journal of the Academy of Nutrition and Dietetics] 2001; **101(6)**: 693-696.
7. Gaddi A, **Cicero AF**, Dormi A, Pasquarelli V, D'Addato S. The realisation of a project aimed at reducing the plasmatic lipid level in a large Italian rural population improves the mean calcium daily intake: the Brisighella Study (BS). *European Journal of Clinical Nutrition* (Eur J Clin Nutr.) 2001; **55(2)**: 97-106.
8. Pini LA, **Cicero AF**, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesics overuse. *Cephalalgia* 2001; **21(9)**: 878-883.
9. Pini LA, **Cicero AF**. Triptans: the experience of a clinical pharmacologist in clinical practice. *Journal of Headache and Pain* (J Headache Pain) 2001; **2(S1)**: 103-106.
10. **Cicero AF**, Fiorito A, Panourgia MP, Sangiorgi Z, Gaddi A. Effects of a new soy/ $\beta$ -sitosterol supplement on plasma lipids in moderately hypercholesterolemic subjects. *Journal of the American Dietetic Association* (J Am Diet Ass.) [currently Journal of the Academy of Nutrition and Dietetics] 2002; **102(12)**: 1807-1811.
11. **Cicero AF**, Piacente S, Plaza A, Sala E, Arletti R, Pizza C. Hexanic Maca extract improves rat sexual performance more effectively than methanolic and chloroformic Maca extracts. *Andrologia* 2002;**34(3)**:177-9.
12. Gaddi A, **Cicero AF**, Poli A, Nascetti S, Inzitari D on behalf of the Italian Study Group for the study of Dysmetabolic Diseases and Atherosclerosis. Cerebrovascular disease in Italy and Europe: it is necessary to prevent a "pandemia". *Journal of Cardiovascular Risk* (J Cardiovasc Risk) [currently European Journal of Preventive Cardiology] 2002; **9(3)**: 143-5. [Editorial]
13. Pini LA, **Cicero AF**, Sandrini M. Long-term follow-up of patients treated for chronic headache with analgesics overuse [Author's reply]. *Cephalalgia* 2002; **22(4)**: 327-328.

### 2003

14. **Cicero AF**, Derosa G, Gaddi A. Homocysteine and cardiovascular risk. *Journal of Headache and Pain* (J Headache Pain) 2003; **4(3)**: 171-172.
15. **Cicero AF**, Forghieri M, Arletti R. Hypercholesterolemia underdiagnosis and undertreatment in psychiatric patients in Italy. *European Journal of Epidemiology* (Eur J Epidemiol.) 2003; **18(4)**: 373-374.
16. **Cicero AF**, Panourgia MP, Linarello S, D'Addato S, Sangiorgi Z, Gaddi A. Serum lipoprotein(a) levels in a large sample of subjects affected by familial combined hyperlipoproteinemia (FCH) and in general population. *Journal of Cardiovascular Risk* (J Cardiovasc Risk) [currently European Journal of Preventive Cardiology] 2003; **10(2)**: 149-151.

17. **Cicero AF**, Panourgia MP, Nascetti S, Sangiorgi Z, Gaddi A. Asymptomatic massive hypertriglyceridemia in an octogenarian. *Medical Principles and Practice* (Med Princ Pract.) 2003;**12(1)**: 51-53.
18. **Cicero AF**, Vitale G, Savino G, Arletti R. *Panax notoginseng* (Burk.) effects on fibrinogen and lipid plasma level in rats fed on a high-fat diet. *Phytotherapy Research* (Phyther Res.) 2003; **17(2)**: 174-178.
19. Derosa G, **Cicero AF**, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. A randomized, double-blind, controlled parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. *Clinical Therapeutics* (Clin Ther.) 2003; **25(7)**: 2006-2021.
20. Derosa G, **Cicero AF**, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. The effect of L-carnitine on plasma lipoprotein (a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. *Clinical Therapeutics* (Clin Ther.) 2003; **25(5)**: 1429-1439.
21. Derosa G, **Cicero AF**, Mugellini A, Ciccarelli L, Fogari R. Perindopril and Candesartan comparative efficacy and safety in type 2 diabetic hypertensive patients. *Journal of Human Hypertension* (J Hum Hypertens.) 2003; **17(6)**: 433-435.
22. Gaddi A, **Cicero AF**, Nascetti S, Poli A, Inzitari D on behalf of the Italian Study Group for the study of Dysmetabolic Diseases and Atherosclerosis. Cerebrovascular disease in Italy and Europe: it is necessary to prevent a "pandemia". *Gerontology* 2003; **49(2)**: 69-79. [Review]
23. Gaddi A, Poli A, **Cicero AF**, Inzitari D on behalf of the Italian Study Group for the study of Dysmetabolic Diseases and Atherosclerosis. It is necessary to prevent a cerebrovascular "pandemia". *Cerebrovascular Disease* (Cerebrovasc Dis.) 2003; **15(1-2)**: 152-153. [Letter]
24. Sternieri E, Ferrari A, **Cicero AF**. Clinical considerations preliminary to the application of the Italian Society for the Study of Headache Guidelines regarding the Migraine Prophylactic Treatment. *Journal of Headache and Pain* (J Headache Pain) 2003; **4(1)**: 14-17.

## 2004

25. **Cicero AF**, Derosa G, Arletti R. Effect of oral chronic isoflavones supplementation on male rat sexual performances and sexual hormone plasma levels. *Phytotherapy Research* (Phyther Res) 2004; **18**: 849-852.
26. **Cicero AF**, Derosa G, Brillante R, Mirembe S, Nascetti S, Gaddi A. Effects of Siberian ginseng (*Eleutherococcus senticosus* maxim.) on elderly quality of life: a randomized clinical trial. *Archives of Gerontology and Geriatrics* (Arch Gerontol Geriatr.) 2004; **38S**: 69-73.
27. **Cicero AF**, Derosa G, Gaddi A. What herbalists suggest to our diabetic patients in order to improve their glycaemic control? Evaluation of scientific evidences and potential risks. *Acta Diabetologica* (Acta Diabetol.) 2004; **41(3)**: 91-98.
28. **Cicero AF**, Minardi M, Mirembe S, Pedro E, Gaddi A. Effects of a new low dose soy protein/□-sitosterol association on plasma lipid levels and oxidation. *European Journal of Nutrition* (Eur J Nutr.) 2004; **43(5)**: 319-322.
29. Derosa G, **Cicero AF**, Bertone G, Piccinni MN, Fogari E, Ciccarelli L, Fogari R. Comparison of the effects of telmisartan and nifedipine gastrointestinal therapeutic system on blood pressure control, glucose metabolism, and the lipid profile in patients with type 2 diabetes mellitus and mild hypertension: a 12-month, randomized, double-blind study. *Clinical Therapeutics* (Clin Ther.) 2004; **26(8)**: 1228-1236.
30. Derosa G, **Cicero AF**, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinini MN. Metabolic effects of Pioglitazone and Rosiglitazone in patients with diabetes and metabolic syndrome treated with Glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. *Clinical Therapeutics* (Clin Ther.) 2004; **26(5)**: 744-754.
31. Derosa G, **Cicero AF**, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month,

randomized, double-blind, controlled trial. *Clinical Therapeutics* (Clin Ther.) 2004; **26(10)**: 1599-607.

32. Ferrari A, Pasciullo G, Savino G, **Cicero AF**, Ottani A, Bertolini A, Sternieri E. Headache treatment before and after the consultation of a specialized centre: a pharmacoepidemiology study. *Cephalalgia* 2004; **24(5)**: 356-362.
33. Gaddi A, **Cicero AF**, Pedro E. Clinical perspectives of anti-inflammatory therapy in the elderly: the Lox-/Cox- inhibition concept. *Archives of Gerontology and Geriatrics* (Arch Gerontol Geriatr.) 2004; **38(3)**: 201-212. [Review]

## 2005

34. **Cicero AF**, Derosa G. Rice bran and its main components: potential role in the management of cardiovascular disease risk. *Current Topics in Nutraceutical Research* (Curr Topics Nutraceut Res.) 2005; **3(1)**: 29-46.
35. **Cicero AF**, Derosa G, Gaddi A. Combined Lipoxygenase/Cicloxygenase inhibition in the elderly: the example of Licofelone. *Drug Aging* 2005; **22(5)**: 393-403.
36. **Cicero AF**, Derosa G, Gaddi A. Statin and IMT. *Diabetes Care* (Diab Care) 2005; **28(5)**: 1262-1263.
37. **Cicero AF**, Derosa G, Miconi A, Laghi L, Nascetti S, Gaddi A. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. *Biomedicine & Pharmacotherapy* (Biomed Pharmacother.) 2005; **59(6)**: 312-317.
38. **Cicero AF**, Brancaloni M, Laghi L, Donati F, Mino M. Antihyperlipidaemic effect of a *Monascus purpureus* brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. *Complementary Therapy in Medicine* (Complem Ther Med.) 2005; **13(4)**: 273-278.
39. **Cicero AF**, Derosa G, Miconi A, Laghi L, Nascetti S, Gaddi A. Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10? *BioFactors* 2005; **23(1)**: 7-14.
40. **Cicero AF**, Dormi A, Nascetti S, D'Addato S, Gaddi A. Relative role of major risk factors for Type 2 Diabetes development in the historical cohort of the Brisighella Heart Study: an 8-years follow-up. *Diabetic Medicine* (Diabetic Med.) 2005; **22(9)**: 1263-1266.
41. **Cicero AF**, Gaddi A. REVERSAL and PROVE-IT: are clinically oriented trials really better than "pure" scientific studies? *International Journal of Cardiology* (Int J Cardiol.) 2005; **103(3)**: 135-137. [Editorial]
42. Derosa G, **Cicero AF**, D'Angelo A, Gaddi A, Ragonesi PD, Piccinni MN, Salvadeo S, Ciccarelli L, Pricolo F, Ghelfi M, Ferrari I, Montagna L, Fogari R. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. *Hypertension Research* (Hypertens Res.) 2005; **28(11)**: 917-924
43. Derosa G, **Cicero AF**, Gaddi A, Mugellini A, Ciccarelli L, Fogari R. Effects of Doxazosin and Irbesartan on Blood Pressure and Metabolic Control in Patients with Type 2 Diabetes and Hypertension. *Journal of Cardiovascular Pharmacology* (J Cardiovasc Pharmacol.) 2005; **45(6)**: 599-604.
44. Derosa G, **Cicero AF**, Gaddi A, Ragonesi PD, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R. A comparison of the effects of Pioglitazone and Rosiglitazone combined with Glimepiride on prothrombotic state in patients with the metabolic syndrome. *Diabetes Research and Clinical Practice* (Diab Res Clin Pract.) 2005; **69(1)**: 5-13.
45. Derosa G, **Cicero AF**, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo S, Pricolo F, Fogari E, Ghelfi M, Ferrari I, Fogari R. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial. *Clinical Therapeutics* (Clin Ther.) 2005; **27(9)**: 1383-1391.

46. Derosa G, **Cicero AF**, Murdolo G, Piccinni MN, Fogari E, Bertone G, Ciccarelli L, Fogari R. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. *Diabetes, Obesity and Metabolism* (Diabetes Obes Metab.) 2005; **7(1)**: 47-55.
47. Derosa G, Gaddi A, Piccinni MN, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, **Cicero AF**. Antithrombotic effects of combination rosiglitazone-metformin vs. combination glimepiride-metformin therapy in patients with type 2 diabetes and metabolic syndrome. *Pharmacotherapy* 2005; **25(5)**: 637-645.
48. Derosa G, Gaddi AV, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, **Cicero AF**. Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: a randomized, double-blind clinical trial. *Journal of International Medical Research* (J Int Med Res.) 2005; **33(3)**: 284-294.
49. Ferrari A, Ottani A, Bertolini A, **Cicero AF**, Coccia CPR, Leone S, Sternieri E. Adverse reactions related to drugs for headache treatment: clinical impact. *European Journal of Clinical Pharmacology* (Eur J Clin Pharmacol.) 2005; **60**: 893-900.

## 2006

50. **Cicero AF**, Nascetti S, Noera G, Gaddi AV for the Massalombarda Project Team. Metabolic Syndrome prevalence in Italy. *Nutrition Metabolism and Cardiovascular Disease* (Nutr Metab Cardiovasc Dis) 2006; **16(6)**: e5-6.
51. Derosa G, **Cicero AF**, D'Angelo A, Tinelli C, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Ghelfi M, Gravina A, Ferrari I, Galli S, Paniga S, Fogari R. Effect of doxazosin on C-reactive protein plasma levels in patients with hypertension. *Journal of Cardiovascular Pharmacology* (J Cardiovasc Pharmacol) 2006; **47(4)**: 508-512.
52. Derosa G, **Cicero AF**, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Ferrari I, Gravina A, Fogari R. Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. *Hypertension Research* (Hypertens Res) 2006; **29(11)**: 849-856. doi: [10.1291/hyres.29.849](https://doi.org/10.1291/hyres.29.849)
53. Derosa G, **Cicero AF**, D'Angelo A, Gaddi AV, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. *Clinical Therapeutics* (Clin Ther) 2006; **28(5)**: 679-688.
54. Derosa G, **Cicero AF**, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Ferrari I, Gravina A, Fogari R. Synergistic effect of doxazosin and acarbose in improving metabolic control in subjects with impaired glucose tolerance. *Clinical Drug Investigation* (Clin Drug Invest) 2006; **26(9)**: 529-539.
55. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, **Cicero AF**. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. *Journal of Clinical Pharmacy and Therapeutics* (J Clin Pharm Ther) 2006; **31(4)**: 375-383.
56. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, **Cicero AF**. Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. *Journal of International Medical Research* (J Int Med Res) 2006; **34(5)**: 545-555.
57. Derosa G, Gaddi AV, Piccinni MN, Bertone G, Ciccarelli L, Fogari E, Ghelfi M, Ferrari I, **Cicero AF**. Differential effect of Glimepiride and Rosiglitazone on metabolic control of Type 2 diabetic patients treated with Metformin: a randomised, double-blind, clinical trial. *Diabetes, Obesity and Metabolism* (Diabetes Obes Metab) 2006; **8(2)**: 197-205.

58. Ferrari A, **Cicero AF**, Bertolini A, Leone S, Pasciullo G, Sternieri E. Need for analgesics/drugs of abuse: a comparison between headache patients and addicts by the Leeds Dependence questionnaire (LDQ). *Cephalalgia* 2005; **26(2)**: 187-193
59. Micali S, Sighinolfi MC, De Stefani S, Grande M, **Cicero AF**, Bianchi G. Can *Phyllanthus niruri* (Uriston ®) affect the efficacy of extracorporeal shock wave lithiotripsy or renal stones. A randomised, prospective, long-term study. *Journal of Urology* (J Urol.) 2006; **176(3)**: 1020-1022.
60. Sighinolfi MC, Mofferdin A, De Stefani S, Celia A, Micali S, **Cicero AF**, Bianchi G. Changes in peak systolic velocity induced by chronic therapy with phosphodiesterase type 5 inhibitor. *Andrologia* 2006; **38(3)**: 84-86.
61. Sulikowska B, Olejniczak H, Muszynska M, Odrowaz-Sypniewska G, Gaddi AV, Savini C, **Cicero AFG**, Laghi L, Manitius J. Effect of Sulodexide on Albuminuria, NAG Excretion and Glomerular Filtration Response to Dopamine in Diabetic Patients. *American Journal of Nephrology* (Am J Nephrol.) 2006; **26(6)**: 621-628.

## 2007

62. Borghi C, Veronesi M, Cosentino E, **Cicero AF**, Kuria F, Dormi A, Ambrosioni E. Interaction between serum cholesterol levels and the renin-angiotensin system on the new onset of arterial hypertension in subjects with high-normal blood pressure. *Journal of Hypertension* (J Hypertens) 2007; **25(10)**: 2051-2057.
63. **Cicero AF**, Bove M, Manca M, Borghi C, Gaddi AV. Detection of Familial Combined Hyperlipoproteinemia patients in the Brisighella Heart Study historical cohort: an epidemiological approach. *Journal of Inherited Metabolic Diseases* (J Inherit Metab Dis.) 2007; **30(2)**: 268.
64. **Cicero AF**, Derosa G, Manca M, Bove M, Borghi C, Gaddi AV. Different effect of psyllium and guar dietary supplementation on blood pressure control in hypertensive overweight patients: a 6-month, randomized clinical trial. *Clinical and Experimental Hypertension* (Clin Exp Hypert.) 2007; **29**: 1-12.
65. **Cicero AF**, Laghi L. Activity and role of Licofelone in osteoarthritis. *Clinical Interventions in Aging* (Clin Interv Aging) 2007; **2(1)**: 73-79.
66. Derosa G, **Cicero AF**, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, Fassi R, Fogari R. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan on diabetic hypertensive patients: a sequential, double-blind, randomized clinical trial. *Clinical Therapeutics* (Clin Ther) 2007; **29(4)**: 602-610.
67. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, **Cicero AF**. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. *Internal Medicine Journal* (Intern Med J) 2007; **37(2)**: 79-86.
68. Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, **Cicero AF**. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. *Internal Medicine* (Intern Med) 2007; **46(22)**: 1837-1846.
69. Derosa G, D'Angelo A, Scalise F, Avanzini MA, Tinelli C, Peros E, Fogari E, **Cicero AF**. Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. *Heart and Vessels* (Heart Vessel) 2007; **22(6)**: 361-370.
70. Derosa G, Fogari E, **Cicero AF**, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Gravina A, Ferrari I, Fogari R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. *Hypertension Research* (Hypertens Res) 2007; **30(5)**: 387-94.
71. Derosa G, Fogari E, D'Angelo A, **Cicero AF**, Salvadeo SAT, Ragonesi PD, Ferrari I, Gravina A, Fassi R, Fogari R. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. *Journal of Clinical Pharmacy and Therapeutics* (J Clin Pharm Ther) 2007; **32(2)**: 261-268.

72. Derosa G, D'Angelo A, Tinelli C, Devangelio E, Consoli A, Miccoli R, Penno G, Del Prato S, Paniga S, **Cicero AF**. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. *Diabetes et Metabolism (Diabetes Metab)* 2007; **33(2)**: 129-134.
73. Prandin MG, **Cicero AF**, Veronesi M, Cosentino E, Dormi A, Strocchi E, Claudio Borghi. Persistence on treatment and blood pressure control with different first-line antihypertensive treatments: A prospective evaluation. *Clinical & Experimental Hypertension (Clin Exp Hypertens)* 2007; **29(8)**:553-62
74. Sighinolfi MC, Mofferdin A, De Stefani S, Micali S, **Cicero AF**, Bianchi G. Immediate improvement in penile hemodynamics after cessation of smoking: previous results. *Urology* 2007; **69(1)**: 163-165.

## 2008

75. **Cicero AF**, Nascetti S, López-Sabater MC, Elosua R, Salonen JT, Nyssönen K, Poulsen HE, Zunft HJF, Kiesewetter H, de la Torre K, Covas MI, Kaikkonen J, Mursu J, Koenbick C, Bäuml H, Gaddi AV for the EUROLIVE Study Group. Changes in LDL fatty acid composition as a response to olive oil treatment are inversely related with the lipid oxidative damage: the EUROLIVE Study. *Journal of the American College of Nutrition (J Am Coll Nutr)* 2008; **27(2)**: 314-320.
76. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, **Cicero AF**. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. *Metabolism*. 2008; **57(11)**: 1552-1557.
77. Derosa G, Salvadeo SA, D'Angelo A, Fogari E, Ragonesi PD, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, **Cicero AF**. Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. *Archives of Medical Research (Arch Med Res)* 2008; **39(4)**:412-419.
78. Poli A, Marangoni F, Paoletti R, Mannarino E, Lupattelli G, Notarbartolo A, Aureli P, Bernini F, **Cicero AF**, Gaddi AV, Catapano A, Cricelli C, Gattone M, Marrocco W, Porrini M, Stella R, Vanotti A, Volpe M, Volpe R, Cannella C, Pinto A, Del Toma E, La Vecchia C, Tavani A, Manzato E, Riccardi G, Sirtori C, Zambon A; Nutritional Foundation of Italy. Non-pharmacological control of plasma cholesterol levels. *Nutrition Metabolism and Cardiovascular Disease (Nutr Metab Cardiovasc Dis)* 2008; **18**: S1-S16.

## 2009

79. Borghi C, **Cicero AF**, Bacchelli S, Degli Esposti D, Ambrosioni E on behalf of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Serum cholesterol levels on admission and survival in patients with acute myocardial infarction treated with zofenopril: a post-hoc analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) trial. *Fundamental and Clinical Pharmacology (Fund Clin Pharmacol)* 2009; **23(5)**: 641-648.
80. **Cicero AF**, Derosa G, Bove M, Di Gregori V, Gaddi AV, Borghi C. Effect of a sequential training program on inflammatory, prothrombotic and vascular remodelling biomarkers in hypertensive overweight patients with or without metabolic syndrome. *European Journal of Cardiovascular Prevention and Rehabilitation (Eur J Cardiovasc Prev Rehab)* [currently European Journal of Preventive Cardiology] 2009; **16(6)**: 698-704
81. **Cicero AF**, Derosa G, D'angelo A, Bove M, Gaddi AV, Borghi C. Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. *Blood Pressure (Blood Press)* 2009; **18(3)**: 111-116.
82. **Cicero AF**, Derosa G, Gaddi AV. Re: The influence of statin medications on Prostate Specific Antigen levels. *Journal of National Cancer Institute (J Natl Cancer Inst)* 2009; **101(8)**: 610
83. **Cicero AF**, Derosa G, Bove M, Imola F, Borghi C, Gaddi AV. Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and

- without metabolic syndrome. *Current Topics in Nutraceutical Research* (Curr Topics Nutr Res) 2009; **7(3-4)**: 121-126.
84. **Cicero AF**, Ertek S, Borghi C. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. *Current Vascular Pharmacology* (Curr Vasc Pharmacol) 2009; **7(3)**: 330-337. doi: 10.2174/157016109788340659#sthash.pzsMChEy.dpuf
85. **Cicero AF**, Veronesi M, Prandin MG, Di Gregori V, Ambrosioni E, Borghi C. Effects of AT1 receptor and beta1 receptor blocking on blood pressure, peripheral hemodynamic and lipid profile in statin treated hypertensive hypercholesterolemic patients. *Fundamental and Clinical Pharmacology* (Fund Clin Pharmacol) 2009; **23(5)**: 583-8.
86. Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, **Cicero AF**. Efficacy and safety of ezetimibe/simvastatin association on non diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. *Journal of Clinical Pharmacy and Therapeutics* (J Clin Pharm Ther) 2009; **34(3)**: 267-276.
87. Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, **Cicero AF**. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin. *Journal of Clinical Pharmacy and Therapeutics* (J Clin Pharm Ther) 2009;**34(1)**:13-23.
88. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, **Cicero AF**. Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. *Biomedicine Pharmacotherapy* (Biomed Pharmacother) 2009; **63(10)**: 723-33
89. Derosa G, Ferrari I, **Cicero AF**. Irbesartan and hydrochlorothiazide association in the treatment of hypertension. *Current Vascular Pharmacology* (Curr Vasc Pharmacol) 2009; **7(2)**: 120-136.
90. Derosa G, Ferrari I, D'Angelo A, Salvadeo SA, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, **Cicero AF**. Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. *Heart Vessels*. 2009; **24(3)**: 204-210.
91. Derosa G, Maffioli P, D'Angelo A, Salvadeo SAT, Ferrari I, Fogari E, Mereu R, Gravina A, Palumbo I, Randazzo S, **Cicero AF**. Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-day insulin injections therapy (MDI). *Endocrine Journal* (Endocr J) 2009; **56 (4)**: 571-578
92. Derosa G, Maffioli P, D'Angelo A, Salvadeo SAT, Ferrari I, Fogari E, Gravina A, Mereu R, Randazzo S, **Cicero AF**. Effects of long chain  $\omega$ -3 fatty acids on metalloproteinases and their inhibitors in combined dyslipidemia patients. *Expert Opinion in Pharmacotherapy* (Expert Opin Pharmacother) 2009; **10(8)**: 1239-47.
93. Derosa G, Maffioli P, D'Angelo A, Salvadeo SAT, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Randazzo S, **Cicero AF**. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. *Clinical and Investigative Medicine*. (Clin Invest Med.) 2009; **32(2)**: E124.
94. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, **Cicero AF**. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. *Metabolism*. 2009; **58(8)**: 1059-1066.
95. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, **Cicero AF**. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. *Current Medical Research and Opinion* (Curr Med Res Opin) 2009; **25(8)**: 1973-1983.
96. Derosa G, Mereu R, Salvadeo SAT, D'Angelo A, Ciccarelli L, Piccinni MN, Ferrari I, Gravina A, Maffioli P, **Cicero AF**. Pioglitazone Metabolic Effect in Metformin-Intolerant Obese Patients Treated with Sibutramine. *Internal Medicine* (Intern Med) 2009; **48(5)**: 265-271.
97. Derosa G, Salvadeo SAT, D'Angelo A, Ferrari I, Mereu R, Palumbo I, Maffioli P, Randazzo S, **Cicero AF**. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic

treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. *Current Medical Research and Opinion* (Curr Med Res Opin) 2009; **25(3)**: 607–615.

98. Sighinolfi MC, Micali S, Stefani SD, **Cicero AF**, Cianci F, Giacometti M, Bianchi G. Retrospective descriptive analysis of the physiological kinetics of prostate-specific antigen in men older than 75 years. *Asian Journal of Andrology* (Asian J Androl). 2009; **11(4)**:493-7.
99. Zenico T, **Cicero AF**, Valmorri L, Mercuriali M, Bercovich E. Subjective effects of *Lepidium Meyenii* (Maca) extract on wellbeing and sexual performances in patients with mild erectile dysfunction: a randomized, double-blind clinical trial. *Andrologia* 2009; **41(2)**: 95-99

## **2010**

100. Borghi C, **Cicero AF**. Rationale for the use of fixed-dose combination in the management of hypertension: efficacy and tolerability of lercanidipine plus enalapril. *Clinical Drug Investigation* (Clin Drug Invest) 2010; **30(12)**: 843-854.
101. Bove M, **Cicero AF**, Grandi E, Carnevali L, Gaddoni M, Noera G, Gaddi AV. Psychosocial factors and metabolic parameters: is there any association in elderly people? The Massa Lombarda Project. *Aging & Mental Health* 2010; **14(7)**: 801-6.
102. **Cicero AF**, Derosa G, Borghi C. Red yeast rice and statin-intolerant patients. *American Journal of Cardiology* (Am J Cardiol) 2010; **105(10)**: 1504.
103. **Cicero AF**, Derosa G, Di Gregori V, Bove M, Gaddi AV, Borghi C. Omega 3 Polyunsaturated Fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study. *Clinical and Experimental Hypertension* (Clin Exp Hypertens) 2010; **32(2)**:137-44
104. **Cicero AF**, Dormi A, D'Addato S, Gaddi AV, Borghi C, on behalf of the Brisighella Heart Study Group. Long-term effect of a dietary education program on postmenopausal cardiovascular risk and metabolic syndrome: The Brisighella Heart Study. *Journal of Women's Health* (J Women Health) 2010; **19(1)**: 133-137.
105. **Cicero AF**, Ertek S. Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans. *Archives of Medical Science* (Arch Med Sci) 2010; **6(4)**: 469-477.
106. **Cicero AF**, Rosticci M, Veronesi M, Bacchelli S, Strocchi E, Melegari C, Grandi E, Borghi C. Haemodynamic effects of Lactotripeptides from casein hydrolysate in Mediterranean normotensive subjects and patients with high-normal blood pressure: a randomized, double-blind, cross-over clinical trial. *Journal of Medicinal Food* (J Med Food) 2010; **13(6)**: 1363-1368.
107. **Cicero AF**. Body weight loss and blood pressure normalization: early intervention to “heal” from hypertension? *Hypertension Research* (Hypertens Res); 2010; **33(3)**: 195-6.
108. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, **Cicero AF**. Oral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patients. *Hormones and Metabolic Research* (Horm Metab Res) 2010; **42(1)**: 8-13.
109. Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, **Cicero AF**. Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. *Microvascular Research* (Microvasc Res) 2010; **79(2)**:144-149.
110. Derosa G, Ferrari I, D'Angelo A, Salvadeo SA, Fogari E, Gravina A, Mereu R, Palumbo I, Maffioli P, Randazzo S, **Cicero AF**. Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. *Microvascular Research* (Microvasc Res) 2010; **80(1)**:110-5.
111. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, **Cicero AF**. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. *Metabolism*. 2010; **59(6)**: 887-95.



112. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, **Cicero AF**. Candesartan effect on inflammation in hypertension. *Hypertension Research* (Hypertens Res); 2010; **33(3)**: 209-13.
113. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, Fogari E, D'Angelo A, **Cicero AF**. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. *Hypertension Research* (Hypertens Res) 2010; **33(8)**: 790-5.
114. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Fogari E, Palumbo I, Randazzo S, **Cicero AF**. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. *Expert Opinion in Pharmacotherapy* (Expert Opin Pharmacother) 2010; **11(12)**: 1971-82.
115. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, **Cicero AF**. Exenatide versus glibenclamide in patients with diabetes. *Diabetes Technology and Therapeutics*. (Diabetes Technol Ther). 2010; **12(3)**: 233-40.
116. Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, **Cicero AF**. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. *Endocrine Journal* (Endocr J). 2010 **57(9)**: 777-786.
117. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, **Cicero AF**. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. *Internal Medicine* (Intern Med). 2010;**49(16)**: 1717-1725.
118. Derosa G, Mereu R, D'Angelo A, Salvadeo SA, Ferrari I, Fogari E, Gravina A, Palumbo I, Maffioli P, Randazzo S, **Cicero AF**. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin. *Journal of Clinical Pharmacy and Therapeutics* (J Clin Pharm Ther). 2010;**35(5)**:565-579.
119. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, **Cicero AF**. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. *Journal of Pharmacy and Pharmaceutical Sciences* (J Pharm Pharm Sci). 2010;**13(3)**:378-390.
120. Ertek S, **Cicero AF**, Caglar O, Erdogan G. Relationship between serum zinc levels, thyroid hormones and thyroid volume following successful iodine supplementation. *Hormones* 2010;**9(3)**:262-68
121. Prandin MG, **Cicero AF**, Dormi A, Veronesi M, Cosentino ER, Borghi C. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practise. *Nutrition, Metabolism & Cardiovascular Diseases* (Nutr Metab Cardiovasc Dis) 2010; **20(7)**:512-8.
122. Tomasoni L, Sitia S, Borghi C, **Cicero AF**, Ceconi C, Cecaro F, Morganti A, Colonna VD, Guazzi M, Morricone L, Malavazos AE, Marino P, Cavallino C, Shoenfeld Y, Turiel M. Effects of treatment strategy on endothelial function. *Autoimmunity Review* (Autoimmun Rev). 2010; **9(12)**: 840-844.

## 2011

123. Akgul Ercan E, Ertek S, Is G, Caglar O, Oztas E, **Cicero AF**, Alhan A, Cehreli S, Tore HF, Erdogan G. Factors Associated With Increased Carotid Intima-Media Thickness and Being Nondipper in Nonobese and Normotensive Young Patients Affected by PCOS. *Angiology*. 2011; **62(7)**: 543-548.
124. Borghi C, **Cicero AF**, Degli Esposti D, Immordino V, Bacchelli S, Rizzo N, Santi F, Ambrosioni E. Hemodynamic and neurohumoral profile in patients with different types of hypertension in pregnancy. *Internal and Emergency Medicine* (Int Emerg Med) 2011; **6(3)**: 227-234.

125. Borghi C, Cosentino ER, Rinaldi ER, Brandolini C, Rimondi MC, Veronesi M, **Cicero AF**, Dormi A, Pirodda A. Tinnitus in elderly patients and prognosis of mild-to-moderate congestive heart failure: a cross-sectional study with a long-term extension of the clinical follow-up. *BMC Medicine* 2011;**9**:80 doi:10.1186/1741-7015-9-80.
126. **Cicero AF**, Ertek S. Hypertension and diabetes incidence: attention to the confounding factors. *Hypertension Research (Hypertens Res)* 2011; **34(10)**: 1069-1070.
127. **Cicero AF**, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. *Journal of Human Hypertension (J Hum Hyper)* 2011; **25(7)**: 425-436.
128. **Cicero AF**, Magni P, Lentini P, Ruscica M, Dozio E, Strollo F, Borghi C for the Brisighella Heart Study Staff. Sex hormones and adipokines in healthy pre-menopausal, post-menopausal and elderly women, and in age-matched men: data from the Brisighella Heart Study. *Journal of Endocrinological Investigation (J Endocrinol Invest)* 2011; **34(7)**: e158-e162.
129. **Cicero AF**, Magni P, Moré M, Ruscica M, Dozio E, Steffani L, Borghi C, Strollo F, for the Brisighella Heart Study Staff. Adipokines and sexual hormones associated with the components of the metabolic syndrome in pharmacologically untreated subjects: data from the Brisighella Heart Study. *International Journal of Endocrinology (Int J Endocrinol)* 2011; 724816. doi:10.1155/2011/724816.
130. **Cicero AF**, Rosticci M, Gerocarni B, Bacchelli S, Veronesi M, Strocchi E, Borghi C. Lactotripeptides effect on office and 24-hour ambulatory blood pressure, blood pressure stress answer, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first degree hypertension: a randomized, double-blind, clinical trial. *Hypertension Research (Hypertens Res)* 2011; **34(9)**: 1035-1040. doi: 10.1038/hr.2011.92
131. Derosa G, Maffioli P, Ferrari I, Fogari E, D'Angelo A, Palumbo I, Randazzo S, Bianchi L, **Cicero AF**. Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. *European Journal of Pharmacology (Eur J Pharmacol.)* 2011; **651(1-3)**: 240-250.
132. Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, **Cicero AF**. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. *Fundamental and Clinical Pharmacology (Fundam Clin Pharmacol)*. 2011; **25(5)**: 642-651.
133. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, **Cicero AF**. Effects of combination of sibutramine and l-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. *Metabolism*. 2011; **60(3)**: 421-429.
134. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, Fogari E, D'Angelo A, **Cicero AF**. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. *Hypertension Research (Hypertens Res)* 2011; **34(1)**: 145-151.
135. Derosa G, Maffioli P, D'Angelo A, Fogari E, Bianchi L, **Cicero AF**. Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study. *Journal of Diabetes and its Complications (J Diabetes Complications)* 2011; **25(4)**: 258-266.
136. Derosa G, **Cicero AF**, Fogari E, D'Angelo A, Bianchi L, Maffioli P. Pioglitazone compared to Glibenclamide on lipid profile and inflammation markers in Type 2 diabetic patients during an oral fat load. *Hormones and Metabolic Research (Horm Metab Res.)* 2011; **43(7)**: 505-512.
137. Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, **Cicero AF**. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. *Journal of Clinical Pharmacy and Therapeutics (J Clin Pharm Ther)*. 2011; **36(5)**: 592-601.
138. Ertek S, **Cicero AF**, Erdogan G. Relationship between calcium metabolism, insulin like growth factor-1 and pulse pressure in normotensive, normolipidemic, non-diabetic subjects: a preliminary observation. *Archives of Medical Science (Arch Med Sci)* 2011; **7(5)**: 776-780.

139. Ertek S, **Cicero AF**, Cesur M, Akcil M, Altuner TK, Avcioglu U, Korkmaz ME. The severity of coronary atherosclerosis in diabetic and non-diabetic metabolic syndrome patients diagnosed according to different criteria and undergoing elective angiography. *Acta Diabetologica* (Acta Diabetol). 2011; **48(1)**: 21-27.

## **2012**

140. Borghi C, **Cicero AF**. Hypertension: management perspectives. *Expert Opinion on Pharmacotherapy* (Expert Opin Pharmacother) 2012; **13(14)**: 1999-2003.
141. Cianci A, **Cicero AF**, Colacurci N, De Leo V. Activity of isoflavones and berberine on vasomotor symptoms and lipid profile in menopausal women. *Gynecological Endocrinology* (Gynecol Endocrinol) 2012; **28(9)**: 699-702.
142. **Cicero AF**, D'Addato S, Veronesi M, Rosticci M, Santi F, Dormi A, Borghi C. Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample: the Brisighella Heart Study. *Journal of Hypertension* (J Hypertens) 2012; **30(3)**: 492-496.
143. **Cicero AF**, D'Addato S, Santi F, Ferroni A, Borghi C on behalf of the the Brisighella Heart Study group. Leisure-time physical activity and cardiovascular disease mortality: the Brisighella Heart Study. *Journal of Cardiovascular Medicine* (J Cardiovasc Med) 2012; **13(9)**: 559-564.
144. **Cicero AF**, De Sando V, Parini A, Borghi C. Polyunsaturated Fatty Acids application in internal medicine: beyond the established cardiovascular effects. *Archives of Medical Science* (Arch Med Sci) 2012; **8(5)**: 784-793. doi: 10.5114/aoms.2012.31613.
145. **Cicero AF**, Ferroni A, Ertek S. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. *Experimental Opinion on Drug Safety* (Expert Opin Drug Saf) 2012; **11(5)**: 753-766.
146. **Cicero AF**, Gerocarni B, Rosticci M, Borghi C. Blood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practice. *Clinical and Experimental Hypertension* (Clin Exp Hypertens) 2012; **34(2)**: 113-117.
147. **Cicero AF**, Magni P, Moré M, Ruscica M, Ruscica M, Strollo F, Borghi C for the Brisighella Heart Study Staff. Metabolic syndrome, adipokines and hormonal factors in pharmacologically untreated adult-elderly subjects from the Brisighella Heart Study historical cohort. *Obesity Facts* 2012; **5(3)**: 319-326.
148. **Cicero AF**, Reggi A. Prescription appropriateness in cardiovascular medicine: an ethical, clinical and pharmaco-economic approach. *Internal and Emergency Medicine* (Intern Emerg Med) 2012; **S1**:52-56.
149. **Cicero AF**, Tartagni E, Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. *Archives of Medical Science* (Arch Med Sci) 2012; **8(5)**: 907-917.
150. **Cicero AF**, Rosticci M, Ferroni A, Bacchelli S, Veronesi M, Strocchi E, Borghi C. Predictors of the short-term effect of Isoleucine-Proline-Proline/Valine-Proline-Proline lactotriptides from casein on office and ambulatory blood pressure in subjects with pharmacologically untreated high-normal blood pressure or first-degree hypertension. *Clinical and Experimental Hypertension* (Clin Exp Hypertens) 2012; **34(8)**: 601-605.
151. Derosa G, Ragonesi PD, Carbone A, Fogari E, Bianchi L, Bonaventura A, Romano D, **Cicero AF**, Maffioli P. Vildagliptin added to metformin on  $\beta$ -cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. *Diabetes Technology and Therapeutics* (Diabetes Technol Therap) 2012; **14(6)**: 475-484.
152. Derosa G, **Cicero AF**, Fogari E, D'Angelo A, Bonaventura A, Romano D, Maffioli P. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. *Journal of Clinical Lipidology* (J Clin Lipidol). 2012; **6(6)**: 553-564. doi: 10.1016/j.jacl.2012.02.010.

153. Derosa G, **Cicero AF**, D'Angelo A, Fogari E, Maffioli P. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. *Journal of Clinical Pharmacy and Therapeutics* (J Clin Pharm Ther.) 2012; **37(2)**: 187-195.
154. Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L, Bonaventura A, Romano D, **Cicero AF**, Maffioli P. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control,  $\beta$ -cell function and insulin resistance in type 2 diabetic patients. *Diabetes Research and Clinical Practice* (Diabetes Res Clin Pract). 2012; **98(1)**: 51-60.
155. Derosa G, Maffioli P, **Cicero AF**. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. *Expert Opinion on Biological Therapy* (Expert Opin Biol Ther.) 2012; **12(8)**: 1113-1124.
156. Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, **Cicero AF**, Maffioli P. Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: A 12-month, placebo-controlled study. *Expert Opinion in Pharmacotherapy* (Expert Opin Pharmacother) 2012; **13(18)**: 2581-2591.
157. Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, **Cicero AF**, Maffioli P. A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and  $\beta$ -cell function. *Expert Opinion in Pharmacotherapy* (Expert Opin Pharmacother) 2012; **13(17)**: 2433-2442.
158. Ertek S, Akgül E, **Cicero AF**, Kütük U, Demirtaş S, Cehreli S, Erdoğan G. 25-Hydroxy vitamin D levels and endothelial vasodilator function in normotensive women. *Archives of Medical Science* (Arch Med Sci) 2012; **8(1)**: 47-52.
159. Ertek S, Yılmaz NC, **Cicero AF**, Vurupalmaz Ö, Demiröz AS, Erdoğan G. Increasing diagnosis of thyroid papillary carcinoma follicular variant in South-East Anatolian region: comparison of characteristics of classical papillary and follicular variant thyroid cancers. *Endocrine Pathology* (Endocr Pathol) 2012; **23(3)**: 157-160.
160. Ertek S, **Cicero AF**. Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions. *Archives of Medical Science* (Arch Med Sci.) 2012; **8(5)**: 794-804
161. Pirodda A, **Cicero AF**, Borghi C. Kidney disease and inner ear impairment: a simpler and closer pathogenic analogy? *Internal and Emergency Medicine* (Intern Emerg Med.) 2012; **7(S2)**: 93-95.

## 2013

162. Borghi C, Ambrosioni E, Omboni S, **Cicero AF**, Bacchelli S, Esposti DD, Vinereanu D, Ambrosio G, Zava D; on behalf of the SMILE-4 Working Party. Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study. *Journal of Hypertension* (J Hypertens) 2013;**31(6)**:1256-64. doi: 10.1097/HJH.0b013e3283605cd8.
163. Borghi C, Ambrosioni E, Omboni S, **Cicero AF**, Bacchelli S, Degli Esposti D, Novo S, Vinereanu D, Ambrosio G, Reggiardo G, Zava D. Cost effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post-hoc analysis of the SMILE-4 study. *Value in Health* (Value Health) 2013;**16(3)**:A286-7. doi: 10.2147/CEOR.S43138. Borghi C, **Cicero AF**. How to avoid the depression of the adherence to antihypertensive treatment? *Journal of Hypertension* (J Hypertens.) 2013;**31**:1362-1363. doi: 10.1097/HJH.0b013e328362a34a. [Editorial]
164. Borghi C, Cosentino ER, Rinaldi ER, **Cicero AF**. Impact of Zofenopril and Ramipril on Cardiovascular Mortality in Patients with Chronic Heart Failure Patients. *American Journal of Cardiology* (Am J Cardiol.) 2013; **112(1)**: 90-93. doi: 10.1016/j.amjcard.2013.02.058.
165. Borghi C, Reggi A, Pavesi A, **Cicero AF**. Increased serum uric acid as a risk factor for cardiovascular diseases. *Current Obesity Report* (Curr Obes Rep.) 2013; **2**: 301–305  
10.1007/s13679-013-0067-6

166. **Cicero AF**, Aubin F, Azais-Braesco V, Borghi C. Do the lactotripeptides IPP&VPP lower systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. *American Journal of Hypertension* (Am J Hypertens) 2013; **26(3)**: 442-9. doi: 10.1093/ajh/hps044.
167. **Cicero AF**, Borghi C. Evidence of Clinically Relevant Efficacy for Dietary Supplements and Nutraceuticals. *Current Hypertension Reports* (Curr Hypertens Rep) 2013; **15(3)**:260-267. doi: 10.1007/s11906-013-0333-8.
168. **Cicero AF**, Reggi A, Tartagni E, Grandi E, D'Addato S, Borghi C on behalf of the Brisighella Heart Study. Dietary Determinants of Oxidized-Low-Density Lipoprotein Antibodies in a Sample of Pharmacologically Untreated Non-Smoker Subjects: Data from the Brisighella Heart Study. *Advances in Clinical and Experimental Medicine* (Adv Clin Exp Med) 2013; **22(1)**:69-76.
169. **Cicero AF**, D'Addato S, Reggi A, Marchesini Reggiani G, Borghi C, on behalf of the Brisighella Heart Study. Hepatic Steatosis Index and Lipid Accumulation Product as middle-term predictors of incident metabolic syndrome in a large population sample: data from the Brisighella Heart Study. *Internal and Emergency Medicine* (Intern Emerg Med) 2013; **8(3)**:265-7.
170. **Cicero AF**, D'Addato S, Reggi A, Marchesini G, Borghi C. on behalf of the Brisighella Heart Study. Gender difference in hepatic steatosis index and lipid accumulation product ability to predict incident metabolic syndrome in the historical cohort of the Brisighella Heart Study. *Metabolic Syndrome and Related Disorders* (Metab Syndr Relat Disord). 2013; **11(6)**: 412-6. doi: 10.1089/met.2012.0147.
171. **Cicero AF**, Derosa G, Maffioli P, Giovannini M, Grandi E, Borghi C. Influence of Metabolic Syndrome superposition on Familial Combined Hyperlipoproteinemia cardiovascular complication rate. *Archives of Medical Science* (Arch Med Sci) 2013; **9(2)**: 238-42. doi: 10.5114/aoms.2013.34537.
172. **Cicero AF**, Derosa G, Parini A, Maffioli P, D'Addato S, Reggi A, Giovannini M, Borghi C. Red yeast rice improves lipid pattern, hs-CRP and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. *Nutrition Research* (Nutr Res.) 2013; **33(8)**: 622-628. doi: 10.1016/j.nutres.2013.05.015.
173. **Cicero AF**, Derosa G, Maffioli P, Reggi A, Parini A, Rosticci M, Grandi E, Borghi C. Berberine induced improvement in Hepatic Steatosis Index in overweight dyslipidaemic patients treated with lipid-lowering nutraceuticals. *Current Topics in Nutraceutical Research* (Curr Topics Nutr Res) 2013; **11(1-2)**: 41-46. doi: 10.1016/j.nutres.2013.05.015.
174. **Cicero AF**, Tartagni E, Ferroni A, De Sando V, Grandi E, Borghi C. Combined nutraceutical approach to postmenopausal syndrome and vascular remodelling biomarkers. *Journal of Alternative and Complementary Medicine* (J Alt Compl Med) 2013; **19(2)**: 1-6. doi: 10.1089/acm.2011.0624.
175. Derosa G, Carbone A, D'Angelo A, Querci F, Fogari E, **Cicero AF**, Maffioli P. Variations in inflammatory biomarkers following the addition of Sitagliptin in patients with Type 2 Diabetes not controlled with Metformin. *Internal Medicine* (Intern Med.) 2013; **52(19)**: 2179-2187.
176. Derosa G, **Cicero AF**, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P. A comparison between sitagliptin or glibenclamide in addition to metformin + pioglitazone on glycaemic control and  $\beta$ -cell function: the triple oral therapy. *Diabetic Medicine* (Diabet Med.) 2013; **30(7)**: 846-854. doi: 10.1111/dme.12158.
177. Derosa G, **Cicero AF**, Franzetti IG, Querci F, Carbone A, Piccinni MN, D'Angelo A, Fogari E, Maffioli P. A Randomized, Double-Blind, Comparative Therapy Evaluating Sitagliptin Versus Glibenclamide in Type 2 Diabetes Patients Already Treated with Pioglitazone and Metformin: A 3-Year Study. *Diabetes Technology and Therapeutics* (Diabetes Technol Ther.) 2013; **15(3)**:214-222. doi: 10.1089/dia.2012.0272.
178. Derosa G, **Cicero AF**, Carbone A, Querci F, Fogari E, D'Angelo A, Maffioli P. Olmesartan/Amlodipine Combination Versus Olmesartan or Amlodipine Monotherapies on Blood Pressure and Insulin Resistance in a Sample of Hypertensive Patients. *Clinical and Experimental Hypertension* (Clin Exp Hypertens.) 2013; **35(5)**: 301-307.

179. Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, **Cicero AF**, Maffioli P. Evaluation of the positive effects on insulin-resistance and  $\beta$ -cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. *Pharmacological Research* (Pharmacol Res.) 2013;**73C**:20-26. doi: 10.1016/j.phrs.2013.04.005.
180. Derosa G, **Cicero AF**, Franzetti IG, Querci F, Carbone A, Ciccarelli L, D'Angelo A, Fogari E, Maffioli P. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy. *Canadian Journal of Physiology and Pharmacology* (Can J Physiol Pharmacol.) 2013;**91(9)**:724-32. doi: 10.1139/cjpp-2012-0300.
181. Ertek S, **Cicero AF**. Hyperthyroidism and cardiovascular complications: a narrative review on the basis of pathophysiology. *Archives of Medical Science* (Arch Med Sci.) 2013;**9(5)**:944–952. doi: 10.5114/aoms.2013.38685.
182. Favari E, Ronda N, Adorni MP, Zimetti F, Salvi P, Manfredini M, Bernini F, Borghi C, **Cicero AF**. ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects. *Journal of Lipid Research* (J Lipid Res.) 2013; **54(1)**: 238-243.
183. Maione D, **Cicero AF**, Bacchelli S, Cosentino E, Degli Esposti D, Senaldi R, Strocchi E, D'Addato S, Borghi C.  $VO_2$  kinetics in supra-anaerobic threshold constant tests allow the visualisation and quantification of the  $O_2$  saving after Cytochrome C oxidase inhibition by aerobic training or nitrate administration. *Physiological Research* (Physiol Res.) 2013; **62(6)**: 671-9.

## 2014

184. Borghi C, **Cicero AF**, Saragoni S, Buda S, Cristofori C, Lilli P, Degli Esposti L. Rate of control of LDL cholesterol and incident hypertension requiring antihypertensive treatment in hypercholesterolemic subjects in daily clinical practice. *Annals of Medicine* (Ann Med.) 2014;**46(2)**:97-102. doi: 10.3109/07853890.2013.870019
185. Borghi C, Cosentino ER, Rinaldi ER, **Cicero AF**. Uricemia and Ejection Fraction in elderly heart failure outpatients. *European Journal of Clinical Investigation* (Eur J Clin Invest.) 2014;**44(6)**:573-8. doi: 10.1111/eci.12273.
186. **Cicero AF**, Derosa G, Parini A, Baronio C, Borghi C. Factors associated with 2-year persistence in fully non reimbursed lipid-lowering treatments. *Atherosclerosis* 2014;**235(1)**:81-83. doi: 10.1016/j.atherosclerosis.2014.04.016.
187. **Cicero AF**, Derosa G, Borghi C. Cardiovascular drugs and mortality in hypertensive patients with atrial fibrillation: evidence of efficacy for a global approach. *Hypertension Research* (Hypertens Res.) 2014; **37(6)**:492-3. doi: 10.1038/hr.2014.64
188. **Cicero AF**, Derosa G. Are there mild and serious metabolic syndromes? The need for a graded diagnosis. *Journal of Cardiovascular Medicine* (J Cardiovasc Med.) 2014;**15(10)**:759-760. doi: 10.2459/JCM.000000000000169.
189. **Cicero AF**, Derosa G, Rosticci M, D'Addato S, Agnoletti D, Borghi C; on behalf of the Brisighella Heart Study group. Long-term predictors of impaired fasting glucose and type 2 diabetes in subjects with family history of type 2 diabetes: A 12-years follow-up of the Brisighella Heart Study historical cohort. *Diabetes Research and Clinical Practice* (Diabetes Res Clin Pract.) 2014;**104(1)**:183-188. doi: 10.1016/j.diabres.2014.02.005.
190. **Cicero AF**, Tartagni E, Ertek S. Role of nutraceuticals in the management of metabolic syndrome: from laboratory to bedside. *Current Vascular Pharmacology* (Curr Vasc Pharmacol.) 2014;**12(4)**:565-571. doi: 10.2174/15701611113119990120
191. **Cicero AF**, Salvi P, D'Addato S, Rosticci M, Borghi C for the Brisighella Heart Study group. Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. *Journal of Hypertension* (J Hypertens.) 2014;**32(1)**:57-64. doi: 10.1097/HJH.0b013e328365b916.
192. **Cicero AF**, Tartagni E, Ertek S. Safety and tolerability of injectable lipid-lowering drugs in advanced development: a review of available clinical data. *Expert Opinion on Drug Safety* (Expert Opin Drug Saf.) 2014; **13(8)**:1023-30.



193. **Cicero AF**, Tartagni E, Ertek S. Efficacy and safety profile of evolocumab (AMG145), an injectable inhibitor of the proprotein convertase subtilisin/kexin type 9: the available clinical evidence. *Expert Opinion on Biological Therapy* (Expert Opin Biol Ther.) 2014;**14(6)**:863-8.
194. **Cicero AF**, Rosticci M, Baronio C, Morbino M, Parini A, Grandi E, D'Addato S, Borghi C, on behalf of the Brisighella Heart Study Group. Serum LDL-Cholesterol levels and new-onset of arterial hypertension: an 8-years follow-up. *European Journal of Clinical Investigation* (Eur J Clin Invest.) 2014;**44(10)**:926-32. doi: 10.1111/eci.12325.
195. **Cicero AF**, Rosticci M, Parini A, Baronio C, D'Addato S, Borghi C for the Brisighella Heart Study group. Serum uric acid is inversely associated to estimated stroke volume and cardiac output in a large sample of pharmacologically untreated subjects: data from the Brisighella Heart Study. *Internal and Emergency Medicine* (Intern Emerg Med.) 2014;**9(6)**:655-60. doi: 10.1007/s11739-013-1016-9
196. **Cicero AF**, Rosticci M, Cagnati M, Urso R, Scapagnini G, Morbini M, Grandi E, D'Addato S, Borghi C; Brisighella Heart Study Group. Serum uric acid and markers of LDL-oxidation in non-smoker healthy subjects: data from the Brisighella Heart Study. *Polish Archives of Internal Medicine* (Pol Arch Med Wewn.) 2014;**124(12)**:661-668.
197. D'Addato S, **Cicero AF**, Rosticci M, Reggi A, Cristino S, Dormi A, Borghi C for the Brisighella Heart Study. Proinflammatory Chemokines in Healthy Elderly taking or not taking Simvastatin –Data from the Brisighella Heart Study. *Advances in Clinical and Experimental Medicine* (Adv Clin Exp Med.) 2014;**23(5)**:723–728.
198. Derosa G, Ragonesi PD, Fogari E, **Cicero AF**, Bianchi L, Bonaventura A, Romano D, Maffioli P. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation. *Fundamental and Clinical Pharmacology* (Fundam Clin Pharmacol.) 2014;**28(2)**:221-9. doi: 10.1111/fcp.12001
199. Malaguti M, Dinelli G, Leoncini E, Bregola V, Bosi S, **Cicero AF**, Hrelia S. Bioactive peptides in cereals and legumes: agronomical, biochemical and clinical aspects. *International Journal of Molecular Sciences* (IJMS) 2014; **15(11)**: 21120-21135. doi: 10.3390/ijms151121120.
200. Pirodda A, **Cicero AF**, Brandolini C, Borghi C. Inner ear symptoms: can we use them to approach cardiovascular diseases? *Internal and Emergency Medicine* (Intern Emerg Med.) 2014; **9(8)**: 825-7. doi: 10.1007/s11739-014-1130-3.
201. Scapagnini G, Davinelli S, Di Renzo L, De Lorenzo A, Olarte HH, Micali G, **Cicero AF**, Gonzalez S. Cocoa Bioactive Compounds: Significance and Potential for the Maintenance of Skin Health. *Nutrients*. 2014; **6(8)**: 3202-3213.
- 2015**
202. Borghi C, Morbini M, **Cicero AF**. Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine. *Journal of Cardiovascular Medicine* (J Cardiovasc Med.) 2015; **16(5)**:390-399. doi: 10.2459/JCM.0000000000000240.
203. Borghi C, Urso R, **Cicero AF**. The cost-effectiveness of irbesartan for hypertension. *Expert Review of Pharmacoeconomics & Outcomes Research* (Expert Rev Pharmacoecon Outcomes Res.) 2015; **15(2)**: 199-207. doi: 10.1586/14737167.2015.1018894
204. Caliceti C, Rizzo P, **Cicero AF**. Potential benefits of Berberine in the management of perimenopausal syndrome. *Oxidative Medicine and Cellular Longevity* (Ox Med Cell Long.) 2015; 2015:723093.
205. **Cicero AF**. Metamucil as an additional source of dietary fiber: impact of the quality of healthcare providers' recommendations on users' experience. *European Review for Medical and Pharmacological Sciences* (Eur Rev Med Pharm Sci.). 2015;**19(7)**:1297-304.
206. **Cicero AF**, Colletti A, Borghi C. Profile of evolocumab and its potential in the treatment of hyperlipidemia. *Drug Design, Development and Therapy* (DDDT) 2015;**9**:3073-82. doi: 10.2147/DDDT.S67498.

207. **Cicero AF**, Degli Esposti D, Immordino V, Morbini M, Baronio C, Rosticci M, Borghi C. Independent Determinants of Maternal and Fetal Outcomes in a Sample of Pregnant Outpatients With Normal Blood Pressure, Chronic Hypertension, Gestational Hypertension, and Preeclampsia. *Journal of Clinical Hypertension (J Clin Hypertens.)*. 2015;**17(10)**:777-82. doi: 10.1111/jch.12614.
208. **Cicero AF**, Derosa G, Borghi C. Is it time to implement a standardized oral glucose and fat load test to detect high-risk patients? *Atherosclerosis*. 2015;**243(1)**:346–347. doi: 10.1016/j.atherosclerosis.2014.10.085.
209. **Cicero AF**, Derosa G, Pisciotta L, Barbagallo C for the SISA-PUFACOL Study Group. Testing the short-term efficacy of a lipid-lowering nutraceutical in the setting of clinical practice: a multi-center study. *Journal of Medicinal Food (J Med Food.)* 2015;**18(11)**:1270-3. doi: 10.1089/jmf.2015.0024.
210. **Cicero AF**, Desideri G, Grossi G, Urso R, Rosticci M, D’Addato S, Borghi C, for the Brisighella Heart Study group. Serum uric acid and impaired cognitive function in a cohort of healthy young elderly: data from the Brisighella Study. *Internal and Emergency Medicine (Intern Emerg Med.)* 2015;**10(1)**:25-31. doi: 10.1007/s11739-014-1098-z.
211. **Cicero AF**, Morbini M, Borghi C. Do we need “new” omega 3 polyunsaturated fatty acids formulation? *Expert Opinion in Pharmacotherapy (Expert Opin Pharmacother.)* 2015;**16(3)**:285-288. doi:10.1517/14656566.2015.991308
212. **Cicero AF**, Rosticci M, Parini A, Morbini M, Urso R, Grandi E, Borghi C. Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. *Nutrition Journal (Nutrition J.)* 2015;**14(1)**:30.
213. **Cicero AF**, Rosticci M, Tocci M, Bacchelli S, Urso R, D’Addato S, Borghi C for the Brisighella Heart Study group. Serum uric acid and other short-term predictors of electrocardiographic alterations in the Brisighella Heart Study cohort. *European Journal of Internal Medicine (Eur J Intern Med.)* 2015; **26(4)**: 255-8. doi: 10.1016/j.ejim.2015.02.007.
214. **Cicero AF**, Tocci G. Metabolic approaches to antihypertensive treatment in diabetic patients. *Hypertension Research (Hypertens Res.)* 2015;**38**:802-803. doi: 10.1038/hr.2015.105.
215. Gitto S, Belli LS, Vukotic R, Lorenzini S, Airoidi A, **Cicero AF**, Vangeli M, Brodosi L, Martello Panno A, Di Donato R, Cescon M, Grazi GL, De Carlis L, Pinna AD, Bernardi M, Andreone P. Hepatitis C virus recurrence after liver transplantation: A 10-year evaluation. *World Journal of Gastroenterology (WJG)* 2015;**21(13)**:3912-20. doi: 10.3748/wjg.v21.i13.3912.
216. Maione D, **Cicero AF**, Bacchelli S, Cosentino ER, Degli Esposti D, Manners DN, Rinaldi ER, Rosticci M, Senaldi R, Ambrosioni E, Borghi C. The VO(2)-on kinetics in constant load exercise sub-anaerobic threshold reflects endothelial function and dysfunction in muscle microcirculation. *Physiological Research (Physiol Res.)*. 2015; **64(6)**:807-19.
217. Sirtori CR, Arnoldi A, **Cicero AF**. Nutraceuticals for blood pressure control. *Annals of Medicine (Ann Med.)* 2015; **47(6)**: 447-56. doi: 10.3109/07853890.2015.1078905.
218. Tocci G, **Cicero AF**, Salvetti M, Francia P, Ferrucci A, Borghi C, Volpe M. Attitudes and preferences for the clinical management of hypertension and hypertension-related cardiac disease in general practice: Results of the Italian Hypertension and Heart Survey. *Journal of Human Hypertension (J Hum Hypertens.)* 2015; **29(7)**:409-16. doi: 10.1038/jhh.2014.115
219. Tocci G, **Cicero AF**, Salvetti M, Passerini J, Musumeci MB, Ferrucci A, Borghi C, Volpe M. Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire. *Internal and Emergency Medicine (Intern Emerg Med.)* 2015;**10(8)**:943-54. doi: 10.1007/s11739-015-1256-y

## **2016**

220. Borghi C, **Cicero AF**. Cardiometabolic Risks and Obesity in the Young. *New England Journal of Medicine (N Engl J Med.)* 2016;**374(6)**:591-2. doi: 10.1056/NEJMc1513890#SA2.



221. Borghi C, Cicero AF. Re: Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *British Medical Journal* (BMJ) 2016; <http://www.bmj.com/content/353/bmj.i1753/rr>
222. Caliceti C, Franco P, Spinuzzi S, Roda A, Cicero AF. Berberine: new insights from pharmacological aspects to clinical evidences in the management of metabolic disorders. *Current Medical Chemistry* (Curr Med Chem.) 2016;**23(14)**:1460-76.
223. Cicero AF, Bagioni A. Berberine and Its Role in Chronic Disease. *Advances in Experimental Medicine and Biology* (Adv Exp Med Biol.) 2016;**928**:27-45.
224. Cicero AF, Colletti A, Rosticci M, Cagnati M, Urso R, Giovannini M, Borghi C, D'Addato S. Effect of lactotripeptides (Isoleucine-Proline-Proline/Valine-Proline-Proline) on blood pressure and arterial stiffness changes in subjects with suboptimal blood pressure control and metabolic syndrome: a double-blind, randomized, cross-over clinical trial. *Metabolic Syndrome and Related Disorders* (Met Synd Rel Dis.) 2016; **14(3)**:161-6. doi: 10.1089/met.2015.0093.
225. Cicero AF, Colletti A, Rosticci M, Grandi E, Borghi C. Efficacy and tolerability of a combined lipid-lowering nutraceutical on cholesterolemia, hs-CRP level and endothelial function in moderately hypercholesterolemic subjects. *Journal of Biological Regulators & Homeostatic Agents* (J Biol Reg Homeostat Agents) 2016; **30(2)**: 593-8.
226. Cicero AF, Colletti A. Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: the available clinical data. *Phytomedicine* 2016;**23**:1113–1118. doi: 10.1016/j.phymed.2015.10.011.
227. Cicero AF, Colletti A. Role of phytochemicals in the management of metabolic syndrome. *Phytomedicine*. 2016; **23**: 1134–1144. doi: 10.1016/j.phymed.2015.11.009.
228. Cicero AF, Morbini M, Bove M, D'Addato S, Fogacci F, Rosticci M, Borghi C. Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. *Current Medical Research and Opinion* (Curr Med Res Opin.) 2016;**32(10)**: 1633-1638. doi: 10.1080/03007995.2016.1190326
229. Cicero AF, Morbini M, Parini A, Urso R, Rosticci M, Grandi E, Borghi C. Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects. *Therapeutics and Clinical Risk Management* (Ther Clin Risk Manag.) 2016;**12**:281-6. doi: 10.2147/TCRM.S91817.
230. Cicero AF, Morbini M, Rosticci M, D'Addato S, Grandi E, Borghi C. Middle-term dietary supplementation with red yeast rice plus Coenzyme Q10 improves lipid pattern, endothelial reactivity and arterial stiffness in moderately hypercholesterolemic subjects. *Annals of Nutrition and Metabolism* (Ann Nutr Metab) 2016; **68(3)**:213-19.
231. Cicero AF, Morbini M, Urso R, Rosticci M, Parini A, Grandi E, D'Addato S, Borghi C; Brisighella Heart Study Group. Association between self-reported snoring and arterial stiffness: data from the Brisighella Heart Study. *Internal and Emergency Medicine* (Intern Emerg Med.) 2016;**11(1)**:77-83. doi: 10.1007/s11739-015-1310-9.
232. Cicero AF, Rosticci M, Morbini M, Cagnati M, Grandi E, Parini A, Borghi C. Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial. *Archives of Medical Sciences* (Arch Med Sci.) 2016;**12(3)**:507-12. doi: 10.5114/aoms.2016.59923.
233. Cicero AF, Rosticci M, Pengo M, Hart N, Borghi C for the Brisighella Heart Study. NoSAS Score is associated with arterial stiffness in a large cohort of overall healthy subjects. *The Lancet Respiratory Medicine* (Lancet Resp Med.). 2016;**4(11)**: e56. doi: 10.1016/S2213-2600(16)30321-6
234. Colletti A, Derosa G, Cicero AF. Retargeting the management of hypercholesterolemia - focus on evolocumab. *Therapeutics and Clinical Risk Management* (Ther Clin Risk Manag.) 2016; **12**:1365-76. doi: 10.2147/TCRM.S116679.

235. Derosa G, **Cicero AF**, D'Angelo A, Borghi C, Maffioli P. Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. *Biofactors*. 2016; **42(3)**: 316-22. doi: 10.1002/biof.1277.
236. Mazza A, **Cicero AF**, Ramazzina E, Lenti S, Schiavon L, Casiglia E, Gussoni G. Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial. *Journal of Biological Regulators & Homeostatic Agents (J Biol Reg Homeostat Agents)* 2016; 30(3):921-927.
237. Sahebkar A, **Cicero AF**, Simental-Mendía LE, Agarwal BB, Gupta SC. Curcumin Downregulates Human Tumor Necrosis Factor- $\alpha$  Levels: A systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research (Pharmacol Res.)* 2016;**107**:234-242. doi: 10.1016/j.phrs.2016.03.026
238. Sahebkar A, Reiner Z, Simental-Mendía LE, Ferretti G, **Cicero AF**. Effect of extended-release niacin on plasma Lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials. *Metabolism*. 2016; **65(11)**:1664-1678. doi: 10.1016/j.metabol.2016.08.007
239. Sahebkar A, Serban MC, Gluba-Brzozka A, Mikhailidis DP, **Cicero AF**, Rysz J, Banach M. Lipid-modifying effects of nutraceuticals: an evidence-based approach. *Nutrition*. 2016;**32(11-12)**:1179-92. doi: 10.1016/j.nut.2016.04.007.
240. Sahebkar A, Pirro M, Reiner Z, **Cicero AF**, Ferretti G, Simental-Mendia M, Simental-Media LE. A systematic review and meta-analysis of controlled trials on the effects of statin and fibrate therapies on plasma homocysteine levels. *Current Medical Chemistry (Curr Med Chem.)* 2016;**23(39)**:4490-4503.

## **2017**

241. Ayati SH, Fazeli B, Momtazi-Borojeni AA, **Cicero AF**, Pirro M, Sahebkar A. Regulatory effects of berberine on microRNome in Cancer and other conditions. *Critical Reviews in Oncology/Hematology (Crit Rev Oncol Hematol.)* 2017;**116**:147-158. doi: 10.1016/j.critrevonc.2017.05.008.
242. Barrios V, Escobar C, **Cicero AF**, Burke D, Fasching P, Banach M, Bruckert E. A nutraceutical approach (Armolidip Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: review of the clinical evidence. *Atherosclerosis Suppl*. 2017;**24**:1-15. doi: 10.1016/j.atherosclerosissup.2016.10.003.
243. Borghi C, **Cicero AF**. Nutraceuticals with clinically detectable blood pressure lowering effect: a review of available randomized clinical trials and their meta-analyses. *British Journal Clinical Pharmacology (Brit J Clin Pharmacol)* 2017; **83(1)**:163-171. doi: 10.1111/bcp.12902.
244. Borghi C, **Cicero AF**. Serum Uric Acid and Cardiometabolic Disease. Another Brick in the Wall? *Hypertension* 2017; **69(6)**:1011-1013. doi: 10.1161/HYPERTENSIONAHA.117.09081.
245. Borghi C, **Cicero AF**. Re: Uric acid: beyond the interpretation of serum levels. *British Medical Journal (BMJ)* 2017;**357**:j2376 <https://www.bmj.com/content/357/bmj.j2376/rr-0>
246. Borghi C, **Cicero AF**. Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia. *Expert Opinion on Drug Metabolism and Toxicology (Expert Opin Drug Metab Toxicol.)* 2017;**13(2)**:205-209. doi: 10.1080/17425255.2017.1262347.
247. Borghi C, Paolillo S, **Cicero AF**, Gargiulo P, Trimarco B, Perrone Filardi P. New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation: an appraisal. *Journal of Hypertension (J Hypertens.)* 2017;**35(4)**:689-695. doi: 10.1097/HJH.0000000000001228
248. Borghi C, Urso R, **Cicero AF**. Hypertension and hypercholesterolemia: from theory to cardiovascular disease risk prevention. *Nutrition Metabolism and Cardiovascular Disease (Nutr Metab Cardiovasc Dis.)* 2017; **27(2)**:115-120. doi: 10.1016/j.numecd.2016.07.013.
249. Bove M, Fogacci F, **Cicero AF**. Pharmacokinetic drug evaluation of ezetimibe/simvastatin for the treatment of hypercholesterolemia. *Expert Opinion on Drug Metabolism and Toxicology*

- (Expert Opin Drug Metab Toxicol.) 2017;**13(10)**:1099-1104. doi: 10.1080/17425255.2017.1381085.
250. Bove M, **Cicero AF**, Borghi C. The Effect of Xanthine Oxidase Inhibitors on Blood Pressure and Renal Function. *Current Hypertension Report (Curr Hypertens Rep.)* 2017;**19(12)**:95. doi: 10.1007/s11906-017-0793-3.
251. Borghi C, Urso R, **Cicero AF**. Renin-angiotensin system at the crossroad of hypertension and hypercholesterolemia. *Nutrition Metabolism and Cardiovascular Disease (Nutr Metab Cardiovasc Dis.)* 2017;**27(2)**:115-120. doi: 10.1016/j.numecd.2016.07.013.
252. Caliceti C, Calabria D, Roda A, **Cicero AF**. Fructose intake, serum uric acid and cardiometabolic disorders: a critical review. *Nutrients*. 2017;**9(4)**. pii: E395. doi: 10.3390/nu9040395.
253. Caliceti C, Rizzo P, Ferrari R, Fortini F, Aquila G, Leoncini E, Zambonin L, Rizzo B, Calabria D, Mirasoli M, Guardigli M, Hrelia S, Roda A, **Cicero AF**. Novel role of the nutraceutical bioactive compound Berberine in lectin-like OxLDL receptor 1-mediated endothelial dysfunction in comparison to Lovastatin. *Nutrition Metabolism and Cardiovascular Disease (Nutr Metab Cardiovasc Dis.)* 2017;**27(6)**:552-563. doi: 10.1016/j.numecd.2017.04.002.
254. **Cicero AF**, Caliceti C, Fogacci F, Giovannini M, Calabria D, Colletti A, Veronesi M, Roda A, Borghi C. Effect of apple polyphenols on vascular oxidative stress and endothelium function: a translational study. *Molecular Nutrition and Food Research (Mol Nutr Food Res.)* 2017;**61(11)**:1700373. doi: 10.1002/mnfr.201700373.
255. **Cicero AF**, Colletti A. Nutraceuticals and dietary supplements to improve quality of life and outcomes in heart failure patients. *Current Pharmaceutical Design (Curr Pharm Des.)* 2017;**23(8)**:1265-1272. doi: 10.2174/1381612823666170124120518.
256. **Cicero AF**, Colletti A. Effects of carotenoids on health: are all the same? Results from clinical trials. *Current Pharmaceutical Design (Curr Pharm Des.)* 2017; **23(17)**:2422-2427. doi: 10.2174/1381612823666170207095459.
257. **Cicero AF**, Colletti A. Food and plant bioactives for reducing cardiometabolic disease: How does the evidence stack up? *Trends in Food Science & Technology (Trends Food Sci Technol.)* 2017;**69(B)**:192-202.
258. **Cicero AF**, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Graham IM, Katsiki N, Langlois M, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Z, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. on behalf of the International Lipid Expert Panel (ILEP). SLIPID-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. *Archives of Medical Sciences (Arch Med Sci.)* 2017;**13(5)**:966–1006. doi: 10.5114/aoms.2017.69326.
259. **Cicero AF**, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Graham IM, Katsiki N, Langlois M, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Z, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. on behalf of the International Lipid Expert Panel (ILEP). SLIPID-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. *Nutrition Reviews (Nutr Rev.)* 2017; **75(9)**:731-767. doi: 10.1093/nutrit/nux047.
260. **Cicero AF**, Fogacci F, Borghi C. Regarding article "Long-term Excessive Body Weight and Adult Left Ventricular Hypertrophy are Linked through Later Life Body Size and Blood Pressure: The Bogalusa Heart Study". *Circulation Research (Circ Res.)* 2017; **120(11)**: e50. doi: 10.1161/CIRCRESAHA.117.311186.
261. **Cicero AF**, Fogacci F, Bove M, Veronesi M, Rizzo M, Giovanni M, Borghi C. Short-term effects of a combined nutraceutical on lipid level, fatty liver biomarkers, haemodynamic parameters and estimated cardiovascular disease risk: a double-blind, placebo-controlled,

- randomized clinical trial. *Advances in Therapy* (Adv Ther.) 2017;**34(8)**:1966-1975. doi: 10.1007/s12325-017-0580-1.
262. **Cicero AF**, Fogacci F, Colletti A. Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review. *British Journal of Pharmacology* (Br J Pharmacol.) 2017; **174(11)**:1378-1394. doi: 10.1111/bph.13608.
263. **Cicero AF**, Fogacci F, Rosticci M, Parini A, Giovannini M, Veronesi M, D'Addato S, Borghi C. Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. *Nutrition & Metabolism* (Nutr Metab.) 2017;**14**:61. doi: 10.1186/s12986-017-0214-2.
264. **Cicero AF**, Rosticci M, Fogacci F, Grandi E, D'Addato S, Borghi C, on behalf of the Brisighella Heart Study Group. Serum uric acid level is associated to poorly controlled blood pressure and arterial stiffness in hypertensive subjects: data from the Brisighella Heart Study. *European Journal of Internal Medicine* (Eur J Intern Med.) 2017; **37**:38-42. doi: 10.1016/j.ejim.2016.07.026.
265. **Cicero AF**, Rosticci M, Bove M, Fogacci F, Giovannini M, Urso R, D'Addato S, Borghi C; Brisighella Heart Study Group. Serum uric acid change and modification of blood pressure and fasting plasma glucose in an overall healthy population sample: data from the Brisighella Heart Study. *Annals of Medicine* (Ann Med.) 2017; **49(4)**:275-282 doi: 10.1080/07853890.2016.1222451.
266. **Cicero AF**, Petrini O, Prasad C. Clinical Studies with Nutraceuticals and How to Carry Them Out. *Current Topics in Nutraceutical Research* (Curr Topics Nutr Res.) 2017;**15(2)**:63-66.
267. Dal Negro R, Wedzicha J, Iversen M, Fontana G, Page C, **Cicero AF**, Pozzi E, Calverley P. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. *European Respiratory Journal* (Eur Resp J.) 2017; **50(4)**. pii: 1700711. doi:10.1183/13993003.00711-2017.
268. Degli Esposti E, Finzi SS, Parini A, **Cicero AF**, Tomassoli G, Bacchelli S, Guarino M, Rondelli F, Borghi C. Echocardiographic characteristics of hypertensive patients affected by transient ischemic attack: a cross-sectional study. *Journal of the American Society of Hypertension* (J Am Soc Hypertens.) 2017; **11(4)**:213-219. doi: 10.1016/j.jash.2017.02.003.
269. Fogacci F, **Cicero AF**, D'Addato S, D'Agostini L, Rosticci M, Giovannini M, Bertagnin E, Bove M, Borghi C. Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study *European Journal of Internal Medicine* (Eur J Intern Med.) 2017; **37**:49-55. doi: 10.1016/j.ejim.2016.08.018.
270. Fogacci F, **Cicero AF**, D'Addato S, Giovannini M, Borghi C; Brisighella Heart Study Group. Effect of spontaneous changes in dietary components and lipoprotein(a) levels: Data from the Brisighella Heart Study. *Atherosclerosis*. 2017;**262**:202-204. doi: 10.1016/j.atherosclerosis.2017.03.036.
271. Petrini O, Prasad C, **Cicero AF**. Clinical studies with botanicals and how to carry them out: the European Union perspective. *Current Topics in Nutraceutical Research* (Curr Topics Nutr Res.) 2017;**15(2)**:57-62.
272. Prasad C, **Cicero AF**, Petrini O. Planning meaningful clinical trials with botanicals and nutraceuticals: need for a cross-talk between science, business and the regulatory demand. *Current Topics in Nutraceutical Research* (Curr Topics Nutr Res.) 2017;**15(2)**:49-56.
273. Pucci G, **Cicero AF**, Borghi C, Schillaci G. Emerging biologic therapies for hypercholesterolaemia. *Expert Opinion on Biological Therapy* (Expert Opin Biol Ther.) 2017;**17(9)**:1077-1087. doi: 10.1080/14712598.2017.1341485.
274. Ruscica M, Ferri N, Fogacci F, Rosticci M, Botta M, Marchiano S, Magni P, D'Addato S, Giovannini M, Borghi C, **Cicero AF**. Circulating levels of PCSK9 and arterial stiffness in a large

population sample: data from the Brisighella Heart Study. *Journal of the American Heart Association* (J Am Heart Assoc.) 2017;**6**(5): pii: e005764. doi: 10.1161/JAHA.117.005764.

275. Ursoniu S, Sahebkar A, Serban MC, Antal D, Mikhailidis DP, **Cicero AF**, Athyros V, Rizzo M, Rysz J, Banach M. Lipid-Modifying Effects of Krill Oil in Humans: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *Nutrition Reviews* (Nutr Rev.) 2017;**75**(5):361-373.doi: 10.1093/nutrit/nuw063

## **2018**

276. Angelini A, Rosticci M, Massimo G, Musti M, Ravegnini G, Consolini N, Sammarini G, D'Addato S, Rizzoli E, Botbayev D, Borghi C, Cantelli-Forti G, **Cicero AF**, Hrelia P. Relationship between Lipid Phenotypes, Overweight, Lipid Lowering Drug Response and *KIF6* and *HMG-CoA* Genotypes in a Subset of the Brisighella Heart Study Population. *International Journal of Molecular Sciences* (Int J Mol Sci.) 2018;**19**(1):49. doi:10.3390/ijms19010049
277. Banach M, Patti AM, Giglio RV, **Cicero AF**, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrablík M, Watts GF, Wong ND, Rizzo M; International Lipid Expert Panel (ILEP). The Role of Nutraceuticals in Statin Intolerant Patients. *Journal of the American College of Cardiology* (J Am Coll Cardiol.) 2018;**72**(1):96-118. doi: 10.1016/j.jacc.2018.04.040.
278. Borghi C, **Cicero AF**. Serum uric acid and acute coronary syndrome: Is there a role for functional markers of residual cardiovascular risk? *International Journal of Cardiology* (Int J Cardiol.) 2018;**250**:62-63. doi: 10.1016/j.ijcard.2017.06.053.
279. Borghi C, **Cicero AF**. Letter by Borghi and Cicero Regarding Article, "Modifiable Risk Factors and Atrial Fibrillation". *Circulation*. 2018;**137**(14):1532-1533. doi: 10.1161/CIRCULATIONAHA.117.031291.
280. Borghi C, **Cicero AF**. Uric acid and early prevention of vascular diseases: women under the looking glass. *International Journal of Cardiology* (Int J Cardiol.) 2018; **272**:314-315. doi: 10.1016/j.ijcard.2018.07.121.
281. **Cicero AF**, Colletti A. Polyphenols effect on circulating lipids and lipoproteins: from biochemistry to clinical evidence. *Current Pharmaceutical Design* (Curr Pharmac Des.) 2018;**24**:178-190. doi: 10.2174/1381612824666171128110408.
282. **Cicero AF**, Colletti A. An update on the safety of nutraceuticals and effects on lipid parameters. *Expert Opinion on Drug Safety* (Expert Opin Drug Saf.) 2018;**17**(3):303-313. doi: 10.1080/14740338.2018.1429404.
283. **Cicero AF**, Bove M, Borghi C. Pharmacokinetics, pharmacodynamics and clinical efficacy of non-statin treatments for hypercholesterolemia. *Expert Opinion on Drug Metabolism and Toxicology* (Expert Opin Drug Metab Toxicol.) 2018;**14**(1):9-15. doi: 10.1080/17425255.2018.1416094.
284. **Cicero AF**, Colletti A, Bellentani S. Nutraceutical approach to Non-alcoholic fatty liver disease (NAFLD): the available clinical evidence. *Nutrients* 2018; **10**(9). pii: E1153. doi: 10.3390/nu10091153
285. **Cicero AF**, Fogacci F. Pericardial fat as a new independent biomarker of vascular aging. *International Journal of Cardiology* (Int J Cardiol.) 2018;**260**:211-212. doi: 10.1016/j.ijcard.2018.03.015.
286. **Cicero AF**, Fogacci F, Banach M. Botanicals and phytochemicals active on cognitive decline: the clinical evidence. *Pharmacological Research* (Pharmacol Res.) 2018;**130**:204-212.doi: 10.1016/j.phrs.2017.12.029



287. **Cicero AF**, Fogacci F, Borghi C. Questioning the Associations of  $\omega$ -3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. *JAMA Cardiology* (JAMA Cardiol.) 2018;**3(8)**:780-781. doi: 10.1001/jamacardio.2018.1306.
288. **Cicero AF**, Fogacci F, Giovannini M, Grandi E, Rosticci M, D'Addato S, Borghi C. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. *Scientific Reports* (Sci Rep.) 2018;**8(1)**:11529. doi: 10.1038/s41598-018-29955-w.
289. **Cicero AF**, Fogacci F, Veronesi M, Grandi E, Dinelli G, Hrelia S, Borghi C. Short-term haemodynamic effects of modern wheat products substitution in diet with ancient wheat products: a cross-over, randomized clinical trial. *Nutrients* 2018;**10**:1666; doi:10.3390/nu10111666
290. **Cicero AF**, Gitto S, Fogacci F, Rosticci M, Giovannini M, D'Addato S, Andreone P, Borghi C for the Brisighella Heart Study Group. Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study. *European Journal of Internal Medicine* (Eur J Intern Med.) 2018; **53**: 29-33. doi: 10.1016/j.ejim.2018.03.010
291. **Cicero AF**, Kuwabara M, Borghi C. A Critical Review of Nebivolol and Its Fixed-Dose Combinations in the Treatment of Hypertension. *Drugs* 2018;**78(17)**:1783-1790. doi: 10.1007/s40265-018-0999-y.
292. **Cicero AF**, Kuwabara M, Johnson R, Bove M, Fogacci F, Rosticci M, Giovannini M, D'Addato S, Borghi C; Brisighella Heart Study group. LDL-oxidation, serum uric acid, kidney function and pulse-wave velocity: Data from the Brisighella Heart Study cohort. *International Journal of Cardiology* (Int J Cardiol.) 2018; **261**: 204-208. doi: 10.1016/j.ijcard.2018.03.077.
293. **Cicero AF**, Pirro M, Watts GF, Mikhailidis DP, Banach M, Sahebkar A. Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. *Drugs*. 2018; **78(1)**:99-109. doi: 10.1007/s40265-017-0839-5.
294. Fogacci F, **Cicero AF**. Gene targeting for chylomicronemia syndrome: the brave new world. *Atherosclerosis*. 2018;**269**:254-255.
295. Fogacci F, Banach M, **Cicero AF**. Resveratrol effect on NAFLD patients: it is a matter of dose and treatment length. *Diabetes Obesity and Metabolism* (Diab Obes Metab.) 2018; **20(7)**:1798-1799.
296. Giglio RV, Patti AM, **Cicero AF**, Lippi G, Rizzo M, Toth PP, Banach M. Polyphenols: Potential Use In The Prevention And Treatment Of Cardiovascular Diseases. *Current Pharmaceutical Design* (Curr Pharm Des.) 2018; **24(2)**:239-258. doi: 10.2174/1381612824666180130112652.
297. Gitto S, **Cicero AF**, Loggi E, Giovannini M, Conti F, Grandini E, Guarneri V, Scuteri A, Vitali G, Cursaro C, Borghi C, Andreone P. Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment. *Annals of Hepatology* (Ann Hepatol.). 2018; 17(1):64-75.
298. Hesari AR, Ghasemi F, **Cicero AF**, Mohajeri M, Rezaei O, Gheibi Hayat SM, Sahebkar A. Berberine: a potential adjunct for the treatment of gastrointestinal cancers? *Journal of Cellular Biochemistry* (J Cell Biochem.) 2018; **119(12)**:9655-9663. doi: 10.1002/jcb.27392
299. Kuwabara M, Borghi C, **Cicero AF**, Hisatome I, Niwa K, Ohno M, Johnson RJ, Lanaspa MA. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan. *International Journal of Cardiology* (Int J Cardiol.) 2018; **261**: 183-188. doi: 10.1016/j.ijcard.2018.03.045.
300. Mazidi M, **Cicero AF**, Kengne AP, Banach M. Association between Plasma Trans-Fatty Acid Concentrations and Measures of Glucose Homeostasis and Cardiovascular Risk Factors in Adults in NHANES 1999-2000. *Angiology*. 2018; **69(7)**: 630-637. doi: 10.1177/0003319717745987.
301. Mazidi M, Kengne AP, Mikhailidis DP, **Cicero AF**, Banach M. Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults. *Annals of Medicine* (Ann Med.) 2018;**50(1)**:1-6. doi: 10.1080/07853890.2017.1325967.
302. Mohajeri M, Behnam B, **Cicero AF**, Sahebkar A. Protective effects of curcumin against aflatoxicosis: A comprehensive review. *Journal of Cellular Physiology* (J Cell Physiol.)

2018;**233(4)**:3552-3577. doi: 10.1002/jcp.26212.

303. Mostacci B, Liguori R, **Cicero AF**. Nutraceutical Approach to Peripheral Neuropathies: Evidence from Clinical Trials. *Current Drug Metabolism (Curr Drug Metab.)* 2018;**19(5)**:460-468. doi: 10.2174/1389200218666171031145419.
304. Patti AM, Al-Rasadi K, Giglio RV, Nikolic D, Mannina C, Castellino G, Chianetta R, Banach M, **Cicero AF**, Lippi G, Montalto G, Rizzo M, Toth PP. Natural approaches in metabolic syndrome management. *Archives of Medical Sciences (Arch Med Sci.)* 2018; **14(2)**:422-441. doi: 10.5114/aoms.2017.68717.
305. Poli A, Barbagallo CM, **Cicero AF**, Corsini A, Manzato E, Trimarco B, Bernini F, Visioli F, Bianchi A, Canzone G, Crescini C, de Kreutzenberg S, Ferrara N, Gambacciani M, Ghiselli A, Lubrano C, Marelli G, Marrocco W, Montemurro V, Parretti D, Pedretti R, Perticone F, Stella R, Marangoni F. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. *Pharmacological Research (Pharmacol Res.)* 2018;**134**: 51-60. doi: 10.1016/j.phrs.2018.05.015.
306. Ricci C, Ruscica M, Camera M, Rossetti L, Macchi C, Colciago A, Zanotti I, Lupo MG, Adorni MP, **Cicero AF**, Fogacci F, Corsini A, Ferri N. PCSK9 induces a pro-inflammatory response in macrophages. *Scientific Reports (Sci Rep.)* 2018;**8(1)**:2267. doi: 10.1038/s41598-018-20425-x.
307. Sahebkar A, Pirro M, Banach M, Mikhailidis DP, Atkin SL, **Cicero AF**. Lipid-lowering activity of artichoke extracts: a systematic review and meta-analysis. *Critical Reviews in Food Science and Nutrition (Crit Rev Food Sci Nutr.)* 2018;**58(15)**:2549-2556. doi: 10.1080/10408398.2017.1332572.
308. Sahebkar A, Simental-Mendía LE, Kovanen PT, Pedone C, Simental-Mendía M, **Cicero AF**. Effects of Orlistat on Blood Pressure: A Systematic Review and Meta-Analysis of 27 randomized placebo-controlled clinical trials. *Journal of the American Society of Hypertension (J Am Soc Hypertens.)* 2018;**12(2)**:80-96. doi: 10.1016/j.jash.2017.12.002.
309. Simental-Mendía LE, **Cicero AF**, Atkin SL, Majeed M, Sahebkar A. A systematic review and meta-analysis of the effect of curcuminoids on adiponectin levels. *Obesity Research and Clinical Practice (Obes Res Clin Pract.)* 2019;**13(4)**:340-344. doi: 10.1016/j.orcp.2019.04.003.

## **2019**

310. Bove M, **Cicero AF**, Borghi C. Emerging drugs for the treatment of hypercholesterolemia. *Expert Opinion on Emerging Drugs (Expert Opin Emerg Drugs.)* 2019;**24(1)**:63-69. doi: 10.1080/14728214.2019.1591372.
311. Borghi C, Fogacci F, **Cicero AF**. Cardiovascular risk reduction with isopent ethyl. *New England Journal of Medicine (New Engl J Med.)* 2019; **380(17)**:1678. doi: 10.1056/NEJMc1902165.
312. Calverley PMA, Page C, Dal Negro RW, Fontana G, Cazzola M, Cicero AF, Pozzi E, Wedzicha JA. Effect of erdosteine on COPD exacerbations in COPD patients with moderate airflow limitation. *International Journal of Chronic Obstructive Pulmonary Disease (Int J Chron Obstruct Pulm Dis.)* 2019;**14**:2733-2744. doi: 10.2147/COPD.S221852.
313. Castellino G, Nikolic D, Magán-Fernández A, Malfa GA, Chianetta R, Patti AM, Amato A, Montalto G, Toth PP, Banach M, **Cicero AFG**, Rizzo M. Altilix(®) Supplement Containing Chlorogenic Acid and Luteolin Improved Hepatic and Cardiometabolic Parameters in Subjects with Metabolic Syndrome: A 6 Month Randomized, Double-Blind, Placebo-Controlled Study. *Nutrients.* 2019;**11(11)**. pii: E2580. doi: 10.3390/nu11112580.
314. **Cicero AF**, Cosentino ER, Kuwabara M, Degli Esposti D, Borghi C. Effects of allopurinol and febuxostat on cardiovascular mortality in elderly heart failure patients. *Internal and Emergency Medicine (Intern Emerg Med.)* 2019;**14(6)**:949-956. doi: 10.1007/s11739-019-02070-y.

315. **Cicero AF**, Fogacci F, Bove M, Giovannini M, Borghi C. Three-arm, placebo controlled, randomized clinical trial evaluating the metabolic effect of a combined nutraceutical containing a bergamot standardized flavonoid extract in dyslipidemic overweight subjects. *Phytotherapy Research* (Phytother Res.) 2019; **33(8)**:2094-2101. doi: 10.1002/ptr.6402.
316. **Cicero AF**, Fogacci F, Bove M, Giovannini M, Veronesi M, Borghi C. Short-Term Effects of Dry Extracts of Artichoke and Berberis in Hypercholesterolemic Patients Without Cardiovascular Disease. *American Journal of Cardiology* (Am J Cardiol.) 2019;**123(4)**:588-591. doi: 10.1016/j.amjcard.2018.11.018.
317. **Cicero AF**, Fogacci F, Desideri G, Grandi E, Rizzoli E, D'Addato S, Borghi C. Arterial Stiffness, Sugar-Sweetened Beverages and Fruits Intake in a Rural Population Sample: Data from the Brisighella Heart Study. *Nutrients*. 2019;11(11). pii: E2674. doi: 10.3390/nu11112674.
318. **Cicero AF**, Fogacci F, Giovannini M, Bove M, Debellis G, Borghi C. Effect of quantitative and qualitative diet prescription on children behavior after diagnosis of heterozygous familial hypercholesterolemia. *International Journal of Cardiology* (Int J Cardiol.). 2019;**293**:193-196. doi: 10.1016/j.ijcard.2019.05.069.
319. **Cicero AF**, Fogacci F, Giovannini M, Grandi E, D'Addato S, Borghi C. Interaction between low-density lipoprotein-cholesterolaemia, serum uric level and incident hypertension: data from the Brisighella Heart Study. *Journal of Hypertension* (J Hypertens.) 2019; **37(4)**:728-731. doi: 10.1097/HJH.0000000000001927.
320. **Cicero AF**, Landolfo M, Ventura F, Borghi C. Current pharmacotherapeutic options for primary dyslipidemia in adults. *Expert Opinion on Pharmacotherapy* (Exp Opin Pharmacother.) 2019; **20(10)**:1277-1288. doi: 10.1080/14656566.2019.1604687.
321. **Cicero AF**, Ruscica M, Banach M. Resveratrol and cognitive decline: a clinician perspective. *Archives of Medical Sciences* (Arch Med Sci.). 2019;**15(4)**: 936-943.
322. **Cicero AF**, Toth PP, Fogacci F, Viridis A, Borghi C. Improvement in arterial stiffness after short-term treatment with PCKS9 inhibitors. *Nutrition, Metabolism and Cardiovascular Disease* (NMCD) 2019; **29(5)**:527-529. doi: 10.1016/j.numecd.2019.01.010.
323. Cosentino ER, Degli Esposti D, Miceli R, Bentivenga C, Landolfo M, **Cicero AF**, Berardi E, Spinardi L, Magir G, Dugato V, Borghi C. Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction. *Current Medical Research Opinion* (Curr Med Res Opin.) 2019;**35(S1)**:9-12. doi: 10.1080/03007995.2019.1576481.
324. Cosentino ER, Landolfo M, Bentivenga C, Spinardi L, Esposti DD, **Cicero AF**, Miceli R, Bui V, Berardi E, Borghi C. Morbidity and mortality in a population of patients affected by heart failure and chronic obstructive pulmonary disease: an observational study. *BMC Cardiovascular Disorders* (BMC Cardiovasc Disord.) 2019;**19(1)**:20. doi: 10.1186/s12872-018-0986-y.
325. D'Addato S, Fogacci F, **Cicero AF**, Palmisano S, Baronio F, Biagi C, Borghi C. Severe hypercholesterolaemia in a paediatric patient with congenital analbuminaemia. *Nutrition Metabolism and Cardiovascular Disease* (Nutr Metab Cardiovasc Dis.) 2019;**29(3)**:316-317. doi: 10.1016/j.numecd.2018.11.005.
326. Derosa G, **Cicero AF**, D'Angelo A, Maffioli P. *Ascophyllum nodosum* and *Fucus vesiculosus* on glycemic status and on endothelial damage markers in dysglycemic patients. *Phytotherapy Research* (Phytother Res.) 2019; **33(3)**:791-797. doi: 10.1002/ptr.6272.
327. Derosa G, Maffioli P, Scelsi L, Bestetti A, Vanasia M, **Cicero AF**, Spinardi L, Bentivenga C, Degli Esposti D, Caprio M, Borghi C, Pitt B, Cosentino E for the COFFEE-IT Study Investigators. Canrenone effects on cardiovascular mortality in patients with congestive heart failure: the COFFEE-IT study. *Pharmacological Research* (Pharmacol Res.) 2019;**141**:46-52. doi: 10.1016/j.phrs.2018.11.037
328. Fogacci F, Banach M, Mikhailidis DP, Bruckert E, Toth PP, Watts GF, Reiner Ž, Mancini J, Rizzo M, Mitchenko O, Pella D, Fras Z, Sahebkar A, Vrablik M, **Cicero AF**; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group the International Lipid Expert Panel



- (ILEP). Safety of red yeast rice supplementation: a systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research* (Pharmacol Res.) 2019;**143**:1-16. S1043-6618(19)30317-2. doi: 10.1016/j.phrs.2019.02.028.
329. Fogacci F, Borghi C, **Cicero AF**. Portrait of the countess Anastasia Spini (1842): Acromegaly in art. *Hormones*. 2019;**18**(4):517-518. doi: 10.1007/s42000-019-00136-2.
330. Fogacci F, **Cicero AF**, Derosa G, Rizzo M, Veronesi M, Borghi C. Effect of pistachio on brachial artery diameter and flow-mediated dilatation: a systematic review and meta-analysis of randomized, controlled-feeding clinical studies. *Critical Reviews in Food Science and Nutrition* (Crit Rev Food Sci Nutr.) 2019;**59**(2):328-335. doi: 10.1080/10408398.2017.1368007.
331. Fogacci F, Ferri N, Toth P, Ruscica M, Corsini A, **Cicero AF**. Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials. *Drugs* 2019;**79**(7):751-766. doi: 10.1007/s40265-019-01114-z.
332. Fogacci F, Grassi D, Rizzo M, **Cicero AF**. Metabolic effect of berberine-silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. *Phytotherapy Research* (Phytother Res.) 2019;**33**:862–870. doi: 10.1002/ptr.6282.
333. Fogacci F, Tocci G, **Cicero AFG**. Are we really sure about the pycnogenol antihypertensive effect? *Pharmacol Res*. 2019;**151**:104543. doi: 10.1016/j.phrs.2019.104543.
334. Fogacci F, Tocci G, Presta V, Fratter A, Borghi C, **Cicero AF**. Effect of resveratrol on blood pressure: a systematic review and meta-analysis of randomized, controlled, clinical trials. *Critical Reviews in Food Science and Nutrition* (Crit Rev Food Sci Nutr.) 2019;**59**(10):1605-1618. doi: 10.1080/10408398.2017.1422480.
335. Fratter A, Mason V, Pellizzato M, Valier S, **Cicero AF**, Tedesco E, Meneghetti E, Benetti F. Lipomatrix: A Novel Ascorbyl Palmitate-Based Lipid Matrix to Enhancing Enteric Absorption of Serenoa Repens Oil. *International Journal of Molecular Sciences* (Int J Mol Sci.) 2019; **20**:669. doi:10.3390/ijms20030669
336. Fratter A, Biagi D, **Cicero AF**. Sublingual delivery of Astaxanthin through a novel Ascorbyl Palmitate-based nanoemulsion: preliminary data. *Marine Drugs*. 2019; **17**(9). pii: E508. doi: 10.3390/md17090508.
337. Mohajeri M, Kovanen PT, Bianconi V, Pirro M, **Cicero AF**, Sahebkar A. Mast cell tryptase - marker and maker of cardiovascular diseases. *Pharmacology and Therapeutics* (Pharmacol Ther.) 2019;**199**:91-110. doi: 10.1016/j.pharmthera.2019.03.008.
338. Mollazadeh H, **Cicero AF**, Blesso CN, Pirro M, Majeed M, Sahebkar A. Immune modulation by curcumin: The role of interleukin-10. *Critical Reviews in Food Science and Nutrition* (Crit Rev Food Sci Nutr.) 2019;**59**(1):89-101. doi: 10.1080/10408398.2017.1358139
339. Nasia M, Patrizi G, Pizzi C, Landolfo M, Boriani G, Dei Cas A, **Cicero AF**, Fogacci F, Rapezzi C, Sisca G, Capucci A, Galiè N, Borghi C, Berrettini U, Piepoli M, Mattioli AV. The role of physical activity in individuals with cardiovascular risk factors. An opinion paper from Italian Society of Cardiology-Emilia Romagna-Marche and SIC-Sport. *Journal of Cardiovascular Medicine* (J Cardiovasc Med.) 2019; **20**(10):631-639. doi: 10.2459/JCM.0000000000000855.
340. Presta V, Figliuzzi I, Miceli F, Coluccia R, Fogacci F, **Cicero AF**, Ferrucci A, Borghi C, Volpe M, Tocci G, on behalf of EFFECTUS Steering Committee. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. *Atherosclerosis* 2019;**285**:40-48. doi: 10.1016/j.atherosclerosis.2019.03.017
341. Rosticci M, Pervjakova N, Kaakinen M, **Cicero AF**, Pfeufer A, Marullo L, Mägi R, Fischer K, Jiang LD, D'Addato S, Rizzoli E, Massimo G, Giovannini M, Angelini S, Hrelia P, Scapoli C, Borghi C, Prokopenko I. A meta-analysis of Italian and Estonian individuals shows an effect of common variants in *HMGCR* to blood Apolipoprotein B levels. *Biomarkers in Medicine* (Biork Med.) 2019;**3**(11):931-940. doi: 10.2217/bmm-2017-0431.
342. Shakeri A, **Cicero AF**, Panahi Y, Mohajeri M, Sahebkar A. Curcumin: a naturally occurring

- autophagy modulator. *Journal of Cellular Physiology* (J Cell Physiol.) 2019;**234**:5643–5654. doi: 10.1002/jcp.27404.
343. Simental-Mendía E, Simental-Mendía M, Sánchez-García M, Banach M, Serban MC, **Cicero AF**, Sahbekar A. Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. *Lipids in Health and Disease* (Lipids Health Dis.) 2019;**18**:88 <https://doi.org/10.1186/s12944-019-1041-4>.
344. Strilchuk L, Fogacci F, **Cicero AF**. Safety and tolerability of available urate-lowering drugs: a critical review. *Expert Opinion on Drug Safety* (Exp Opin Drug Saf.) 2019;**18**(4):261-271. doi: 10.1080/14740338.2019.1594771.
345. Strilchuk L, Tocci G, Fogacci F, **Cicero AF**. An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. *Expert Opinion on Pharmacotherapy* (Expert Opin Pharmacother.) 2020;**21**(5):531-539. doi: 10.1080/14656566.2020.1714028.

## **2020**

346. Alidadi M, Jamialahmadi T, **Cicero AF**, Bianconi V, Pirro M, Banach M, Sahebkar A. The potential role of plant-derived natural products in improving arterial stiffness: a review of dietary intervention studies. *Trends in Food Sciences and Technology* (Trends Food Sci Technol.) 2020;**99**:426-440.
347. Borghi C, **Cicero AF**. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *N Engl J Med*. 2020;**382**(10):972. doi:10.1056/NEJMc1917241.
348. Borghi C, Tsioufis K, Agabiti-Rosei E, Burnier M, **Cicero AF**, Clement D, Coca A, Desideri G, Grassi G, Lovic D, Lurbe E, Kahan T, Kreutz R, Jelakovic B, Polonia J, Redon J, Van De Borne P, Mancia G. Nutraceuticals and blood pressure control: a European Society of Hypertension position document. *J Hypertens*. 2020;**38**(5):799-812. doi: 10.1097/HJH.0000000000002353.
349. Casiglia E, Tikhonoff V, Virdis A, Masi S, Barbagallo CM, Bombelli M, Bruno B, **Cicero AFG**, Cirillo M, Cirillo P, Desideri G, D'Elia L, Ferri C, Galletti F, Gesualdo L, Giannattasio C, Iaccarino G, Lippa L, Mallamaci F, Maloberti A, Mazza A, Muiesan ML, Nazzaro P, Palatini P, Parati G, Pontremoli R, Quarti-Trevano F, Rattazzi M, Rivasi G, Salvetti M, Tocci G, Ungar A, Verdecchia P, Viazzi F, Volpe M, Grassi G, Borghi C; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Serum uric acid and fatal myocardial infarction: detection of prognostic cut-off values: The URRAH (Uric Acid Right for Heart Health) study. *Journal of Hypertension* (J Hypertens.) 2020;**38**(3):412-419. doi: 10.1097/HJH.0000000000002287.
350. **Cicero AF**, Colletti A, von Haehling S, Vinereanu D, Bielecka-Dabrowa A, Sahebkar A, Toth PP, Reiner Ž, Wong ND, Mikhailidis DP, Ferri C, Banach M. Nutraceutical support in heart failure: a position paper of the International Lipid Expert Panel (ILEP). *Nutrition Research Reviews* (Nutr Res Rev.) 2020;**33**(1):155-179. doi: 10.1017/S0954422420000049.
351. **Cicero AF**, Fogacci F, Borghi C. Cost-effectiveness analysis of different hypertension management strategies. *Internal and Emergency Medicine* (Intern Emerg Med.) 2020;**15**(2):181-182. doi: 10.1007/s11739-019-02153-w.
352. **Cicero AF**, Fogacci F, Borghi C. Uric acid and thrombotic risk: an emerging link. *Internal and Emergency Medicine* (Int Emerg Med.) 2020;**15**(7):1167-1168. doi: 10.1007/s11739-020-02322-2.
353. **Cicero AF**, Fogacci F, Bove M, Borghi C. Successful treatment of a patient with mitochondrial myopathy with alirocumab. *Journal of Clinical Lipidology* (J Clin Lipidol.) 2020;**14**(5):646-648. doi: 10.1016/j.jacl.2020.07.007.
354. **Cicero AF**, Fogacci F, Hernandez AV, Banach M on behalf of the *Lipid and Blood Pressure Meta-Analysis Collaboration* (LBPMC) Group and the *International Lipid Expert Panel* (ILEP). Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic

- review and meta-analysis. *PLOS Medicine* (PLOS Med.) 2020; **17(7)**:e1003121. doi: 10.1371/journal.pmed.1003121.
355. **Cicero AF**, Fogacci F, Tocci G, Ventura F, Presta V, Grandi E, Rizzoli E, D'Addato S, Borghi C on behalf of the Brisighella Heart Study Group. Awareness of major cardiovascular risk factors and its relationship with markers of vascular aging: data from the Brisighella Heart Study. *Nutrition Metabolism and Cardiovascular Disease* (Nutr Metab Cardiovasc Dis.) 2020;**30(6)**:907-914. doi: 10.1016/j.numecd.2020.03.005
356. **Cicero AF**, Fogacci F, Veronesi M, Strocchi E, Grandi E, Rizzoli E, Poli A, Marangoni F, Borghi C. A randomized Placebo-Controlled Clinical Trial to Evaluate the Medium-Term Effects of Oat Fibers on Human Health: The Beta-Glucan Effects on Lipid Profile, Glycemia and intestinal Health (BELT) Study. *Nutrients*. 2020;**12(3)**. pii: E686. doi: 10.3390/nu12030686.
357. **Cicero AF**, Fogacci F, Grandi E, Rizzoli E, Bove M, D'Addato S, Borghi C on behalf of the Brisighella Heart Study Group. Prevalent seasoning and cooking fats, arterial stiffness and lipid pattern in a rural population sample: data from the Brisighella Heart Study. *Nutrients* 2020;**12**:3063. doi:10.3390/nu12103063.
358. **Cicero AF**, Grassi D, Rizzo M, Tocci G. Drug Induced Liver Injury (DILI) due to variability in monacolin K content in Red Yeast Rice (RYR): An expert opinion. *European Journal of Integrative Medicine* (Eur J Integr Med.). 2020;**37**:101164. doi: 10.1016/j.eujim.2020.101164
359. **Cicero AF**, Landolfo M, Borghi C. Are monotherapies still valuable to the treatment of hypertension? *Expert Opinion on Pharmacotherapy* (Exp Opin Pharmacother.) 2020; doi: 10.1080/14656566.2020.1770728
360. **Cicero AF**, Pontremoli R, Fogacci F, Viazzi F, Borghi C. Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies. *Drug Safety* 2020; **43(8)**:727-736. doi: 10.1007/s40264-020-00931-6.
361. **Cicero AF**, Sahebkar A, Fogacci F, Bove M, Giovannini M, Borghi C. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial. *European Journal of Nutrition* (Eur J Nutr.) 2020;**59(2)**:477-483. doi: 10.1007/s00394-019-01916-7.
362. Crosta F, Stefani A, Melani F, Fabrizzi P, Nizzardo A, Grassi D, Bocale R, Necozone S, Lombardi F, Castelli V, **Cicero AF**, Cimini A, Ferri C, Desideri G. Improvement of Executive Function after Short-Term Administration of an Antioxidants Mix Containing Bacopa, Lycopene, Astaxanthin and Vitamin B12: The BLATwelve Study. *Nutrients*. 2020;**13(1)**:E56. doi: 10.3390/nu13010056.
363. Derosa G, Colletti A, Maffioli P, D'Angelo A, Lupi A, Zito GB, Mureddu GF, Raddino R, Fedele F, **Cicero AF**. Lipid-lowering nutraceuticals update on scientific evidence. *Journal of Cardiovascular Medicine* (J Cardiovasc Med.) 2020; **21(11)**:845-859. doi: 10.2459/JCM.0000000000000970.
364. Fogacci F, Borghi C, **Cicero AF**. Misinterpreting data in the era of COVID-19. *Journal of Clinical Lipidology* (J Clin Lipidol.) 2020;**14(4)**:543-544. doi: 10.1016/j.jacl.2020.07.004.
365. Fogacci S, Fogacci F, **Cicero AF**. Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence. *Nutrients* 2020;**12(2)**:378. doi:10.3390/nu12020378
366. Fogacci F, Tocci G, Sahebkar A, Presta V, Banach M, **Cicero AF**. Effect of pycnogenol on blood pressure: findings from a PRISMA compliant systematic review and meta-analysis of randomized, double-blind, placebo controlled, clinical studies. *Angiology* 2020; **71(3)**:217-225. doi: 10.1177/0003319719889428.
367. Fogacci F, Strocchi E, Veronesi M, Borghi C, **Cicero AF**. Effect of Omega-3 Polyunsaturated Fatty Acids Treatment on Lipid Pattern of HIV Patients: A Meta-Analysis of Randomized Clinical Trials. *Marine Drugs* (Mar Drugs.) 2020;**18(6)**:E292. doi: 10.3390/md18060292.
368. Fogacci S, Fogacci F, Banach M, Michos ED, Hernandez AV, Lip GYH, Blaha MJ, Toth PP,

- Borghi C, Cicero AF on behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Vitamin D supplementation and incident preeclampsia: A systematic review and meta-analysis of randomized clinical trials. *Clinical Nutrition* (Clin Nutr.) 2020; **39(6)**:1742-1752. doi: 10.1016/j.clnu.2019.08.015.
369. Giglio RV, Carruba G, Cicero AF, Banach M, Patti AM, Nikolic D, Cocciadiferro L, Zarcone M, Montalto G, Stoian AP, Banerjee Y, Rizvi AA, Toth PP, Rizzo M. Pasta Supplemented with *Opuntia ficus-indica* Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. *Metabolites*. 2020;10(11):428. doi: 10.3390/metabo10110428.
370. Giannaccare G, Pellegrini M, Senni C, Bernabei F, Scordia V, Cicero AF. Clinical Applications of Astaxanthin in the Treatment of Ocular Diseases: the available evidences. *Marine Drugs* (Mar Drugs). 2020; **18(5)**:239. doi:10.3390/md18050239
371. Katsiki N, Mikhailidis DP, Bajraktari G, Miserez AR, Cicero AF, Bruckert E, Serban MC, Mirrakhimov E, Alnouri F, Reiner Z, Paragh G, Sahebkar A, Banach M. Statin therapy in athletes and patients performing regular intense exercise – Position Paper from the International Lipid Expert Panel (ILEP). *Pharmacological Research* (Pharmacol Res.) 2020; **155**:104719. doi: 10.1016/j.phrs.2020.104719.
372. Macchi C, Greco MF, Botta M, Sperandeo P, Dongiovanni P, Valenti L, Cicero AF, Borghi C, Lupo MG, Romeo S, Corsini A, Magni P, Ferri N, Ruscica M. Leptin, Resistin, and PCSK9 - the role of STAT3. *American Journal of Pathology* (Am J Pathol.) 2020;**190(11)**:2226-2236. doi: 10.1016/j.ajpath.2020.07.016.
373. Martelli A, Testai L, Colletti A, Cicero AF. Coenzyme Q10: clinical applications in cardiovascular diseases. *Antioxidants*. 2020; **9(4)**:E341. doi: 10.3390/antiox9040341.
374. Muiesan ML, Salvetti M, Virdis A, Masi S, Casiglia E, Tikhonoff V, Barbagallo CM, Bombelli M, Cicero AF, Cirillo M, Cirillo P, Desideri G, D'Elia L, Ferri C, Galletti F, Gesualdo L, Giannattasio C, Iaccarino G, Mallamaci F, Maloberti A, Mazza A, Nazzaro P, Palatini P, Parati G, Pontremoli R, Rattazzi M, Rivasi G, Tocci G, Ungar A, Verdecchia P, Viazzi F, Volpe M, Grassi G, Borghi C; from the Working Group on Uric Acid, Cardiovascular Risk of the Italian Society of Hypertension. Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. *Journal of Hypertension* (J Hypertens.) 2020; **39(1)**:62-69. doi: 10.1097/HJH.0000000000002589.
375. Norata GD, Fogacci F, Toth PP, Arca M, Cicero AF. Efficacy and safety of volanesorsen (ISIS 304801): a systematic review and meta-analysis of phase 2 and 3 clinical studies. *Current Atherosclerosis Report* (Curr Ather Rep.) 2020; **22(5)**:18. doi: 10.1007/s11883-020-00836-w.
376. Pellegrini M, Senni C, Bernabei F, Cicero AF, Maestri A, Scordia V, Giannaccare G. The Role of Nutrition and Nutritional Supplements in Ocular Surface Diseases. *Nutrients* 2020;**12(4)**: pii: E952. doi: 10.3390/nu12040952.
377. Patti AM, Carruba G, Cicero AF, Banach M, Nikolic D, Giglio RV, Terranova A, Soresi M, Giannitrapani L, Montalto G, Stoian AP, Banerjee Y, Rizvi AA, Toth PP, Rizzo M. Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. *Metabolites*. 2020 Oct 2;**10(10)**:E392. doi: 10.3390/metabo10100392.
378. Ruscica M, Macchi C, Fogacci F, Ferri N, Grandi E, Rizzoli E, D'Addato S, Borghi C, Cicero AF; Brisighella Heart Study Group. Angiopoietin-like 3 and subclinical peripheral arterial disease: Evidence from the Brisighella Heart Study. *European Journal of Preventive Cardiology* (Eur J Prev Cardiol.) 2020; **27(19)**:2251-2254. doi: 10.1177/2047487319884378.
379. Sahebkar A, Cicero AF, Di Giosia P, Pomilio I, Stamerra CA, Giorgini P, Ferri C, Jamialahmadi T, von Haehling S, Banach M. Pathophysiological mechanisms of statin-associated myopathies: possible role of the ubiquitin-proteasome system. *Journal of Cachexia, Sarcopenia and Muscle* (J Cach Sarc Muscle). 2020; **11(5)**:1177-1186. doi: 10.1002/jcsm.12579.



380. Strilchuk L, Cincione Ivan, Fogacci F, **Cicero AF**. Dietary interventions in blood pressure lowering: current evidence in 2020. *Polish Heart Journal* (Pol Heart J.) 2020; doi: 10.1007/s11883-020-00836-w.
381. Torlasco C, Faini A, Ferri C, Grassi G, Salvetti M, Destro M, **Cicero AF**, Galletti F, Ghiadoni L, Carugo S, Sarzani R, Minuz P, Morganti A, Mulatero P, Mulè G, Savoia C, Volpe M, Borghi C, Beaney T, Ster AC, Poulter NR, Xia X, Parati G. May Measurement Month 2018: an analysis of blood pressure screening results from Italy. *Eur Heart J Suppl.* 2020;**22(Suppl H)**:H70-H73. doi: 10.1093/eurheartj/suaa032.
382. Viridis A, Masi S, Casiglia E, Tikhonoff V, **Cicero AF**, Ungar A, Rivasi G, Salvetti M, Barbagallo CM, Bombelli M, Dell'Oro R, Bruno B, Lippa L, D'Elia L, Verdecchia P, Mallamaci F, Cirillo M, Rattazzi M, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Georgiopoulou G, Iaccarino G, Nazzaro P, Parati G, Palatini P, Galletti F, Ferri C, Desideri G, Viazzi F, Pontremoli R, Muiesan ML, Grassi G, Borghi C; from the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension. Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. *Hypertension.* 2020;**75(2)**:302-308. doi: 10.1161/HYPERTENSIONAHA.119.13643.

## **2021**

383. Agnoletti D, **Cicero AFG**, Borghi C. The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems. *Cardiology Clinics* (Cardiol Clin.) 2021;**39(3)**:365-376. doi: 10.1016/j.ccl.2021.04.009.
384. Banach M, Katsiki N, Latkovskis G, Rizzo M, Pella D, Penson PE, Reiner Z, **Cicero AFG**. Postmarketing nutriviigilance safety profile: a line of dietary food supplements containing red yeast rice for dyslipidemia. *Archives of Medical Sciences* (Arch Med Sci.) 2021;**17(4)**:856-863. doi: 10.5114/aoms/133716.
385. Borghi C, **Cicero AFG**. Improving adherence with treatment-resistant hypertension. *Expert Opinion on Pharmacotherapy* (Expert Opin Pharmacother.). 2021: **22(11)**:1373-1375. doi: 10.1080/14656566.2021.1915290.
386. Bove M, Fogacci F, Quattrocchi S, Veronesi M, **Cicero AFG**. Effect of Synaid on cognitive functions and mood in elderly subjects with self-perceived loss of memory after COVID-19 infection. *Archives of Medical Sciences* (Arch Med Sci.) 2021;**17(6)**:1797-1799. doi: 10.5114/aoms/141502.
387. **Cicero AFG**, Fogacci F, Bove M, Giovannini M, Borghi C. Impact of a short-term synbiotic supplementation on metabolic syndrome and systemic inflammation in elderly patients: a randomized placebo-controlled clinical trial. *European Journal of Nutrition* (Eur J Nutr). 2021; **60(2)**:655-663. doi: 10.1007/s00394-020-02271-8.
388. **Cicero AFG**, Fogacci F, Cincione I. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia. *Expert Opinion on Drug Metabolism and Toxicology.* (Expert Opin Drug Metab Toxicol). 2021; **17(9)**:1031-1038. doi: 10.1080/17425255.2021.1951222.
389. **Cicero AFG**, Fogacci F, Cincione RI, Tocci G, Borghi C. Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients. *Medical Principles and Practice* (Med Princ Pract). 2021;**30(2)**:122-130. doi: 10.1159/000512178.
390. **Cicero AFG**, Fogacci F, Giovannini M, Mezzadri M, Grandi E, Borghi C, The Brisighella Heart Study Group. Nutrients. COVID-19-Related Quarantine Effect on Dietary Habits in a Northern Italian Rural Population: Data from the Brisighella Heart Study. *Nutrients* 2021;**13(2)**:309. doi: 10.3390/nu13020309.
391. **Cicero AFG**, Fogacci F, Kuwabara M, Borghi C. Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update. *Medicina.* 2021; **57(1)**:58. doi: 10.3390/medicina57010058.
392. **Cicero AFG**, Fogacci F, Patrono D, Mancini R, Ramazzotti E, Borghi C, D'Addato S; BLIP Study group. Application of the Sampson equation to estimate LDL-C in children: Comparison with LDL direct measurement and Friedewald equation in the BLIP study. *Nutrition, Metabolism*

- and Cardiovascular Diseases* (Nutr Metab Cardiovasc Dis). 2021; **31(6)**:1911-1915. doi: 10.1016/j.numecd.2021.02.034
393. **Cicero AFG**, Fogacci F, Stoian AP, Vrablik M, Al Rasadi K, Banach M, Toth PP, Rizzo M. Nutraceuticals in the Management of Dyslipidemia: Which, When, and for Whom? Could Nutraceuticals Help Low-Risk Individuals with Non-optimal Lipid Levels? *Current Atherosclerosis Report* (Curr Atheroscler Rep.) 2021;**23(10)**:57. doi: 10.1007/s11883-021-00955-y.
394. **Cicero AFG**, Fogacci F, Rizzoli E, D'Addato S, Borghi C. Long-Term Impact of Different Triple Combination Antihypertensive Medications on Blood Pressure Control, Metabolic Pattern and Incident Events: Data from the Brisighella Heart Study. *Journal of Clinical Medicine* (J Clin Med.) 2021;**10(24)**:5921. doi: 10.3390/jcm10245921.
395. **Cicero AFG**, Fogacci F, Zambon A. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. *Journal of American College of Cardiology* (JACC) 2021; **77(5)**:620-628. doi: 10.1016/j.jacc.2020.11.056.
396. **Cicero AFG**, Kennedy C, Knežević T, Bove M, Georges CMG, Šatrauskienė A, Toth PP, Fogacci F. Efficacy and safety of Armolipid Plus®: an updated PRISMA compliant systematic review and meta-analysis of randomized controlled clinical trials. *Nutrients* 2021; **13(2)**:638. doi: 10.3390/nu13020638.
397. Colletti A, **Cicero AFG**. Nutraceutical Approach to Chronic Osteoarthritis: From Molecular Research to Clinical Evidence.(Int J Mol Sci.) 2021;**22(23)**:12920. doi: 10.3390/ijms222312920.
398. Colletti A, Cravotto G, Citi V, Martelli A, Testai L, **Cicero AFG**. Advances in Technologies for Highly Active Omega-3 Fatty Acids from Krill Oil: Clinical Applications. *Marine Drugs*. (Mar Drugs) 2021; **19(6)**:306. doi: 10.3390/md19060306.
399. Colletti A, Sangiorgio L, Martelli A, Testai L, **Cicero AFG**, Cravotto G. Highly Active Cranberry's Polyphenolic Fraction: New Advances in Processing and Clinical Applications. *Nutrients*. 2021;**13(8)**:2546. doi: 10.3390/nu13082546.
400. Coppola P, **Cicero AFG**, Fogacci F, D'Addato S, Bacchelli S, Borghi C, On Behalf Of The Brisighella Heart Study Group. Laboratory and Instrumental Risk Factors Associated with a Sudden Cardiac Death Prone ECG Pattern in the General Population: Data from the Brisighella Heart Study. *Journal of Clinical Medicine* (J Clin Med). 2021; **10(4)**:640. doi: 10.3390/jcm10040640.
401. Cosentino ER, **Cicero AFG**, Bentivenga C, Burchi M, Borghi C. Iron deficiency correction in heart failure patients with preserved ejection fraction: a case series study. *Archives of Medical Sciences* (Arch Med Sci.) 2021;**17(4)**:1137-1139. doi: 10.5114/aoms/136068.
402. Favari E, Grassi D, **Cicero AFG**. Interpreting data on alpha-lipoic acid safety considering the number of subjects exposed. *Clinical Nutrition* (Clin Nutr.) 2021; **40(2)**:654. doi: 10.1016/j.clnu.2020.12.003.
403. Fogacci F, Borghi C, **Cicero AFG**. Diets, Foods and Food Components' Effect on Dyslipidemia. *Nutrients*. 2021; **13(3)**:741. doi: 10.3390/nu13030741
404. Fogacci F, Borghi C, Di Micoli A, **Cicero AFG**. Sudden Fall in the Lipid-Lowering Effect of Evolocumab: The Butler Is Not Always Guilty. *Medicina*. 2021;**57(8)**:857. doi: 10.3390/medicina57080857.
405. Fogacci F, Borghi C, Di Micoli A, Degli Esposti D, **Cicero AFG**. Inequalities in enrollment of women and racial minorities in trials testing uric acid lowering drugs. *Nutrition, Metabolism and Cardiovascular Diseases* (Nutr Metab Cardiovasc Dis.) 2021;**31(12)**:3305-3313. doi: 10.1016/j.numecd.2021.09.011.
406. Fogacci S, Fogacci F, Favari E, Toth PP, Borghi C, **Cicero AFG**. Management of pregnancy-related hypertensive disorders in patients infected with SARS CoV-2: pharmacological and clinical issues. *European Heart Journal - Cardiovascular Pharmacotherapy* (Eur Heart J Cardiovasc Pharmacother.) 2021; **7(4)**:346-351. doi: 10.1093/ehjcvp/pvaa105.
407. Fogacci F, Gori D, **Cicero AFG**. Representativity of women and racial/ethnic minorities in

- randomized clinical trials on bempedoic acid: Positive efforts and lacking data. *European Journal of Internal Medicine* (Eur J Intern Med.) 2022 Feb; **96**:122-123. doi: 10.1016/j.ejim.2021.11.006.
408. Hosseini A, Penson PE, **Cicero AF**, Golledge J, Al-Rasadi K, Jamialahmadi T, Sahebkar A. Potential benefits of phytochemicals for abdominal aortic aneurysm. *Current Medicinal Chemistry* (Curr Med Chem) 2021;**28(41)**:8595-8607. doi: 10.2174/0929867328666210614113116.
409. Imbalzano E, Orlando L, Sciacqua A, Nato G, Dentali F, Nassisi V, Russo V, Camporese G, Bagnato G, **Cicero AFG**, Dattilo G, Vatrano M, Versace AG, Squadrito G, Di Micco P. Machine Learning to Calculate Heparin Dose in COVID-19 Patients with Active Cancer. *Journal of Clinical Medicine* (J Clin Med.) 2021;**11(1)**:219. doi: 10.3390/jcm11010219.
410. Maloberti A, Bombelli M, Facchetti R, Barbagallo CM, Bernardino B, Rosei EA, Casiglia E, **Cicero AF**, Cirillo M, Cirillo P, Desideri G, D'elia L, Dell'Oro R, Ferri C, Galletti F, Giannattasio C, Loreto G, Iaccarino G, Lippa L, Mallamaci F, Masi S, Mazza A, Muiesan ML, Nazzaro P, Parati G, Palatini P, Pauletto P, Pontremoli R, Quarti-Trevano F, Rattazzi M, Rivasi G, Salvetti M, Tikhonoff V, Tocci G, Ungar A, Verdecchia P, Viazzi F, Volpe M, Virdis A, Grassi G, Borghi C; Working Group on Uric Acid, Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. *Journal of Hypertension* (J Hypertens.) 2021;**39(2)**:333-340. doi: 10.1097/HJH.0000000000002600.
411. Muiesan ML, Salvetti M, Virdis A, Masi S, Casiglia E, Tikhonoff V, Barbagallo CM, Bombelli M, **Cicero AFG**, Cirillo M, Cirillo P, Desideri G, D'Elia L, Ferri C, Galletti F, Gesualdo L, Giannattasio C, Iaccarino G, Mallamaci F, Maloberti A, Mazza A, Nazzaro P, Palatini P, Parati G, Pontremoli R, Rattazzi M, Rivasi G, Tocci G, Ungar A, Verdecchia P, Viazzi F, Volpe M, Grassi G, Borghi C; from the Working Group on Uric Acid, Cardiovascular Risk of the Italian Society of Hypertension. Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. *Journal of Internal Medicine* (J Hypertens). 2021; **39(1)**:62-69. doi: 10.1097/HJH.0000000000002589.
412. Nicolini G, Degli Esposti D, Ianniello E, Moroni L, Bacchelli S, **Cicero AFG**, Fogacci F, Borghi C. Long-term consequences of previous preeclampsia and complicated pregnancy: analysis of echocardiographic aspects. *Journal of Cardiovascular Medicine* (J Cardiovasc Med.) 2021;**22(12)**:939-945. doi: 10.2459/JCM.0000000000001229.
413. Palatini P, Parati G, Virdis A, Reboldi G, Masi S, Mengozzi A, Casiglia E, Tikhonoff V, **Cicero AFG**, Ungar A, Rivasi G, Salvetti M, Barbagallo CM, Bombelli M, Dell'Oro R, Bruno B, Lippa L, D'Elia L, Verdecchia P, Angeli F, Mallamaci F, Cirillo M, Rattazzi M, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Georgiopoulos G, Iaccarino G, Nazzaro P, Galletti F, Ferri C, Desideri G, Viazzi F, Pontremoli R, Muiesan ML, Grassi G, Borghi C; from the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. *European Journal of Preventive Cardiology* (Eur J Prev Cardiol). 2021: zwab023. doi: 10.1093/eurjpc/zwab023. Online ahead of print.
414. Piani F, **Cicero AFG**, Borghi C. Uric Acid and Hypertension: Prognostic Role and Guide for Treatment. *Journal of Clinical Medicine* (J Clin Med). 2021; **10(3)**:448. doi: 10.3390/jcm10030448.
415. Piani F, **Cicero AFG**, Borghi C, D'Addato S; BLIP Study group. Is the 2020 Sampson equation the best formula for LDL-C estimation? *European Journal of Internal Medicine* (Eur J Intern Med.) 2021; **83**:99-101. doi: 10.1016/j.ejim.2020.09.009.
416. Piani F, **Cicero AF**, D'Addato S, Borghi C; Brisighella Heart Study Group. From classical to innovative clinical epidemiology: the 50 years' experience of the Brisighella Heart Study. *Panminerva medica* (Panminerva Med.) 2021;**63(4)**:424-429. doi: 10.23736/S0031-0808.21.04387-1.

417. Piani F, **Cicero AFG**, Ventura F, Dormi A, Fogacci F, Patrono D, Mancini R, Ramazzotti E, Borghi C, D'Addato S; BLIP Study Group. Evaluation of twelve formulas for LDL-C estimation in a large, blinded, random Italian population. *International Journal of Cardiology (Int J Cardiol.)* 2021; **330**:221-227. doi: 10.1016/j.ijcard.2021.02.009.
418. Pugliese NR, Mengozzi A, Viridis A, Casiglia E, Tikhonoff V, **Cicero AFG**, Ungar A, Rivasi G, Salvetti M, Barbagallo CM, Bombelli M, Dell'Oro R, Bruno B, Lippa L, D'Elia L, Verdecchia P, Mallamaci F, Cirillo M, Rattazzi M, Cirillo P, Gesualdo L, Mazza A, Giannattasio C, Maloberti A, Volpe M, Tocci G, Georgiopoulos G, Iaccarino G, Nazzaro P, Parati G, Palatini P, Galletti F, Ferri C, Desideri G, Viazzi F, Pontremoli R, Muiesan ML, Grassi G, Masi S, Borghi C; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (in wich **Cicero AFG**). The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. *Clinical Research in Cardiology (Clin Res Cardiol)*. 2021; **110**(7):1073-1082. doi: 10.1007/s00392-021-01815-0.
419. Russo E, Viazzi F, Pontremoli R, Barbagallo CM, Bombelli M, Casiglia E, **Cicero AFG**, Cirillo M, Cirillo P, Desideri G, D'Elia L, Ferri C, Galletti F, Gesualdo L, Giannattasio C, Iaccarino G, Leoncini G, Mallamaci F, Maloberti A, Masi S, Mengozzi A, Mazza A, Muiesan ML, Nazzaro P, Palatini P, Parati G, Rattazzi M, Rivasi G, Salvetti M, Tikhonoff V, Tocci G, Ungar A, Verdecchia P, Viridis A, Volpe M, Grassi G, Borghi C; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension. Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. *Journal of Nephrology (J Nephrol)*. 2022 Jan; **35**(1):211-221. doi: 10.1007/s40620-021-00985-4.
420. Russo E, Viazzi F, Pontremoli R, Barbagallo CM, Bombelli M, Casiglia E, **Cicero AFG**, Cirillo M, Cirillo P, Desideri G, D'Elia L, Dell'Oro R, Ferri C, Galletti F, Gesualdo L, Giannattasio C, Iaccarino G, Leoncini G, Mallamaci F, Maloberti A, Masi S, Mengozzi A, Mazza A, Muiesan ML, Nazzaro P, Palatini P, Parati G, Rattazzi M, Rivasi G, Salvetti M, Tikhonoff V, Tocci G, Quarti Trevano FAL, Ungar A, Verdecchia P, Viridis A, Volpe M, Grassi G, Borghi C. Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. *Frontiers in Cardiovascular Medicine (Front Cardiovasc Med.)* 2021;**8**:713652. doi: 10.3389/fcvm.2021.713652.
421. Soltani S, Boozari M, **Cicero AFG**, Jamialahmadi T, Sahebkar A. Effects of phytochemicals on macrophage cholesterol efflux capacity: impact on atherosclerosis. *Phytotherapy Research (Phytother Res.)*. 2021; **35**(6):2854-2878. doi: 10.1002/ptr.6991.
422. Testai L, Martelli A, Flori L, **Cicero AFG**, Colletti A. Coenzyme Q<sub>10</sub>: Clinical Applications beyond Cardiovascular Diseases. *Nutrients*. 2021; **13**(5):1697. doi: 10.3390/nu13051697.
423. Ungar A, Rivasi G, Di Bari M, Viridis A, Casiglia E, Masi S, Mengozzi A, Barbagallo CM, Bombelli M, Bruno B, **Cicero AFG**, Cirillo M, Cirillo P, Desideri G, D'elia L, Ferri C, Galletti F, Gesualdo L, Giannattasio C, Iaccarino G, Ciccarelli M, Lippa L, Mallamaci F, Maloberti A, Mazza A, Muiesan ML, Nazzaro P, Palatini P, Parati G, Pontremoli R, Quarti-Trevano F, Rattazzi M, Salvetti M, Tikhonoff V, Tocci G, Cianci R, Verdecchia P, Viazzi F, Volpe M, Grassi G, Borghi C; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study. *Journal of Hypertension (J Hypertens.)* 2021 Dec 22. doi: 10.1097/HJH.0000000000003068. Epub ahead of print.
424. Vahedian-Azimi A, Shojaie S, Banach M, Heidari F, **Cicero AFG**, Khoshfetrat M, Jamialahmadi T, Sahebkar A. Statin therapy in chronic viral hepatitis: a systematic review and meta-analysis of nine studies with 195,602 participants. *Annals of Medicine (Ann Med.)* 2021;**53**(1):1227-1242. doi: 10.1080/07853890.2021.1956686.

## 2022

425. Fogacci F, Borghi C, **Cicero AF**. New evidences on the association between HDL-C and cardiovascular risk: a never ending research story. *European Journal of Preventive Cardiology (Eur J Prev Cardiol.)* 2022 Jan 28;zwac015.; doi: 10.1093/eurjpc/zwac015.



426. Banerjee Y, Pantea Stoian A, **Cicero AFG**, Fogacci F, Nikolic D, Sachinidis A, Rizvi AA, Janez A, Rizzo M. Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. *Expert opinion on drug safety (Expert Opin Drug Saf.)* 2022;**21(1)**:9-20. doi: 10.1080/14740338.2022.1988568.
427. Tikhonoff V, Casiglia E, Spinella P, Barbagallo CM, Bombelli M, **Cicero AFG**, Cirillo M, Cirillo P, Desideri G, D'elia L, Ferri C, Galletti F, Gesualdo L, Giannattasio C, Iaccarino G, Mallamaci F, Maloberti A, Masi S, Mazza A, Muiesan ML, Nazzaro P, Palatini P, Parati G, Pontremoli R, Quarti-Trevano F, Rattazzi M, Rivasi G, Salvetti M, Tocci G, Ungar A, Verdecchia P, Viazzi F, Virdis A, Volpe M, Grassi G, Borghi C; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. *Journal of human hypertension. (J Hum Hypertens.)* 2021. doi: 10.1038/s41371-021-00613-5. Online ahead of print.

**Full paper publications in international press with IF as part of a study group**

1. Borghi C, Dormi A, Ambrosioni E, Gaddi A; On behalf of the Brisighella Heart Study working party (including **Cicero AF**). Relative role of systolic, diastolic and pulse pressure as risk factors for cardiovascular events in the Brisighella Heart Study. *Journal of Hypertension (J Hypertens.)* 2002; **20(9)**:1737-1742.
2. Borghi C, Dormi A, L'Italien G, Lapuerta P, Franklin SS, Collatina S, Gaddi A on behalf of the Brisighella Heart Study working party (including **Cicero AF**). The relationship between systolic blood pressure and cardiovascular risk--results of the Brisighella Heart Study. *Journal of Clinical Hypertension (J Clin Hypertens)* 2003; **5(1)**: 47-52.
3. Borghi C, Dormi A, D'Addato S, Gaddi A, Ambrosioni E on behalf of the Brisighella Heart Study Working Party (including **Cicero AF**). Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study. *Journal of Hypertension (J Hypertens.)* 2004;**22**:1707-16.
4. Borghi C, Dormi A, Veronesi M, Sangiorgi Z, Gaddi A on behalf of the Brisighella Heart Study Working Party (including **Cicero AF**). Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. *American Heart Journal (Am Heart J.)* 2004; **148**: 285-292. doi: [10.1016/j.ahj.2004.02.003](https://doi.org/10.1016/j.ahj.2004.02.003)
5. Banach M, Dinca M, Ursoniu S, Serban MC, Howard G, Mikhailidis DP, Nicholls S, Lip GYH, Glasser S, Martin SS, Muntner P, Rysz J, Toth PP, Sahebkar A; Lipid Blood Pressure Meta-analysis Collaboration Group (including **Cicero AF**). A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. *Pharmacological Research (Pharmacol Res.)* 2016;**111**:343-356. doi: 10.1016/j.phrs.2016.06.005.
6. Brie D, Sahebkar A, Penson PE, Dinca M, Ursoniu S, Serban MC, Zanchetti A, Howard G, Ahmed A, Aronow WS, Muntner P, Lip GY, Wong ND, Rysz J, Banach M; Lipid, Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Effects of pentoxifylline on inflammatory markers and blood pressure: a systematic review and meta-analysis of randomized controlled trials. *Journal of Hypertension (J Hypertens.)* 2016;**34(12)**:2318-2329.
7. Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, Jones SR, Mosteoru S, Blaha MJ, Martin SS, Rysz J, Toth PP, Lip GY, Pencina MJ, Ray KK, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. *Atherosclerosis.* 2016;**253**:194-208. doi: 10.1016/j.atherosclerosis.2016.07.897.

8. Dinca M, Serban MC, Sahebkar A, Mikhailidis DP, Toth PP, Martin SS, Blaha MJ, Blüher M, Gurban C, Penson P, Michos ED, Hernandez AV, Jones SR, Banach M; for Lipid Blood Pressure Meta-analysis Collaboration LBPMC Group (including **Cicero AF**). Does vitamin D supplementation alter plasma adipokines concentrations? A systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research* (Pharmacol Res.) 2016;**107**:360-371. doi: 10.1016/j.phrs.2016.03.035.
9. Sahebkar A, Serban MC, Mikhailidis DP, Toth PP, Muntner P, Ursoniu S, Mosterou S, Glasser S, Martin SS, Jones SR, Rizzo M, Rysz J, Sniderman AD, Pencina MJ, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. *Pharmacological Research* (Pharmacol Res.) 2016;**103**:236-52. doi: 10.1016/j.phrs.2015.12.001.
10. Serban MC, Sahebkar A, Zanchetti A, Mikhailidis DP, Howard G, Antal D, Andrica F, Ahmed A, Aronow WS, Muntner P, Lip GY, Graham I, Wong N, Rysz J, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Effects of Quercetin on Blood Pressure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Journal of the American Heart Association* (J Am Heart Assoc.) 2016;**5**(7). pii: e002713. doi: 10.1161/JAHA.115.002713.
11. Awad K, Mikhailidis DP, Toth PP, Jones SR, Moriarty P, Lip GYH, Muntner P, Catapano AL, Pencina MJ, Rosenson RS, Rysz J, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. *Cardiovascular Drugs Therapy* (Cardiovasc Drugs Ther.) 2017;**31**(4):419-431. doi: 10.1007/s10557-017-6743-0.
12. Awad K, Serban MC, Penson P, Mikhailidis DP, Toth PP, Jones SR, Rizzo M, Howard G, Lip GYH, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Effects of morning vs evening statin administration on lipid profile: A systematic review and meta-analysis. *Journal of Clinical Lipidology* (J Clin Lipidol.) 2017;**11**(4):972-985.e9. doi: 10.1016/j.jacl.2017.06.001.
13. Bała M, Sahebkar A, Ursoniu S, Serban MC, Undas A, Mikhailidis DP, Lip GYH, Rysz J, Banach M; Lipid Blood Pressure Meta-Analysis Collaboration Group (including **Cicero AF**). Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. *Pharmacological Research* (Pharmacol Res.) 2017;**124**:64-73. doi: 10.1016/j.phrs.2017.07.024.
14. Bytyçi I, Bajraktari G, Bhatt DL, Morgan CJ, Ahmed A, Aronow WS, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Hydrophilic vs lipophilic statins in coronary artery disease: A meta-analysis of randomized controlled trials. *Journal of Clinical Lipidology* (J Clin Lipidol.) 2017;**11**(3):624-637. doi: 10.1016/j.jacl.2017.03.003.
15. Kotani K, Sahebkar A, Serban MC, Ursoniu S, Mikhailidis DP, Mariscalco G, Jones SR, Martin S, Blaha MJ, Toth PP, Rizzo M, Kostner K, Rysz J, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Lipoprotein(a) Levels in Patients With Abdominal Aortic Aneurysm. *Angiology*. 2017;**68**(2):99-108. doi: 10.1177/0003319716637792.
16. Maiorean SM, Serban MC, Sahebkar A, Ursoniu S, Serban A, Penson P, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis. *Journal of Clinical Lipidology* (J Clin Lipidol.) 2017;**11**(6):1393-1406. doi: 10.1016/j.jacl.2017.08.004.
17. Sahebkar A, Serban MC, Penson P, Gurban C, Ursoniu S, Toth PP, Jones SR, Lippi G, Kotani K, Kostner K, Rizzo M, Rysz J, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). The Effects of Tamoxifen on Plasma

- Lipoprotein(a) Concentrations: Systematic Review and Meta-Analysis. *Drugs*. 2017;**77(11)**:1187-1197. doi: 10.1007/s40265-017-0767-4.
18. Sahebkar A, Simental-Mendía LE, Watts GF, Serban MC, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. *BMC Medicine* (BMC Med.) 2017;**15(1)**:22. doi: 10.1186/s12916-017-0787-7.
  19. Ursoniu S, Mikhailidis DP, Serban MC, Penson P, Toth PP, Ridker PM, Ray KK, Kees Hovingh G, Kastelein JJ, Hernandez AV, Manson JE, Rysz J, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research* (Pharmacol Res.) 2017;**122**:105-117. doi: 10.1016/j.phrs.2017.06.002.
  20. Awad K, Mikhailidis DP, Katsiki N, Muntner P, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group (including **Cicero AF**). Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Drugs*. 2018;**78(4)**:453-462. doi: 10.1007/s40265-018-0870-1.
  21. Maiorean SM, Serban MC, Sahebkar A, Ursoniu S, Serban A, Penson P, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group Ursoniu S, Sahebkar A, Serban MC, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration Group (including **Cicero AF**). The impact of argan oil on plasma lipids in humans: Systematic review and meta-analysis of randomized controlled trials. *Phytotherapy Research* (Phytother Res.) 2018;**32(3)**:377-383. doi: 10.1002/ptr.5959.
  22. Mazidi M, Kengne AP, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration Group (including **Cicero AF**). Effects of coenzyme Q10 supplementation on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research* (Pharmacol Res.) 2018;**128**:130-136. doi: 10.1016/j.phrs.2017.08.011.
  23. Penson P, Serban MC, Ursoniu S, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Does coffee consumption alter plasma lipoprotein(a) concentrations? A systematic review. *Critical Reviews in Food Sciences and Nutrition* (Crit Rev Food Sci Nutr.) 2018;**58(10)**:1706-1714. doi: 10.1080/10408398.2016.1272045.
  24. Penson PE, Mancini GBJ, Toth PP, Martin SS, Watts GF, Sahebkar A, Mikhailidis DP, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group (including **Cicero AF**) & International Lipid Expert Panel (ILEP). Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions. *Journal of Cachexia, Sarcopenia and Muscle*. (J Cachexia Sarcopenia Muscle.) 2018;**9(6)**:1023-1033. doi: 10.1002/jcsm.12344.
  25. Ursoniu S, Sahebkar A, Serban MC, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration Group (including **Cicero AF**). The impact of argan oil on plasma lipids in humans: Systematic review and meta-analysis of randomized controlled trials. *Phytotherapy Research* (Phytother Res.) 2018;**32(3)**:377-383. doi: 10.1002/ptr.5959.
  26. Mazidi M, Katsiki N, Mikhailidis DP, Pencina MJ, Banach M. Egg Consumption and Risk of Total and Cause-Specific Mortality: An Individual-Based Cohort Study and Pooling Prospective Studies on Behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). *Journal of the American College of Nutrition* (J Am Coll Nutr.) 2019;**38(6)**:552-563. doi: 10.1080/07315724.2018.1534620.
  27. Ursoniu S, Sahebkar A, Serban MC, Pinzaru I, Dehelean C, Noveanu L, Rysz J, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group (including **Cicero AF**)

- (including **Cicero AF**). A systematic review and meta-analysis of clinical trials investigating the effects of flaxseed supplementation on plasma C-reactive protein concentrations. *Archives of Medical Sciences (Arch Med Sci.)* 2019;**15(1)**:12-22. doi: 10.5114/aoms.2018.81034.
28. Banach M, Penson PE, Fras Z, Vrablik M, Pella D, Reiner Ž, Nabavi SM, Sahebkar A, Kayikcioglu M, Daccord M; FH Europe and the International Lipid Expert Panel (ILEP) (including **Cicero AF**). Brief recommendations on the management of adult patients with familial hypercholesterolemia during the COVID-19 pandemic. *Pharmacol Res.* 2020;**158**:104891. doi: 10.1016/j.phrs.2020.104891.
  29. Del Pinto R, Pagliacci S, De Feo M, Grassi D, Ferri C; Italian Society of Hypertension (including **Cicero AF**) and Federfarma. Prevalence of hypertension and associated cardiovascular risk factors among pharmacies customers: an Italian nationwide epidemiological survey. *European Journal of Preventive Cardiology (Eur J Prev Cardiol.)* 2020; **27(11)**:1228-1230. doi: 10.1177/2047487319851301.
  30. Iaccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe M; SARS-RAS Investigators (including **Cicero AF**). Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension. *Hypertension.* 2020;**76(2)**:366-372. doi: 10.1161/HYPERTENSIONAHA.120.15324.
  31. Mazidi M, Katsiki N, Mikhailidis DP, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group (including **Cicero AF**). Associations of serum uric acid with total and cause-specific mortality: Findings from individuals and pooling prospective studies. *Atherosclerosis.* 2020;**296**:49-58. doi: 10.1016/j.atherosclerosis.2019.07.019.
  32. Mazidi M, Katsiki N, George ES, Banach M. Tomato and Lycopene Consumption Is Inversely Associated with Total and Cause-Specific Mortality: A Population-based Cohort Study, on behalf of the International Lipid Expert Panel (ILEP; including **Cicero AF**). *British Journal of Nutrition (Brit J Nutr.)* 2020; **124(12)**:1303-1310. doi: 10.1017/S0007114519002150.
  33. Mazidi M, Katsiki N, Mikhailidis DP, Banach M; International Lipid Expert panel (ILEP) (including **Cicero AF**). Effect of Dietary Insulinemia on All-Cause and Cause-Specific Mortality: Results from a Cohort Study. *Journal of the American College of Nutrition (J Am Coll Nutr.)* 2020;**39(5)**:407-413. doi: 10.1080/07315724.2019.1646167.
  34. Mazidi M, Mikhailidis DP, Sattar N, Toth PP, Judd S, Blaha MJ, Hernandez AV, Penson PE, Banach M; International Lipid Expert Panel (ILEP) & Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (including **Cicero AF**). Association of types of dietary fats and all-cause and cause-specific mortality: A prospective cohort study and meta-analysis of prospective studies with 1,148,117 participants. *Clinical Nutrition (Clin Nutr.)* 2020;**39(12)**:3677-3686. doi: 10.1016/j.clnu.2020.03.028.
  35. Zhubi-Bakija F, Bajraktari G, Bytyçi I, Mikhailidis DP, Henein MY, Latkovskis G, Rexhaj Z, Zhubi E, Banach M; International Lipid Expert Panel (ILEP) (including **Cicero AF**). The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: A position paper from the International Lipid Expert Panel (ILEP). *Clinical Nutrition (Clin Nutr.)* 2020;**40(1)**:255-276. doi: 10.1016/j.clnu.2020.05.017.
  36. Awad K, Mohammed M, Zaki MM, Abushouk AI, Lip GYH, Blaha MJ, Lavie CJ, Toth PP, Jukema JW, Sattar N, Banach M; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group and the International Lipid Expert Panel (ILEP) (including **Cicero AFG**). Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies. *BMC Medicine (BMC Med.)*. 2021;**19(1)**:139. doi: 10.1186/s12916-021-02009-1.
  37. Banach M, Penson PE, Vrablik M, Bunc M, Dyrbus K, Fedacko J, Gaita D, Gierlotka M, Jarai Z, Magda SL, Margetic E, Margoczy R, Durak-Nalbantic A, Ostadal P, Pella D, Trbusic M, Udroi CA, Vlachopoulos C, Vulic D, Fras Z, Dudek D, Reiner Ž; ACS EuroPath Central & South European Countries Project including **Cicero AFG**). Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid

- Expert Panel (ILEP). *Pharmacological Research* (Pharmacol Res.) 2021;**166**:105499. doi: 10.1016/j.phrs.2021.105499.
38. Bianconi V, Banach M, Pirro M; International Lipid Expert Panel (ILEP) (including **Cicero AFG**). Why patients with familial hypercholesterolemia are at high cardiovascular risk? Beyond LDL-C levels. *Trends in Cardiovascular Medicine* (Trends Cardiovasc Med. 2021;**31(4)**):205-215. doi: 10.1016/j.tcm.2020.03.004.
  39. Bytyçi I, Bajraktari G, Penson PE, Henein MY, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group; International Lipid Expert Panel (ILEP) (including **Cicero AF**). Efficacy and safety of colchicine in patients with coronary artery disease: A systematic review and meta-analysis of randomized controlled trials. *British Journal of Clinical Pharmacology* (Br J Clin Pharmacol.) 2021 Aug 18. doi: 10.1111/bcp.15041. Epub ahead of print.
  40. Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M; International Lipid Expert Panel (ILEP) (including **Cicero AFG**). How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. *Progress in Cardiovascular Diseases*. (Prog Cardiovasc Dis.) 2021;**67**:65-74. doi: 10.1016/j.pcad.2020.12.008.
  41. Enayati A, Banach M, Jamialahmadi T, Sahebkar A; endorsed by the International Lipid Expert Panel (ILEP) (including **Cicero AFG**). Protective role of nutraceuticals against myocarditis. *Biomedicine and Pharmacotherapy* (Biomed Pharmacother.) 2022 Feb; **146**:112242. doi: 10.1016/j.biopha.2021.112242.
  42. Global Burden of Disease 2020 Health Financing Collaborator Network (including **Cicero AFG**). Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050. *Lancet*. 2021; **398(10308)**:1317-1343. doi: 10.1016/S0140-6736(21)01258-7.
  43. Ruscica M, Penson PE, Ferri N, Sirtori CR, Pirro M, Mancini GBJ, Sattar N, Toth PP, Sahebkar A, Lavie CJ, Wong ND, Banach M; International Lipid Expert Panel (ILEP) and International Lipid Expert Panel Experts (including **Cicero AFG**). Impact of nutraceuticals on markers of systemic inflammation: Potential relevance to cardiovascular diseases - A position paper from the International Lipid Expert Panel (ILEP). *Progress in Cardiovascular Disease* (Prog Cardiovasc Dis.) 2021;**67**:40-52. doi: 10.1016/j.pcad.2021.06.010.
  44. Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, Freiburger T, Harada-Shiba M, Blom DJ, Raal FJ, Cuchel M, and the Homozygous Familial Hypercholesterolaemia International Clinical Collaborators (including **Cicero AFG**). Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. *The Lancet* 2022; doi: 10.1016/S0140-6736(21)02001-8 Epub ahead of print.

#### **Other publications:**

#### **Full papers published in international press without IF: 105**

1. Corsini F, **Cicero AF**, Giannuzzi A, Gaddi A. Application of a new processing method to post-LDL-apheresis data. *Journal of Theoretical Medicine* (J Theoretical Med.) 2002; **4(3)**: 191-196.
2. **Cicero AF**, Fiorito A, Rontini T, Nascetti S, Sangiorgi Z, Dormi A, Gaddi A. Dietary habits did not influence plasma antibodies against oxidized LDL level in a wide sample of healthy subjects: the Brisighella Heart Study. *Vaccine* 2003; **21(S 2)**:S35-S37.

3. **Cicero AF**, Derosa G, Forghieri M, Cipressi F, Arletti R. Cardiovascular risk factors clustering and management in a wide population of psychiatric patients: a pharmacoepidemiology report. *Minerva Psichiatrica (Min Psych.)* 2004; **45(1)**: 37-42.
4. **Cicero AF**. Screening long-stay psychiatric patients for risk factors for coronary heart disease. *International Journal of Therapy and Rehabilitation (Int J Ther Rehab.)* 2004; **11(3)**: 118.
5. Derosa G, **Cicero AF**, Murdolo G, Ciccarelli L, Fogari R. Comparison of metabolic effects of orlistat and sibutramine treatment in type 2 diabetic obese patients. *Diabetes Nutrition and Metabolism (Diab Nutr Metab.)* 2004; **17(4)**: 222-230.
6. **Cicero AF**, Gaddi AV, Borghi C. Complementary medicine for hypertension: what evidence for herbalists suggestion? Evaluation of risks and potential applications. *Evidence Based Integrative Medicine (Evid Based Integrative Med.)* 2005; **2(1)**: 47-55.
7. Gaddi AV, **Cicero AF**. Treatment of peripheral obstructive artery disease: a battle that could be won also with drugs? *Minerva Cardioangiologica (Minerva Cardioangiol.)* 2005; **53(6)**: 605-610.
8. Borghi C, **Cicero AF**. Omega-3 polyunsaturated fatty acids: their potential role in blood pressure prevention and management. *Heart International (Heart Int.)* 2006; **2(2)**: 98-105.
9. Borghi C, **Cicero AF**. Recent evidences of the role of  $\omega$ -3 polyunsaturated fatty acids on blood pressure control and hypertension related complication. *Future in Lipidology (Future Lipidol)* [currently *Clinical Lipidology*] 2006; **1(5)**: 569-577.
10. Borghi C, **Cicero AF**. Fixed combination of zofenopril plus hydrochlorothiazide in the management of hypertension: a review of available data. *Vascular Health and Risk Management (Vasc Health Risk Manag.)* 2006; **2(4)**: 341-349.
11. Borghi C, Ertek S, **Cicero AF**. Irbesartan: a review of its use alone and in combination with hydrochlorothiazide. *Therapy* 2006; **3(6)**: 733-749.
12. Derosa G, **Cicero AF**, D'Angelo A, Tinelli C, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SAT, Montagna L, Fogari E, Gravina A, Ferrari I, Galli S, Paniga S, Fogari R. Matrix Metalloproteinase-2, -9 and Tissue Inhibitor Metalloproteinase-1 in Patients with Hypertension Before and After Doxazosin Therapy. *High Blood Pressure & Cardiovascular Prevention (High Blood Press Cardio Prev)* 2006; **13(2)**: 47-52.
13. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo S, Montagna L, Gravina A, Ferrari I, Galli S, Paniga S, Tinelli C, **Cicero AFG**. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. *Endothelium*. 2006; **13(3)**: 227-231.
14. Derosa G, Salvadeo S, **Cicero AF**. Fixed-dose combination rosiglitazone/glimepiride in the treatment of Type 2 diabetes mellitus. *Therapy* 2006; **3(5)**: 559-569.
15. Derosa G, Salvadeo S, **Cicero AF**. Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials. *Current Clinical Pharmacology (Curr Clin Pharmacol)* 2006; **1(31)**: 21-33.
16. Derosa G, Salvadeo S, **Cicero AF**. Prospects for the development of novel anti-hyperlipidemic drugs. *Current Opinion in Investigational Drugs (Curr Opin Invest Drugs)* 2006; **7(9)**: 826-833. [Review]
17. Manca M, Rusticali F, Gaddi AV, **Cicero AF**. Physical activity, exercise and cardiovascular health. *Future in Lipidology (Fut Lipidol)* [currently *Clinical Lipidology*] 2006; **1(5)**: 513-516.
18. Bove M, **Cicero AF**, Manca M, Georgoulis I, Motta R, Giovannini M, Poggiopollini G, Gaddi AV. Sources of variability of plasma HDL-cholesterol levels. *Future in Lipidology (Fut Lipidol)* [currently *Clinical Lipidology*] 2007; **2(5)**: 557-569.
19. Borghi C, **Cicero AF**. New management strategies of the hypertensive patient: from the disease to the patient. *European Cardiovascular Disease (Eur Cardiovasc Dis)* 2007; **1(1)**: 103-104.

20. Borghi C, **Cicero AF**. Blood pressure modulating properties of Omega-3 polyunsaturated fatty acids (PUFA). Another PUFA heart protective effect? *High Blood Pressure and Cardiovascular Prevention* (High Blood Press Cardiovas Prev) 2007; **14(2)**: 1-7.
21. **Cicero AF**, Dormi A, Bove M, Lucicesare A, Poggiopollini G, Borghi C, Gaddi AV on behalf of the Brisighella Heart Study group. Estimation of Familial Combined Hyperlipoproteinemia prevalence in a large rural population: the Brisighella Heart Study. *Vascular Disease Prevention* (Vasc Dis Prev) 2007; **4(3)**:185-89.
22. **Cicero AF**, Rovati L, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol-lowering agents in humans. *Arzneimittelforschung/Drug Research* 2007; **57(1)**:26-30.
23. Derosa G, **Cicero AF**, Scalise F, Avanzini MA, Tinelli C, Piccinni MN, Peros E, Geroldi D, Fogari E, D'Angelo A. Metalloproteinase-2 and -9 in Diabetic and Nondiabetic Subjects during Acute Coronary Syndromes. *Endothelium* 2007; **14(1)**: 45-51.
24. Derosa G, **Cicero AF**, Scalise F, Avanzini MA, Tinelli C, Peros E, Fogari E, D'Angelo A. Metalloproteinases in diabetics and non diabetics during acute coronary syndromes and after 3 months. *Endothelium*. 2007; **14(4)**: 175-183.
25. **Cicero AF**, Derosa G, Manca M, Bove M, Borghi C, Gaddi AV. Vascular remodelling and prothrombotic markers in subjects affected by Familial Combined Hyperlipidemia and/or Metabolic Syndrome in primary prevention for cardiovascular disease. *Endothelium* 2007; **14(4)**: 193-198.
26. Gaddi AV, **Cicero AF**, Odofo FO, Poli A, Paoletti R on behalf of the Atherosclerosis and Metabolic Diseases Study Group. Practical recommendations for Familial Combined Hyperlipidemia diagnosis and management: an update. *Vascular Disease Prevention* (Vasc Dis Prev) 2007; **4(3)**: 229-236.
27. Gaddi AV, **Cicero AF**, Odofo FO, Poli A, Paoletti R on behalf of the Atherosclerosis and Metabolic Diseases Study Group. Practical guidelines for familial combined hyperlipidemia diagnosis: An up-date. *Vascular Health and Risk Management* (Vasc Health Risk Manag) 2007; **3(6)**: 877-86.
28. Veronesi M, **Cicero AF**, Prandin MG, Dormi A, Cosentino E, Strocchi E, Borghi C. A prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practice. *Vascular Health and Risk Management* (Vasc Health Risk Manag) 2007; **3(6)**: 999-1005.
29. Ambrosioni E, **Cicero AF**, Parretti D, Filippi A, Rossi A, Peruzzi E, Borghi C on behalf of the LesScore Investigators. Global Cardiovascular Disease Risk Management in Italian Patients with Metabolic Syndrome in the Clinical Practice Setting. *High Blood Pressure and Cardiovascular Prevention* (High Blood Press Cardiovasc Prev.) 2008; **15 (2)**: 37-45.
30. Borghi C, **Cicero AF**. Hypertension and hypercholesterolemia: from theory to cardiovascular prevention. *Hot Topics in Cardiology Series*. FBCommunication Ed. 2008; **12**: 7-16.
31. Borghi C, **Cicero AF**, Ambrosioni E on behalf of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study. Effects of early treatment with zofenopril in patients with myocardial infarction and metabolic syndrome: the SMILE study. *Vascular Health and Risk Management* (Vasc Health Risk Manag) 2008; **4(3)**: 665-671.
32. **Cicero AF**, Derosa G, Bove M, Grandi E, Uliassi E, Borghi C, Gaddi AV. A nutraceutical based approach to reduce cholesterolemia in patients previously intolerant to more than a statin: a pilot study. *Mediterranean Journal of Nutrition and Metabolism* (Med J Nutr Metab.) 2008; **1(1)**: 33-36.
33. **Cicero AF**, Ertek S. Natural sources of antidyslipidaemic agents: is there an evidence-based approach for their prescription? *Mediterranean Journal of Nutrition and Metabolism* (Med J Nutr Metab.) 2008; **1(2)**:85-93.



34. Derosa G, Ferrari I, D'Angelo A, Tinelli C, Salvadeo SA, Ciccarelli L, Piccinni MN, Gravina A, Ramondetti F, Maffioli P, **Cicero AF**. Matrix metalloproteinase-2 and -9 levels in obese patients. *Endothelium*. 2008; **15(4)**: 219-224.
35. Borghi G, Conficoni E, **Cicero AF**. Role of the renin-angiotensin-aldosterone system in the interaction between hypertension and lipid disorders. *European Cardiovascular Disease (Eur Cardiovasc Dis.)* 2009; **1(2)**: 30-32.
36. **Cicero AF**, D'Addato S, Fiorito A, Poli A, Gaddi AV. Plasma lipid effects of corn oil and extra-virgin olive oil in hypercholesterolemic subjects: a randomized, controlled trial. *Mediterranean Journal of Nutrition and Metabolism (Med J Nutr Metab.)* 2009; **1 (3)**: 187-192.
37. **Cicero AF**, Ertek S. Berberine: metabolic and cardiovascular effects in preclinical and clinical trials. *Nutrition and Dietary Supplements (Nutr Diet Suppl.)* 2009; **1**: 1-10.
38. **Cicero AF**, Ertek S. Metabolic and cardiovascular effects of berberine: from preclinical evidences to clinical trial results. *Clinical Lipidology (Clin Lipidol.)* 2009; **4(5)**: 553-563
39. Veronesi M, **Cicero AF**, Prandin MG, Di Gregori V, Ambrosioni E, Borghi C. Effects of telmisartan and bisoprolol on blood pressure, peripheral haemodynamic and lipid profile in statin-treated hypertensive hypercholesterolemic patients. *High Blood Pressure and Cardiovascular Prevention (High Blood Press Cardiovasc Prev.)* 2009; **16(1)**: 7-12.
40. Gaddi AV, **Cicero AF**, Gambaro G. Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered. *International Journal of Nephrology and Renovascular Disease (Int J Nephrol Renovasc Dis.)* 2010; **3**: 99-105
41. Borghi C, **Cicero AF**. The treatment of hypertension in the elderly population. What's new? *Cardiology and Clinical Practice (Cardiol Clin Pract.)* 2010; **2(1)**: 25-40
42. Ardigò D, Bernini F, Borghi C, Calandra S, **Cicero AF**, Favari E, Fellin R, Franzini L, Vigna GB, Zimetti F, Zavaroni I on behalf of the ADSL project investigators. Advanced diagnostic support in lipidology project: role for phenotypic and functional evaluation of lipoproteins in dyslipidemias. *Clinical Lipidology (Clin Lipidol)* 2010; **5(3)**: 329-337
43. **Cicero AF**, Derosa G, Bove M, Imola F, Gaddi AV, Borghi C. Psyllium improves dyslipidemia, hyperglycemia and hypertension, while guar gum reduces more rapidly body weight in patients affected by metabolic syndrome following an AHA Step 2 diet. *Mediterranean Journal of Nutrition and Metabolism (Med J Nutr Metab.)* 2010; **3(1)**: 47-54.
44. Bove M, Carnevali L, **Cicero AF**, Gaddi AV. Diffused intima-media thickness regression after 20 months of pravastatin 40 mg treatment: a case report. *Scripta Medica* 2010; **83(2)**: 121-123.
45. Borghi C, Laghi L, **Cicero AF**. From lipid disorders to high blood pressure: is it possible to extend the paradigm of CV prevention? *Cardiology and Clinical Practice (Cardiol Clin Pract)* 2010; **2(3)**: 109-112.
46. **Cicero AF**, Benvenuti C, ARMoweb study Group. Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice. *Mediterranean Journal of Nutrition and Metabolism (Med J Nutr Metab.)* 2010; **3**: 239-246.
47. Bove M, Carnevali L, **Cicero AF**, Tarugi P, Gaddi AV. Novel mutation in the ApoB Gene (Apo B-15.56): A Case Report. *Balkan Journal of Medical Genetics (BJMG)* 2010;**13(2)**:9-10.
48. Borghi C, **Cicero AF**. Diuretics and CV prevention: not all that glitters is gold. *Cardiology and Clinical Practice (Cardiol Clin Pract)* 2011; **3(2)**: 51-53.
49. **Cicero AF**, Bove M, Gerocarni B, Giovannini M, Borghi C. Evaluation of the short term efficacy and tolerability of a combined nutraceutical with lipid lowering properties: a randomized clinical trial. *Mediterranean Journal of Nutrition and Metabolism (Med J Nutr Metab.)* 2011; **4(3)**:197-202.

50. **Cicero AF**, Dormi A, D'Addato S, Borghi C on behalf of the Brisighella Heart Study Staff. From risk factor assessment to cardiovascular disease risk and mortality modification: the first 40 years of the Brisighella Heart Study. *Clinical Lipidology* (Clin Lipidol.) 2011;**6(3)**: 269-276.
51. **Cicero AF**, Borghi C, Del Corso F, Vinereanu D. n-3 Polyunsaturated fatty acids and the patient at high cardiovascular risk with co-morbidities: A pleiotropic drug. *Cardiology and Clinical Practice* (Cardiol Clin Pract.) 2012; **4(1)**: 1-12.
52. **Cicero AF**, Tartagni E, Borghi C. Nutraceuticals with lipid-lowering activity: do they have any effect beyond cholesterol reduction? *Clinical Lipidology* (Clin Lipidol.) 2012; **7(5)**: 549-559.
53. **Cicero AF**, Tartagni E. Antidiabetic properties of berberine: from cellular pharmacology to clinical effects. *Hospital Practice* 2012;**40(2)**: 56-63.
54. **Cicero AF**, De Sando V, Benedetto D, Cevenini M, Grandi E, Borghi C. Long-term efficacy and tolerability of a largely marketed multicomponent nutraceutical in overweight and normoweight dyslipidaemic patients. *Nutrafoods* 2012; **11(2)**: 15-21.
55. **Cicero AF**, De Sando V, Izzo R, Vasta A, Trimarco B, Borghi C. Effect of a combined nutraceutical containing *Orthosiphon stamineus* effect on blood pressure and metabolic syndrome components in hypertensive dyslipidaemic patients: a randomized clinical trial. *Complementary Therapies in Clinical Practice* (Compl Ther Clin Pract.) 2012; **12(8)**: 1113-1124.
56. Borghi C, **Cicero AF**. Irbesartan and evidences among ARBs class: A comprehensive and practical review. *High Blood Pressure and Cardiovascular Prevention* (High Blood Press Cardiovasc Prev.) 2012; **19(1)**: 19-31.
57. Borghi C, **Cicero AF**. Which statin is the ideal statin for polymedicated patients? *Clinical Lipidology* (Clin Lipidol.) 2012; **7(3 Suppl. 1)**: 11-16.
58. Borghi C, Rosticci M, **Cicero AF**. Cardiovascular diseases and risk factors: is it time to move forward? *Cardiology and Clinical Practice* (Cardiol Clin Pract.) 2012; **4(2)**: 51-52.
59. Ertek S, **Cicero AF**, Erdogan G. Factors related with non alcoholic fatty liver disease in normolipidemic patients with 1-hour hyperglycemia. *Turkish Journal of Endocrinology and Metabolism* (Turk JEM) 2012;**16**:52-57.
60. Borghi C, Ambrosioni E, Omboni S, **Cicero AF**, Bacchelli S, Degli Esposti D, Novo S, Vinereanu D, Ambrosio G, Reggiardo G, Zava D. Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction a post hoc analysis of SMILE4. *ClinicoEconomics and Outcomes Research* (Clinicoecon Outcomes Res.) 2013; **5**: 317-25.
61. **Cicero AF**, Parini A, Rosticci M, Brancaloni B, Derosa G, Grandi E, Borghi C. Effect of a lipid-lowering nutraceutical on pulse-wave-velocity in hypercholesterolemic patients with or without chronic kidney disease. *The Open Hypertension Journal* (TOJH) 2013; **5**: 18-22
62. **Cicero AF**, Rosticci M, D'Addato S, Baronio C, Grossi G, Grandi E, Borghi C, for the Brisighella Heart Study Group. Population health needs assessment and healthcare services use in a three years follow-up on administrative and clinical data: results from the Brisighella Heart Study. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2013;**21(1)**:45-51. doi: 10.1007/s40292-013-0033-0
63. **Cicero AF**, Reggi A, Parini A, Morbini M, Rosticci M, Grandi E, Borghi C. Berberine and Monacolin Effects on the Cardiovascular Risk Profile of Women with Oestrogen-Induced Hypercholesterolemia. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2014;**21(3)**:221-226. doi: 10.1007/s40292-014-0052-5.
64. Borghi C, Verardi FM, Pareo I, Bentivenga C, **Cicero AF**. Hyperuricemia and cardiovascular disease risk. *Expert Review of Cardiovascular Therapy* (Expert Opin Cardiovasc Ther.) 2014;**12(10)**:1219-25. doi: 10.1586/14779072.2014.957675.

65. **Cicero AF**, Tartagni E. Diet, dietary supplements and age-related macular degeneration (AMD). *Nutrafoods* 2014; **13(1)**: 5-11. doi: 10.1007/s13749-014-0017-2
66. Pirodda A, Raimondi MC, **Cicero AF**, Rosticci M, Rinaldi ER, Bellacosa L, Stanghellini V, Borghi C. Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users. *Hearing, Balance and Communication* 2014;**12(2)**:84-87. doi: 10.3109/21695717.2014.902554
67. Borghi C, **Cicero AF**. Hyperuricemia as a risk factor for cardiovascular disease. [Letter] *Expert Review of Cardiovascular Therapy* (Exp Opin Cardiovasc Ther.) 2015;**13(1)**:21-2. doi: 10.1586/14779072.2015.987130.
68. Borghi C, Omboni S, **Cicero AF**, Bacchelli S, Degli Esposti D, Novo S, Vinereanu D, Ambrosio G, Ambrosioni E. Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a post hoc analysis of the SMILE-4 Study in patients according to levels of left ventricular ejection fraction at entry. *Open Heart*. 2015;**2(1)**:e000195. doi: 10.1136/openhrt-2014-000195.
69. **Cicero AF**, Benelli M, Brancaleoni M, Dainelli G, Merlini D, Negri R. Middle and long-term impact of a very low-carbohydrate ketogenic diet on cardiometabolic factors: a multi-center, cross-sectional, clinical study. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2015;**22(4)**:389-94. doi: 10.1007/s40292-015-0096-1.
70. **Cicero AF**, Colletti A. Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability. *Clinical Lipidology* (Clin Lipidol.) 2015;**10(1)**:1-4.
71. **Cicero AF**, Colletti A. Nutraceuticals and Blood Pressure Control: results from clinical trials and meta-analyses. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2015;**22(3)**:203-13. doi: 10.1007/s40292-015-0081-8.
72. **Cicero AF**, Parini A, Rosticci M. Nutraceuticals and cholesterol-lowering action. *IJC Metabolic & Endocrine* 2015; **6**:1-4. doi: 10.1016/j.ijcme.2014.10.009
73. **Cicero AF**, Rosticci M. Combination therapy with olmesartan/hydrochlorothiazide to improve blood pressure control. *Journal of Clinical and Experimental Cardiology* (J Clin Exp Cardiol.) 2015;6. doi:10.4172/2155-9880.1000384
74. **Cicero AF**, Rosticci M, Reggi A, Derosa G, Parini A, Grandi E, D'Addato S, Borghi C for the Brisighella Heart Study group. Relationship between serum uric acid and electrocardiographic alterations in a large sample of general population: data from the Brisighella Heart Study. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2015; **22(2)**:129-34. doi: 10.1007/s40292-014-0077-9
75. **Cicero AF**, Rosticci M, Derosa G, Cagnati M, D'Addato S, Parini A, Borghi C. Subjective effects of a combined lipid-lowering nutraceutical or ezetimibe on wellbeing and sexual performances in patients with perceived worsening of erectile function during statin treatment: a randomized clinical trial. *Nutrafoods* 2015;**14(3)**:127-131. doi: 10.1007/s13749-015-0022-0
76. Bove M, **Cicero AF**, Veronesi M, Borghi C. An evidence-based review on urate lowering treatments: Implications for optimal treatment of chronic hyperuricaemia. *Vascular Health and Risk Management* (Vasc Health Risk Manag.) 2016;**13**:23-28. doi: 10.2147/VHRM.S115080.
77. Millán J, **Cicero AF**, Torres F, Anguera A. Effects of a nutraceutical combination containing berberine (BRB), policosanol, and red yeast rice (RYR), on lipid profile in hypercholesterolemic patients: A meta-analysis of randomised controlled trials. *Clinical Investigation in Arteriosclerosis* (Clin Investig Arterioscler) 2016;**28(4)**:178-87. doi: 10.1016/j.arteri.2016.03.002.
78. **Cicero AF**, Bove M, Colletti A, Rizzo M, Fogacci F, Giovannini M, Borghi C. Short-term impact of a combined nutraceutical on cognitive function, perceived stress and depression in young elderly with cognitive impairment: a pilot, double-blind, randomized clinical trial.

- Journal of Prevention of Alzheimer Disease* (J Prev Alzh Dis.) 2017;4(1):12-15. doi: 10.14283/jpad.2016.110
79. Pirodda A, Brandolini C, Raimondi MC, Pelligra I, Strocchi E, **Cicero AF**, Rosticci M, Borghi C. The possible role of Vicorder® apparatus in the diagnostic protocol of inner ear diseases *Hearing, Balance and Communication* 2015; **13 (4)**: 175-177.
  80. Pirodda A, Brandolini C, Raimondi MC, Pelligra I, Strocchi E, **Cicero AF**, Rosticci M, Borghi C. Metabolic alterations and hearing acuity: lack of a significant clinical correlation. *Hearing, Balance and Communication* 2016; **14(2)**: 91-93.
  81. **Cicero AF**, Colletti A, Fogacci F, Bove M, Rosticci M, Borghi C. Effects of a Combined Nutraceutical on Lipid Pattern, Glucose Metabolism and Inflammatory Parameters in Moderately Hypercholesterolemic Subjects: A Double-blind, Cross-over, Randomized Clinical Trial. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2017;**24(1)**:13-18. doi: 10.1007/s40292-016-0163-2.
  82. Tocci G, **Cicero AF**, Salvetti M, Musumeci MB, Ferrucci A, Borghi C, Volpe M. Attitudes and preferences for the clinical management of hypertension and hypertension-related cerebrovascular disease in the general practice: Results of the Italian Hypertension and Brain Survey. *Clinical Hypertension* (Clin Hypertens.) 2017; **23**: 10. doi: 10.1186/s40885-017-0066-0.
  83. **Cicero AF**, Fogacci F, Morbini M, Colletti A, Bove M, Veronesi M, Giovannini M, Borghi C. Nutraceutical Effects on Glucose and Lipid Metabolism in Patients with Impaired Fasting Glucose: A Pilot, Double-Blind, Placebo-Controlled, Randomized Clinical Trial on a Combined Product. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2017;**24(3)**:283-288. doi: 10.1007/s40292-017-0206-3.
  84. **Cicero AF**, Colletti A, Fogacci F, Bove M, Giovannini M, Borghi C. Is it Possible to Significantly Modify Blood Pressure with a Combined Nutraceutical on Top of a Healthy Diet? The Results of a Pilot Clinical Trial. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2018;**25(4)**:401-405. doi: 10.1007/s40292-018-0289-5.
  85. **Cicero AF**, Fogacci F, Bove M, Ventura F, Giovannini M, Borghi C. Optimizing Lipid Pattern by Adding a Combined Nutraceutical or Pravastatin to Fenofibrate Treatment in Hypertriglyceridemic Subjects: Single Site, Randomized, Open-Label, Post-Market Clinical Investigation. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2018;**25(4)**:355-359. doi: 10.1007/s40292-018-0277-9.
  86. **Cicero AF**, Fogacci F, Colletti A. Commentary to: "The Effects of Coenzyme Q10 Supplementation on Blood Pressures Among Patients with Metabolic Diseases: A Systematic Review and Meta-analysis of Randomized Controlled Trials". *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2018;**25(1)**:51-52. Jan 19. doi: 10.1007/s40292-018-0248-1.
  87. Desideri G, Virdis A, Casiglia E, Borghi C; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension [among which **Cicero AF**]. Exploration into Uric Acid and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observational Study. *High Blood Pressure and Cardiovascular Disease Prevention* (High Blood Press Cardiovasc Prev.) 2018;**25(2)**:197-202. doi: 10.1007/s40292-018-0250-7.
  88. Catapano AL, Barrios V, **Cicero AF**, Pirro M. Lifestyle interventions and nutraceuticals: Guideline-based approach to cardiovascular disease prevention. *Atherosclerosis X* 2019;**1**:100003 doi: 10.1016/j.athx.2019.100003
  89. **Cicero AF**, Allkanjari O, Busetto GM, Cai T, Larganà G, Magri V, Perletti G, Robustelli Della Cuna FS, Russo GI, Stamatiou K, Trinchieri A, Vitalone A. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. *Archivi Italiani di Urologia e Andrologia* (Arch Ital Urol Androl.) 2019;**91(3)**. doi: 10.4081/aiua.2019.3.139.

90. **Cicero AF**, Colletti A, Fogacci F, Garcia-Molina L, Veronesi M, Salamone M, Vynckier AK, Van Den Driessche M, Borghi C. Efficacy of a multicomponent nutraceutical on the normalization of liver functional parameters in patients with NAFLD: a double blind, randomized, clinical trial. *Journal of Food Nutrition and Metabolism (J Food Nutr Metab.)* 2019. doi: 10.31487/j.JFNM.2018.01.004
91. **Cicero AF**, Fogacci F, Banach M. Red yeast rice for hypercholesterolemia. *Methodist Debaquey Cardiovascular Journal (Methodist Debaquey Cardiovasc J.)*, 2019;**15(3)**:192-199.
92. **Cicero AF**, Grassi D, Tocci G, Galletti F, Borghi C, Ferri C. Nutrients and nutraceuticals for the management of high normal blood pressure: an evidence-based consensus document. *High Blood Pressure and Cardiovascular Disease Prevention (High Blood Press Cardiovasc Prev.)* 2019;**26(1)**:9-25. doi: 10.1007/s40292-018-0296-6.
93. Fogacci F, Fogacci S, **Cicero AF**. Resveratrol for High Blood Pressure: A Total Failure or the Need to Identify the Right Patient? *High Blood Pressure and Cardiovascular Disease Prevention (High Blood Press Cardiovasc Prev.)* 2019;**26(5)**:421-423. doi: 10.1007/s40292-019-00333-5.
94. **Cicero AF**, Girolimetto N, Bentivenga C, Grandi E, Fogacci F, Borghi C. Short-term effect of a new oral sodium hyaluronate formulation on knee osteoarthritis: a double-blind, randomized, placebo-controlled, clinical trial. *Diseases* 2020;**8(3)**:26; doi: 10.3390/diseases8030026
95. Iaccarino G, Borghi C, **Cicero AF**, Ferri C, Minuz P, Muiesan ML, Mulatero P, Mulè G, Pucci G, Salvetti M, Savoia C, Sechi LA, Volpe M, Grassi G. Renin-Angiotensin System Inhibition in Cardiovascular Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension. *High Blood Pressure and Cardiovascular Disease Prevention (High Blood Press Cardiovasc Prev.)* 2020;**27(2)**:105-108. doi: 10.1007/s40292-020-00380-3.
96. Maloberti A, Giannattasio C, Bombelli M, Desideri G, **Cicero AF**, Muiesan ML, Rosei EA, Salvetti M, Ungar A, Rivasi G, Pontremoli R, Viazzi F, Facchetti R, Ferri C, Bernardino B, Galletti F, D'Elia L, Palatini P, Casiglia E, Tikhonoff V, Barbagallo CM, Verdecchia P, Masi S, Mallamaci F, Cirillo M, Rattazzi M, Pauletto P, Cirillo P, Gesualdo L, Mazza A, Volpe M, Tocci G, Iaccarino G, Nazzaro P, Lippa L, Parati G, Dell'Oro R, Quarti-Trevano F, Grassi G, Virdis A, Borghi C; Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Hyperuricemia and Risk of Cardiovascular Outcomes: The Experience of the URRAH (Uric Acid Right for Heart Health) Project. *High Blood Pressure and Cardiovascular Disease Prevention (High Blood Press Cardiovasc Prev.)* 2020;**27(2)**:121-128. doi: 10.1007/s40292-020-00368-z.
97. Pecchioli V, **Cicero AF**, Lomartire N, Gemmiti MP, Colangeli A, Germanò R, Corsi MP, Germanò GIW. A double-blind, placebo-controlled clinical trial to assess the effects of a combined nutraceutical on endothelial function in patients with mild-to-moderate hypercholesterolemia. *Archives of Medical Sciences – Atherosclerotic Diseases (Arch Med Sci – Atheroscl Dis)*. 2020;**5**:e36-e42. doi: 10.5114/amsad.2020.94986.
98. **Cicero AF**, Girolimetto N, Bentivenga C, Grandi E, Fogacci F, Borghi C. Short-Term Effect of a New Oral Sodium Hyaluronate Formulation on Knee Osteoarthritis: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial. *Diseases*. 2020; **8(3)**:E26. doi: 10.3390/diseases8030026.
99. D'Avolio A, Isaia GC on behalf of "COVID-Vitamin D Study Group (among which **Cicero AF**). Vitamin D in the COVID-19 prevention and treatment: emerging evidence. *PharmAdvance* 2021;**3(2)**:350-356. doi: [10.36118/pharmadvances.2021.01](https://doi.org/10.36118/pharmadvances.2021.01).
100. **Cicero AFG**, Bove M, Cincione RI, Fogacci F, Veronesi M. Effect of combined lipid-lowering and antioxidant nutraceutical on plasma lipids, endothelial function, and estimated cardiovascular disease risk in moderately hypercholesterolemic patients: a double-blind, placebo-controlled randomized clinical trial. *Archives of Medical Sciences – Atherosclerotic*

- Diseases* (Arch Med Sci Atheroscler Dis.) 2021;**6**:e145-e151. doi: 10.5114/amsad.2021.107843.
101. Cicero AFG, Veronesi M, Fogacci F. Dietary Intervention to Improve Blood Pressure Control: Beyond Salt Restriction. *High Blood Pressure & Cardiovascular Prevention* (High Blood Press Cardiovasc Prev). 2021;**28(6)**:547-553. doi: 10.1007/s40292-021-00474-6.
  102. Grassi G, Del Pinto R, Agabiti Rosei C, Agnoletti D, Borghi C, Cicero AFG, De Ciuceis C, Desideri G, Grassi D, Muiesan ML, Paini A, Salvetti M, Tocci G, Veglio F, Volpe M, Ferri C. Reduction of High Cholesterol Levels by a Preferably Fixed-Combination Strategy as the First Step in the Treatment of Hypertensive Patients with Hypercholesterolemia and High/Very High Cardiovascular Risk: A Consensus Document by the Italian Society of Hypertension. *High Blood Pressure & Cardiovascular Prevention* (High Blood Press Cardiovasc Prev). 2022 Jan 3. doi: 10.1007/s40292-021-00501-6. Epub ahead of print.
  103. De Feo M, Del Pinto R, Pagliacci S, Grassi D, Ferri C; Italian Society of Hypertension and Federfarma (including Cicero AFG). Real-World Hypertension Prevalence, Awareness, Treatment, and Control in Adult Diabetic Individuals: An Italian Nationwide Epidemiological Survey. *High Blood Pressure & Cardiovascular Prevention* (High Blood Press Cardiovasc Prev). 2021; **28(3)**:301-307. doi: 10.1007/s40292-021-00449-7.
  104. Del Pinto R, Grassi G, Ferri C, Pengo MF, Lombardi C, Pucci G, Salvetti M, Parati G; Italian Society of Hypertension (SIIA); SIIA Young Researchers Study Group; President of SIIA; Past President of SIIA; Italian Society of Hypertension (SIIA). Diagnostic and Therapeutic Approach to Sleep Disorders, High Blood Pressure and Cardiovascular Diseases A Consensus Document by the Italian Society of Hypertension (SIIA) (including Cicero AFG). *High Blood Pressure & Cardiovascular Prevention* (High Blood Press Cardiovasc Prev). 2021; **28(2)**:85-102. doi: 10.1007/s40292-021-00436-y.
  105. Mancusi C, Grassi G, Borghi C, Ferri C, Muiesan ML, Volpe M, Iaccarino G; SARS-RAS Investigator Group (including Cicero AFG). Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. *High Blood Pressure & Cardiovascular Prevention* (High Blood Press Cardiovasc Prev). 2021; **28(1)**:5-11. doi: 10.1007/s40292-020-00429-3.

- **Full papers published in Italian scientific press: N. 150**
- **Full scientific books in Italian language: N. 14**
- **Chapters of books with international divulgation: N. 16**
- **Didactic CD-Roms for physicians: N. 6**
- **Papers published in proceedings of international courses/congresses: N. 8**
- **Papers published in proceedings of Italian national courses/congresses: N. 32**
- **Abstracts published in proceedings of international congresses: N. 122**
- **Abstracts published in proceedings of Italian national congresses: N. 215**